#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=A Preliminary Study of DBH (Encoding Dopamine Beta-Hydroxylase) Genetic Variation and Neural Correlates of Emotional and Motivational Processing in Individuals With and Without Pathological Gambling
#Text=Background and aims
#Text=Corticostriatal-limbic neurocircuitry, emotional and motivational processing, dopaminergic and noradrenergic systems and genetic factors have all been implicated in pathological gambling (PG).
1-1	0-1	A	_	
1-2	2-13	Preliminary	_	
1-3	14-19	Study	_	
1-4	20-22	of	_	
1-5	23-26	DBH	_	
1-6	27-28	(	_	
1-7	28-36	Encoding	_	
1-8	37-45	Dopamine	_	
1-9	46-62	Beta-Hydroxylase	_	
1-10	62-63	)	_	
1-11	64-71	Genetic	_	
1-12	72-81	Variation	_	
1-13	82-85	and	_	
1-14	86-92	Neural	_	
1-15	93-103	Correlates	_	
1-16	104-106	of	_	
1-17	107-116	Emotional	_	
1-18	117-120	and	_	
1-19	121-133	Motivational	_	
1-20	134-144	Processing	_	
1-21	145-147	in	_	
1-22	148-159	Individuals	_	
1-23	160-164	With	_	
1-24	165-168	and	_	
1-25	169-176	Without	_	
1-26	177-189	Pathological	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling[1]	
1-27	190-198	Gambling	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling[1]	
1-28	199-209	Background	_	
1-29	210-213	and	_	
1-30	214-218	aims	_	
1-31	219-241	Corticostriatal-limbic	_	
1-32	242-256	neurocircuitry	_	
1-33	256-257	,	_	
1-34	258-267	emotional	_	
1-35	268-271	and	_	
1-36	272-284	motivational	_	
1-37	285-295	processing	_	
1-38	295-296	,	_	
1-39	297-309	dopaminergic	_	
1-40	310-313	and	_	
1-41	314-327	noradrenergic	_	
1-42	328-335	systems	_	
1-43	336-339	and	_	
1-44	340-347	genetic	_	
1-45	348-355	factors	_	
1-46	356-360	have	_	
1-47	361-364	all	_	
1-48	365-369	been	_	
1-49	370-380	implicated	_	
1-50	381-383	in	_	
1-51	384-396	pathological	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling[2]	
1-52	397-405	gambling	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling[2]	
1-53	406-407	(	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling[2]	
1-54	407-409	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling[2]	
1-55	409-410	)	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling[2]	
1-56	410-411	.	_	

#Text=However, allelic variants of genes influencing dopaminergic and noradrenergic neurotransmitters have not been investigated with respect to the neural correlates of emotional and motivational states in PG.
2-1	412-419	However	_	
2-2	419-420	,	_	
2-3	421-428	allelic	_	
2-4	429-437	variants	_	
2-5	438-440	of	_	
2-6	441-446	genes	_	
2-7	447-458	influencing	_	
2-8	459-471	dopaminergic	_	
2-9	472-475	and	_	
2-10	476-489	noradrenergic	_	
2-11	490-507	neurotransmitters	_	
2-12	508-512	have	_	
2-13	513-516	not	_	
2-14	517-521	been	_	
2-15	522-534	investigated	_	
2-16	535-539	with	_	
2-17	540-547	respect	_	
2-18	548-550	to	_	
2-19	551-554	the	_	
2-20	555-561	neural	_	
2-21	562-572	correlates	_	
2-22	573-575	of	_	
2-23	576-585	emotional	_	
2-24	586-589	and	_	
2-25	590-602	motivational	_	
2-26	603-609	states	_	
2-27	610-612	in	_	
2-28	613-615	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
2-29	615-616	.	_	

#Text=Dopamine beta-hydroxylase (DBH) converts dopamine to norepinephrine; the T allele of a functional single-nucleotide polymorphism rs1611115 (C-1021T) in the DBH gene is associated with less DBH activity and has been linked to emotional processes and addiction.
3-1	617-625	Dopamine	_	
3-2	626-642	beta-hydroxylase	_	
3-3	643-644	(	_	
3-4	644-647	DBH	_	
3-5	647-648	)	_	
3-6	649-657	converts	_	
3-7	658-666	dopamine	_	
3-8	667-669	to	_	
3-9	670-684	norepinephrine	_	
3-10	684-685	;	_	
3-11	686-689	the	_	
3-12	690-691	T	_	
3-13	692-698	allele	_	
3-14	699-701	of	_	
3-15	702-703	a	_	
3-16	704-714	functional	_	
3-17	715-732	single-nucleotide	_	
3-18	733-745	polymorphism	_	
3-19	746-755	rs1611115	_	
3-20	756-757	(	_	
3-21	757-758	C	_	
3-22	758-759	-	_	
3-23	759-764	1021T	_	
3-24	764-765	)	_	
3-25	766-768	in	_	
3-26	769-772	the	_	
3-27	773-776	DBH	_	
3-28	777-781	gene	_	
3-29	782-784	is	_	
3-30	785-795	associated	_	
3-31	796-800	with	_	
3-32	801-805	less	_	
3-33	806-809	DBH	_	
3-34	810-818	activity	_	
3-35	819-822	and	_	
3-36	823-826	has	_	
3-37	827-831	been	_	
3-38	832-838	linked	_	
3-39	839-841	to	_	
3-40	842-851	emotional	_	
3-41	852-861	processes	_	
3-42	862-865	and	_	
3-43	866-875	addiction	_	
3-44	875-876	.	_	

#Text=Here, we investigate the influence of rs1611115 on the neural correlates of emotional and motivational processing in PG and healthy comparison (HC) participants.
4-1	877-881	Here	_	
4-2	881-882	,	_	
4-3	883-885	we	_	
4-4	886-897	investigate	_	
4-5	898-901	the	_	
4-6	902-911	influence	_	
4-7	912-914	of	_	
4-8	915-924	rs1611115	_	
4-9	925-927	on	_	
4-10	928-931	the	_	
4-11	932-938	neural	_	
4-12	939-949	correlates	_	
4-13	950-952	of	_	
4-14	953-962	emotional	_	
4-15	963-966	and	_	
4-16	967-979	motivational	_	
4-17	980-990	processing	_	
4-18	991-993	in	_	
4-19	994-996	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
4-20	997-1000	and	_	
4-21	1001-1008	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-22	1009-1019	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-23	1020-1021	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-24	1021-1023	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-25	1023-1024	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-26	1025-1037	participants	_	
4-27	1037-1038	.	_	

#Text=Methods
#Text=While undergoing functional magnetic resonance imaging, 18 PG and 25 HC participants, all European Americans, viewed gambling-, sad-, and cocaine-related videotapes.
5-1	1039-1046	Methods	_	
5-2	1047-1052	While	_	
5-3	1053-1063	undergoing	_	
5-4	1064-1074	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
5-5	1075-1083	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
5-6	1084-1093	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
5-7	1094-1101	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
5-8	1101-1102	,	_	
5-9	1103-1105	18	_	
5-10	1106-1108	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
5-11	1109-1112	and	_	
5-12	1113-1115	25	_	
5-13	1116-1118	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
5-14	1119-1131	participants	_	
5-15	1131-1132	,	_	
5-16	1133-1136	all	_	
5-17	1137-1145	European	_	
5-18	1146-1155	Americans	_	
5-19	1155-1156	,	_	
5-20	1157-1163	viewed	_	
5-21	1164-1172	gambling	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
5-22	1172-1173	-	_	
5-23	1173-1174	,	_	
5-24	1175-1178	sad	_	
5-25	1178-1179	-	_	
5-26	1179-1180	,	_	
5-27	1181-1184	and	_	
5-28	1185-1200	cocaine-related	_	
5-29	1201-1211	videotapes	_	
5-30	1211-1212	.	_	

#Text=Analyses focused on brain activation differences related to DBH genotype (CC/T-carrier [i.e., CT and TT]) and condition (sad/gambling/cocaine).
6-1	1213-1221	Analyses	_	
6-2	1222-1229	focused	_	
6-3	1230-1232	on	_	
6-4	1233-1238	brain	_	
6-5	1239-1249	activation	_	
6-6	1250-1261	differences	_	
6-7	1262-1269	related	_	
6-8	1270-1272	to	_	
6-9	1273-1276	DBH	_	
6-10	1277-1285	genotype	_	
6-11	1286-1287	(	_	
6-12	1287-1289	CC	_	
6-13	1289-1290	/	_	
6-14	1290-1299	T-carrier	_	
6-15	1300-1301	[	_	
6-16	1301-1304	i.e	_	
6-17	1304-1305	.	_	
6-18	1305-1306	,	_	
6-19	1306-1307	 	_	
6-20	1307-1309	CT	_	
6-21	1310-1313	and	_	
6-22	1314-1316	TT	_	
6-23	1316-1317	]	_	
6-24	1317-1318	)	_	
6-25	1319-1322	and	_	
6-26	1323-1332	condition	_	
6-27	1333-1334	(	_	
6-28	1334-1337	sad	_	
6-29	1337-1338	/	_	
6-30	1338-1346	gambling	_	
6-31	1346-1347	/	_	
6-32	1347-1354	cocaine	_	
6-33	1354-1355	)	_	
6-34	1355-1356	.	_	

#Text=Results
#Text=CC participants demonstrated greater recruitment of corticostriatal-limbic regions, relative to T-carriers.
7-1	1357-1364	Results	_	
7-2	1365-1367	CC	_	
7-3	1368-1380	participants	_	
7-4	1381-1393	demonstrated	_	
7-5	1394-1401	greater	_	
7-6	1402-1413	recruitment	_	
7-7	1414-1416	of	_	
7-8	1417-1439	corticostriatal-limbic	_	
7-9	1440-1447	regions	_	
7-10	1447-1448	,	_	
7-11	1449-1457	relative	_	
7-12	1458-1460	to	_	
7-13	1461-1471	T-carriers	_	
7-14	1471-1472	.	_	

#Text=DBH variants were also associated with altered corticostriatal-limbic activations across the different videotape conditions, and this association appeared to be driven by greater activation in CC participants relative to T-carriers during the sad condition.
8-1	1473-1476	DBH	_	
8-2	1477-1485	variants	_	
8-3	1486-1490	were	_	
8-4	1491-1495	also	_	
8-5	1496-1506	associated	_	
8-6	1507-1511	with	_	
8-7	1512-1519	altered	_	
8-8	1520-1542	corticostriatal-limbic	_	
8-9	1543-1554	activations	_	
8-10	1555-1561	across	_	
8-11	1562-1565	the	_	
8-12	1566-1575	different	_	
8-13	1576-1585	videotape	_	
8-14	1586-1596	conditions	_	
8-15	1596-1597	,	_	
8-16	1598-1601	and	_	
8-17	1602-1606	this	_	
8-18	1607-1618	association	_	
8-19	1619-1627	appeared	_	
8-20	1628-1630	to	_	
8-21	1631-1633	be	_	
8-22	1634-1640	driven	_	
8-23	1641-1643	by	_	
8-24	1644-1651	greater	_	
8-25	1652-1662	activation	_	
8-26	1663-1665	in	_	
8-27	1666-1668	CC	_	
8-28	1669-1681	participants	_	
8-29	1682-1690	relative	_	
8-30	1691-1693	to	_	
8-31	1694-1704	T-carriers	_	
8-32	1705-1711	during	_	
8-33	1712-1715	the	_	
8-34	1716-1719	sad	_	
8-35	1720-1729	condition	_	
8-36	1729-1730	.	_	

#Text=CC relative to T-carrier subjects also reported greater subjective sadness to the sad videotapes.
9-1	1731-1733	CC	_	
9-2	1734-1742	relative	_	
9-3	1743-1745	to	_	
9-4	1746-1755	T-carrier	_	
9-5	1756-1764	subjects	_	
9-6	1765-1769	also	_	
9-7	1770-1778	reported	_	
9-8	1779-1786	greater	_	
9-9	1787-1797	subjective	_	
9-10	1798-1805	sadness	_	
9-11	1806-1808	to	_	
9-12	1809-1812	the	_	
9-13	1813-1816	sad	_	
9-14	1817-1827	videotapes	_	
9-15	1827-1828	.	_	

#Text=Conclusions
#Text=Individual differences in genetic composition linked to aminergic function contribute significantly to emotional regulation across diagnostic groups and warrant further investigation in PG.
10-1	1829-1840	Conclusions	_	
10-2	1841-1851	Individual	_	
10-3	1852-1863	differences	_	
10-4	1864-1866	in	_	
10-5	1867-1874	genetic	_	
10-6	1875-1886	composition	_	
10-7	1887-1893	linked	_	
10-8	1894-1896	to	_	
10-9	1897-1906	aminergic	_	
10-10	1907-1915	function	_	
10-11	1916-1926	contribute	_	
10-12	1927-1940	significantly	_	
10-13	1941-1943	to	_	
10-14	1944-1953	emotional	_	
10-15	1954-1964	regulation	_	
10-16	1965-1971	across	_	
10-17	1972-1982	diagnostic	_	
10-18	1983-1989	groups	_	
10-19	1990-1993	and	_	
10-20	1994-2001	warrant	_	
10-21	2002-2009	further	_	
10-22	2010-2023	investigation	_	
10-23	2024-2026	in	_	
10-24	2027-2029	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
10-25	2029-2030	.	_	

#Text=Introduction
#Text=Pathological gambling (PG; gambling disorder in DSM-5) has an estimated heritability of 50%–66%.
11-1	2031-2043	Introduction	_	
11-2	2044-2056	Pathological	_	
11-3	2057-2065	gambling	_	
11-4	2066-2067	(	_	
11-5	2067-2069	PG	_	
11-6	2069-2070	;	_	
11-7	2071-2079	gambling	_	
11-8	2080-2088	disorder	_	
11-9	2089-2091	in	_	
11-10	2092-2095	DSM	_	
11-11	2095-2096	-	_	
11-12	2096-2097	5	_	
11-13	2097-2098	)	_	
11-14	2099-2102	has	_	
11-15	2103-2105	an	_	
11-16	2106-2115	estimated	_	
11-17	2116-2128	heritability	_	
11-18	2129-2131	of	_	
11-19	2132-2135	50%	_	
11-20	2135-2136	–	_	
11-21	2136-2139	66%	_	
11-22	2139-2140	.	_	

#Text=Most reported genetic studies of PG are limited to very small-scale (in terms of a genetic association design for complex traits) candidate-gene approaches (N = 68 to 186 PGs) for candidate genes involving mainly in dopaminergic and serotonergic systems with weak or inconsistent effects.
12-1	2141-2145	Most	_	
12-2	2146-2154	reported	_	
12-3	2155-2162	genetic	_	
12-4	2163-2170	studies	_	
12-5	2171-2173	of	_	
12-6	2174-2176	PG	_	
12-7	2177-2180	are	_	
12-8	2181-2188	limited	_	
12-9	2189-2191	to	_	
12-10	2192-2196	very	_	
12-11	2197-2208	small-scale	_	
12-12	2209-2210	(	_	
12-13	2210-2212	in	_	
12-14	2213-2218	terms	_	
12-15	2219-2221	of	_	
12-16	2222-2223	a	_	
12-17	2224-2231	genetic	_	
12-18	2232-2243	association	_	
12-19	2244-2250	design	_	
12-20	2251-2254	for	_	
12-21	2255-2262	complex	_	
12-22	2263-2269	traits	_	
12-23	2269-2270	)	_	
12-24	2271-2285	candidate-gene	_	
12-25	2286-2296	approaches	_	
12-26	2297-2298	(	_	
12-27	2298-2299	N	_	
12-28	2300-2301	=	_	
12-29	2302-2304	68	_	
12-30	2305-2307	to	_	
12-31	2308-2311	186	_	
12-32	2312-2315	PGs	_	
12-33	2315-2316	)	_	
12-34	2317-2320	for	_	
12-35	2321-2330	candidate	_	
12-36	2331-2336	genes	_	
12-37	2337-2346	involving	_	
12-38	2347-2353	mainly	_	
12-39	2354-2356	in	_	
12-40	2357-2369	dopaminergic	_	
12-41	2370-2373	and	_	
12-42	2374-2386	serotonergic	_	
12-43	2387-2394	systems	_	
12-44	2395-2399	with	_	
12-45	2400-2404	weak	_	
12-46	2405-2407	or	_	
12-47	2408-2420	inconsistent	_	
12-48	2421-2428	effects	_	
12-49	2428-2429	.	_	

#Text=The first large-scale genome-wide association study (GWAS) on a PG-related trait identified no gene variants reaching genome-wide significance.
13-1	2430-2433	The	_	
13-2	2434-2439	first	_	
13-3	2440-2451	large-scale	_	
13-4	2452-2463	genome-wide	_	
13-5	2464-2475	association	_	
13-6	2476-2481	study	_	
13-7	2482-2483	(	_	
13-8	2483-2487	GWAS	_	
13-9	2487-2488	)	_	
13-10	2489-2491	on	_	
13-11	2492-2493	a	_	
13-12	2494-2504	PG-related	_	
13-13	2505-2510	trait	_	
13-14	2511-2521	identified	_	
13-15	2522-2524	no	_	
13-16	2525-2529	gene	_	
13-17	2530-2538	variants	_	
13-18	2539-2547	reaching	_	
13-19	2548-2559	genome-wide	_	
13-20	2560-2572	significance	_	
13-21	2572-2573	.	_	

#Text=However, larger effect sizes may be observed in regard to functional variants of enzyme-encoding genes; these may relate to brain activations and treatment outcome in PG.
14-1	2574-2581	However	_	
14-2	2581-2582	,	_	
14-3	2583-2589	larger	_	
14-4	2590-2596	effect	_	
14-5	2597-2602	sizes	_	
14-6	2603-2606	may	_	
14-7	2607-2609	be	_	
14-8	2610-2618	observed	_	
14-9	2619-2621	in	_	
14-10	2622-2628	regard	_	
14-11	2629-2631	to	_	
14-12	2632-2642	functional	_	
14-13	2643-2651	variants	_	
14-14	2652-2654	of	_	
14-15	2655-2670	enzyme-encoding	_	
14-16	2671-2676	genes	_	
14-17	2676-2677	;	_	
14-18	2678-2683	these	_	
14-19	2684-2687	may	_	
14-20	2688-2694	relate	_	
14-21	2695-2697	to	_	
14-22	2698-2703	brain	_	
14-23	2704-2715	activations	_	
14-24	2716-2719	and	_	
14-25	2720-2729	treatment	_	
14-26	2730-2737	outcome	_	
14-27	2738-2740	in	_	
14-28	2741-2743	PG	_	
14-29	2743-2744	.	_	

#Text=Both dopamine and norepinephrine alterations have been implicated in PG.
15-1	2745-2749	Both	_	
15-2	2750-2758	dopamine	_	
15-3	2759-2762	and	_	
15-4	2763-2777	norepinephrine	_	
15-5	2778-2789	alterations	_	
15-6	2790-2794	have	_	
15-7	2795-2799	been	_	
15-8	2800-2810	implicated	_	
15-9	2811-2813	in	_	
15-10	2814-2816	PG	_	
15-11	2816-2817	.	_	

#Text=The DBH gene variant, which regulates the enzyme DBH’s conversion of dopamine to norepinephrine, is linked with various addiction and impulsive phenotypes.
16-1	2818-2821	The	_	
16-2	2822-2825	DBH	_	
16-3	2826-2830	gene	_	
16-4	2831-2838	variant	_	
16-5	2838-2839	,	_	
16-6	2840-2845	which	_	
16-7	2846-2855	regulates	_	
16-8	2856-2859	the	_	
16-9	2860-2866	enzyme	_	
16-10	2867-2870	DBH	_	
16-11	2870-2871	’	_	
16-12	2871-2872	s	_	
16-13	2873-2883	conversion	_	
16-14	2884-2886	of	_	
16-15	2887-2895	dopamine	_	
16-16	2896-2898	to	_	
16-17	2899-2913	norepinephrine	_	
16-18	2913-2914	,	_	
16-19	2915-2917	is	_	
16-20	2918-2924	linked	_	
16-21	2925-2929	with	_	
16-22	2930-2937	various	_	
16-23	2938-2947	addiction	_	
16-24	2948-2951	and	_	
16-25	2952-2961	impulsive	_	
16-26	2962-2972	phenotypes	_	
16-27	2972-2973	.	_	

#Text=In European Americans (EAs), the functional promoter variant in DBH, single-nucleotide polymorphism (SNP) rs1611115, is associated with 35%–52% of the variance in plasma DBH activity; in a dosage-effect fashion, the TT genotype is associated with the lowest DBH plasma activity, followed by CT demonstrating intermediary activity, and CC showing the greatest levels of enzymatic function.
17-1	2974-2976	In	_	
17-2	2977-2985	European	_	
17-3	2986-2995	Americans	_	
17-4	2996-2997	(	_	
17-5	2997-3000	EAs	_	
17-6	3000-3001	)	_	
17-7	3001-3002	,	_	
17-8	3003-3006	the	_	
17-9	3007-3017	functional	_	
17-10	3018-3026	promoter	_	
17-11	3027-3034	variant	_	
17-12	3035-3037	in	_	
17-13	3038-3041	DBH	_	
17-14	3041-3042	,	_	
17-15	3043-3060	single-nucleotide	_	
17-16	3061-3073	polymorphism	_	
17-17	3074-3075	(	_	
17-18	3075-3078	SNP	_	
17-19	3078-3079	)	_	
17-20	3080-3089	rs1611115	_	
17-21	3089-3090	,	_	
17-22	3091-3093	is	_	
17-23	3094-3104	associated	_	
17-24	3105-3109	with	_	
17-25	3110-3113	35%	_	
17-26	3113-3114	–	_	
17-27	3114-3117	52%	_	
17-28	3118-3120	of	_	
17-29	3121-3124	the	_	
17-30	3125-3133	variance	_	
17-31	3134-3136	in	_	
17-32	3137-3143	plasma	_	
17-33	3144-3147	DBH	_	
17-34	3148-3156	activity	_	
17-35	3156-3157	;	_	
17-36	3158-3160	in	_	
17-37	3161-3162	a	_	
17-38	3163-3176	dosage-effect	_	
17-39	3177-3184	fashion	_	
17-40	3184-3185	,	_	
17-41	3186-3189	the	_	
17-42	3190-3192	TT	_	
17-43	3193-3201	genotype	_	
17-44	3202-3204	is	_	
17-45	3205-3215	associated	_	
17-46	3216-3220	with	_	
17-47	3221-3224	the	_	
17-48	3225-3231	lowest	_	
17-49	3232-3235	DBH	_	
17-50	3236-3242	plasma	_	
17-51	3243-3251	activity	_	
17-52	3251-3252	,	_	
17-53	3253-3261	followed	_	
17-54	3262-3264	by	_	
17-55	3265-3267	CT	_	
17-56	3268-3281	demonstrating	_	
17-57	3282-3294	intermediary	_	
17-58	3295-3303	activity	_	
17-59	3303-3304	,	_	
17-60	3305-3308	and	_	
17-61	3309-3311	CC	_	
17-62	3312-3319	showing	_	
17-63	3320-3323	the	_	
17-64	3324-3332	greatest	_	
17-65	3333-3339	levels	_	
17-66	3340-3342	of	_	
17-67	3343-3352	enzymatic	_	
17-68	3353-3361	function	_	
17-69	3361-3362	.	_	

#Text=These genotypes are further associated with alterations in emotional/motivational processing; for example, T-carriers demonstrate diminished empathic ability relative to CC genotypes.
18-1	3363-3368	These	_	
18-2	3369-3378	genotypes	_	
18-3	3379-3382	are	_	
18-4	3383-3390	further	_	
18-5	3391-3401	associated	_	
18-6	3402-3406	with	_	
18-7	3407-3418	alterations	_	
18-8	3419-3421	in	_	
18-9	3422-3431	emotional	_	
18-10	3431-3432	/	_	
18-11	3432-3444	motivational	_	
18-12	3445-3455	processing	_	
18-13	3455-3456	;	_	
18-14	3457-3460	for	_	
18-15	3461-3468	example	_	
18-16	3468-3469	,	_	
18-17	3470-3480	T-carriers	_	
18-18	3481-3492	demonstrate	_	
18-19	3493-3503	diminished	_	
18-20	3504-3512	empathic	_	
18-21	3513-3520	ability	_	
18-22	3521-3529	relative	_	
18-23	3530-3532	to	_	
18-24	3533-3535	CC	_	
18-25	3536-3545	genotypes	_	
18-26	3545-3546	.	_	

#Text=The TT genotype (relative to CC or CT) is also associated with higher neuroticism and novelty seeking but lower conscientiousness, suggestive of an impulsive personality style.
19-1	3547-3550	The	_	
19-2	3551-3553	TT	_	
19-3	3554-3562	genotype	_	
19-4	3563-3564	(	_	
19-5	3564-3572	relative	_	
19-6	3573-3575	to	_	
19-7	3576-3578	CC	_	
19-8	3579-3581	or	_	
19-9	3582-3584	CT	_	
19-10	3584-3585	)	_	
19-11	3586-3588	is	_	
19-12	3589-3593	also	_	
19-13	3594-3604	associated	_	
19-14	3605-3609	with	_	
19-15	3610-3616	higher	_	
19-16	3617-3628	neuroticism	_	
19-17	3629-3632	and	_	
19-18	3633-3640	novelty	_	
19-19	3641-3648	seeking	_	
19-20	3649-3652	but	_	
19-21	3653-3658	lower	_	
19-22	3659-3676	conscientiousness	_	
19-23	3676-3677	,	_	
19-24	3678-3688	suggestive	_	
19-25	3689-3691	of	_	
19-26	3692-3694	an	_	
19-27	3695-3704	impulsive	_	
19-28	3705-3716	personality	_	
19-29	3717-3722	style	_	
19-30	3722-3723	.	_	

#Text=The TT genotype is also associated with increased severity of heroin use and poorer cocaine treatment outcomes.
20-1	3724-3727	The	_	
20-2	3728-3730	TT	_	
20-3	3731-3739	genotype	_	
20-4	3740-3742	is	_	
20-5	3743-3747	also	_	
20-6	3748-3758	associated	_	
20-7	3759-3763	with	_	
20-8	3764-3773	increased	_	
20-9	3774-3782	severity	_	
20-10	3783-3785	of	_	
20-11	3786-3792	heroin	_	
20-12	3793-3796	use	_	
20-13	3797-3800	and	_	
20-14	3801-3807	poorer	_	
20-15	3808-3815	cocaine	_	
20-16	3816-3825	treatment	_	
20-17	3826-3834	outcomes	_	
20-18	3834-3835	.	_	

#Text=Moreover, drugs affecting DBH activity, such as disulfiram, demonstrate promise in treatment of substance and non-substance addictions.
21-1	3836-3844	Moreover	_	
21-2	3844-3845	,	_	
21-3	3846-3851	drugs	_	
21-4	3852-3861	affecting	_	
21-5	3862-3865	DBH	_	
21-6	3866-3874	activity	_	
21-7	3874-3875	,	_	
21-8	3876-3880	such	_	
21-9	3881-3883	as	_	
21-10	3884-3894	disulfiram	_	
21-11	3894-3895	,	_	
21-12	3896-3907	demonstrate	_	
21-13	3908-3915	promise	_	
21-14	3916-3918	in	_	
21-15	3919-3928	treatment	_	
21-16	3929-3931	of	_	
21-17	3932-3941	substance	_	
21-18	3942-3945	and	_	
21-19	3946-3959	non-substance	_	
21-20	3960-3970	addictions	_	
21-21	3970-3971	.	_	

#Text=The current study used functional magnetic resonance imaging (fMRI) to investigate effects of DBH polymorphisms on emotional/motivational processing.
22-1	3972-3975	The	_	
22-2	3976-3983	current	_	
22-3	3984-3989	study	_	
22-4	3990-3994	used	_	
22-5	3995-4005	functional	_	
22-6	4006-4014	magnetic	_	
22-7	4015-4024	resonance	_	
22-8	4025-4032	imaging	_	
22-9	4033-4034	(	_	
22-10	4034-4038	fMRI	_	
22-11	4038-4039	)	_	
22-12	4040-4042	to	_	
22-13	4043-4054	investigate	_	
22-14	4055-4062	effects	_	
22-15	4063-4065	of	_	
22-16	4066-4069	DBH	_	
22-17	4070-4083	polymorphisms	_	
22-18	4084-4086	on	_	
22-19	4087-4096	emotional	_	
22-20	4096-4097	/	_	
22-21	4097-4109	motivational	_	
22-22	4110-4120	processing	_	
22-23	4120-4121	.	_	

#Text=Given the infrequency of TT homozygotes and prior studies highlighting the clinical relevance of T-carrier status, we investigated T-carriers and those with CC genotypes.
23-1	4122-4127	Given	_	
23-2	4128-4131	the	_	
23-3	4132-4143	infrequency	_	
23-4	4144-4146	of	_	
23-5	4147-4149	TT	_	
23-6	4150-4161	homozygotes	_	
23-7	4162-4165	and	_	
23-8	4166-4171	prior	_	
23-9	4172-4179	studies	_	
23-10	4180-4192	highlighting	_	
23-11	4193-4196	the	_	
23-12	4197-4205	clinical	_	
23-13	4206-4215	relevance	_	
23-14	4216-4218	of	_	
23-15	4219-4228	T-carrier	_	
23-16	4229-4235	status	_	
23-17	4235-4236	,	_	
23-18	4237-4239	we	_	
23-19	4240-4252	investigated	_	
23-20	4253-4263	T-carriers	_	
23-21	4264-4267	and	_	
23-22	4268-4273	those	_	
23-23	4274-4278	with	_	
23-24	4279-4281	CC	_	
23-25	4282-4291	genotypes	_	
23-26	4291-4292	.	_	

#Text=Both PG and healthy comparison (HC) participants were scanned while watching videos designed to elicit sad feelings, gambling urges, or cocaine cravings.
24-1	4293-4297	Both	_	
24-2	4298-4300	PG	_	
24-3	4301-4304	and	_	
24-4	4305-4312	healthy	_	
24-5	4313-4323	comparison	_	
24-6	4324-4325	(	_	
24-7	4325-4327	HC	_	
24-8	4327-4328	)	_	
24-9	4329-4341	participants	_	
24-10	4342-4346	were	_	
24-11	4347-4354	scanned	_	
24-12	4355-4360	while	_	
24-13	4361-4369	watching	_	
24-14	4370-4376	videos	_	
24-15	4377-4385	designed	_	
24-16	4386-4388	to	_	
24-17	4389-4395	elicit	_	
24-18	4396-4399	sad	_	
24-19	4400-4408	feelings	_	
24-20	4408-4409	,	_	
24-21	4410-4418	gambling	_	
24-22	4419-4424	urges	_	
24-23	4424-4425	,	_	
24-24	4426-4428	or	_	
24-25	4429-4436	cocaine	_	
24-26	4437-4445	cravings	_	
24-27	4445-4446	.	_	

#Text=Sad, gambling, and cocaine videos were studied with the following rationale and goals.
25-1	4447-4450	Sad	_	
25-2	4450-4451	,	_	
25-3	4452-4460	gambling	_	
25-4	4460-4461	,	_	
25-5	4462-4465	and	_	
25-6	4466-4473	cocaine	_	
25-7	4474-4480	videos	_	
25-8	4481-4485	were	_	
25-9	4486-4493	studied	_	
25-10	4494-4498	with	_	
25-11	4499-4502	the	_	
25-12	4503-4512	following	_	
25-13	4513-4522	rationale	_	
25-14	4523-4526	and	_	
25-15	4527-4532	goals	_	
25-16	4532-4533	.	_	

#Text=Experiential sadness has been linked to changes in dopaminergic and noradrenergic function, and the DBH polymorphism is associated with empathic responses.
26-1	4534-4546	Experiential	_	
26-2	4547-4554	sadness	_	
26-3	4555-4558	has	_	
26-4	4559-4563	been	_	
26-5	4564-4570	linked	_	
26-6	4571-4573	to	_	
26-7	4574-4581	changes	_	
26-8	4582-4584	in	_	
26-9	4585-4597	dopaminergic	_	
26-10	4598-4601	and	_	
26-11	4602-4615	noradrenergic	_	
26-12	4616-4624	function	_	
26-13	4624-4625	,	_	
26-14	4626-4629	and	_	
26-15	4630-4633	the	_	
26-16	4634-4637	DBH	_	
26-17	4638-4650	polymorphism	_	
26-18	4651-4653	is	_	
26-19	4654-4664	associated	_	
26-20	4665-4669	with	_	
26-21	4670-4678	empathic	_	
26-22	4679-4688	responses	_	
26-23	4688-4689	.	_	

#Text=As some investigators have considered PG within an affective framework, PG has been associated with negative affective states and mood disorders and prior findings using the same task have identified alterations in the neural correlates of sad states in PG subjects, sad videos were included in this study.
27-1	4690-4692	As	_	
27-2	4693-4697	some	_	
27-3	4698-4711	investigators	_	
27-4	4712-4716	have	_	
27-5	4717-4727	considered	_	
27-6	4728-4730	PG	_	
27-7	4731-4737	within	_	
27-8	4738-4740	an	_	
27-9	4741-4750	affective	_	
27-10	4751-4760	framework	_	
27-11	4760-4761	,	_	
27-12	4762-4764	PG	_	
27-13	4765-4768	has	_	
27-14	4769-4773	been	_	
27-15	4774-4784	associated	_	
27-16	4785-4789	with	_	
27-17	4790-4798	negative	_	
27-18	4799-4808	affective	_	
27-19	4809-4815	states	_	
27-20	4816-4819	and	_	
27-21	4820-4824	mood	_	
27-22	4825-4834	disorders	_	
27-23	4835-4838	and	_	
27-24	4839-4844	prior	_	
27-25	4845-4853	findings	_	
27-26	4854-4859	using	_	
27-27	4860-4863	the	_	
27-28	4864-4868	same	_	
27-29	4869-4873	task	_	
27-30	4874-4878	have	_	
27-31	4879-4889	identified	_	
27-32	4890-4901	alterations	_	
27-33	4902-4904	in	_	
27-34	4905-4908	the	_	
27-35	4909-4915	neural	_	
27-36	4916-4926	correlates	_	
27-37	4927-4929	of	_	
27-38	4930-4933	sad	_	
27-39	4934-4940	states	_	
27-40	4941-4943	in	_	
27-41	4944-4946	PG	_	
27-42	4947-4955	subjects	_	
27-43	4955-4956	,	_	
27-44	4957-4960	sad	_	
27-45	4961-4967	videos	_	
27-46	4968-4972	were	_	
27-47	4973-4981	included	_	
27-48	4982-4984	in	_	
27-49	4985-4989	this	_	
27-50	4990-4995	study	_	
27-51	4995-4996	.	_	

#Text=Finally, the cocaine videos served as an active control condition to identify specificity of neural responses to the gambling (a main focus of the study) and sad videos; previous evidence demonstrates that the cocaine videos elicit emotional responses in people with and without cocaine dependence (CD).
28-1	4997-5004	Finally	_	
28-2	5004-5005	,	_	
28-3	5006-5009	the	_	
28-4	5010-5017	cocaine	_	
28-5	5018-5024	videos	_	
28-6	5025-5031	served	_	
28-7	5032-5034	as	_	
28-8	5035-5037	an	_	
28-9	5038-5044	active	_	
28-10	5045-5052	control	_	
28-11	5053-5062	condition	_	
28-12	5063-5065	to	_	
28-13	5066-5074	identify	_	
28-14	5075-5086	specificity	_	
28-15	5087-5089	of	_	
28-16	5090-5096	neural	_	
28-17	5097-5106	responses	_	
28-18	5107-5109	to	_	
28-19	5110-5113	the	_	
28-20	5114-5122	gambling	_	
28-21	5123-5124	(	_	
28-22	5124-5125	a	_	
28-23	5126-5130	main	_	
28-24	5131-5136	focus	_	
28-25	5137-5139	of	_	
28-26	5140-5143	the	_	
28-27	5144-5149	study	_	
28-28	5149-5150	)	_	
28-29	5151-5154	and	_	
28-30	5155-5158	sad	_	
28-31	5159-5165	videos	_	
28-32	5165-5166	;	_	
28-33	5167-5175	previous	_	
28-34	5176-5184	evidence	_	
28-35	5185-5197	demonstrates	_	
28-36	5198-5202	that	_	
28-37	5203-5206	the	_	
28-38	5207-5214	cocaine	_	
28-39	5215-5221	videos	_	
28-40	5222-5228	elicit	_	
28-41	5229-5238	emotional	_	
28-42	5239-5248	responses	_	
28-43	5249-5251	in	_	
28-44	5252-5258	people	_	
28-45	5259-5263	with	_	
28-46	5264-5267	and	_	
28-47	5268-5275	without	_	
28-48	5276-5283	cocaine	_	
28-49	5284-5294	dependence	_	
28-50	5295-5296	(	_	
28-51	5296-5298	CD	_	
28-52	5298-5299	)	_	
28-53	5299-5300	.	_	

#Text=Recently, we reported on data from this sample.
29-1	5301-5309	Recently	_	
29-2	5309-5310	,	_	
29-3	5311-5313	we	_	
29-4	5314-5322	reported	_	
29-5	5323-5325	on	_	
29-6	5326-5330	data	_	
29-7	5331-5335	from	_	
29-8	5336-5340	this	_	
29-9	5341-5347	sample	_	
29-10	5347-5348	.	_	

#Text=In this study, we restricted the sample to EA subjects given the genetic focus and thus focused on PG and HC to have sufficient samples for each group.
30-1	5349-5351	In	_	
30-2	5352-5356	this	_	
30-3	5357-5362	study	_	
30-4	5362-5363	,	_	
30-5	5364-5366	we	_	
30-6	5367-5377	restricted	_	
30-7	5378-5381	the	_	
30-8	5382-5388	sample	_	
30-9	5389-5391	to	_	
30-10	5392-5394	EA	_	
30-11	5395-5403	subjects	_	
30-12	5404-5409	given	_	
30-13	5410-5413	the	_	
30-14	5414-5421	genetic	_	
30-15	5422-5427	focus	_	
30-16	5428-5431	and	_	
30-17	5432-5436	thus	_	
30-18	5437-5444	focused	_	
30-19	5445-5447	on	_	
30-20	5448-5450	PG	_	
30-21	5451-5454	and	_	
30-22	5455-5457	HC	_	
30-23	5458-5460	to	_	
30-24	5461-5465	have	_	
30-25	5466-5476	sufficient	_	
30-26	5477-5484	samples	_	
30-27	5485-5488	for	_	
30-28	5489-5493	each	_	
30-29	5494-5499	group	_	
30-30	5499-5500	.	_	

#Text=We also focused on sustained emotional/motivational responses as we have done previously.
31-1	5501-5503	We	_	
31-2	5504-5508	also	_	
31-3	5509-5516	focused	_	
31-4	5517-5519	on	_	
31-5	5520-5529	sustained	_	
31-6	5530-5539	emotional	_	
31-7	5539-5540	/	_	
31-8	5540-5552	motivational	_	
31-9	5553-5562	responses	_	
31-10	5563-5565	as	_	
31-11	5566-5568	we	_	
31-12	5569-5573	have	_	
31-13	5574-5578	done	_	
31-14	5579-5589	previously	_	
31-15	5589-5590	.	_	

#Text=We hypothesized observing main effects of DBH genotype on corticolimbic activations and interactions with condition and DBH genotype.
32-1	5591-5593	We	_	
32-2	5594-5606	hypothesized	_	
32-3	5607-5616	observing	_	
32-4	5617-5621	main	_	
32-5	5622-5629	effects	_	
32-6	5630-5632	of	_	
32-7	5633-5636	DBH	_	
32-8	5637-5645	genotype	_	
32-9	5646-5648	on	_	
32-10	5649-5662	corticolimbic	_	
32-11	5663-5674	activations	_	
32-12	5675-5678	and	_	
32-13	5679-5691	interactions	_	
32-14	5692-5696	with	_	
32-15	5697-5706	condition	_	
32-16	5707-5710	and	_	
32-17	5711-5714	DBH	_	
32-18	5715-5723	genotype	_	
32-19	5723-5724	.	_	

#Text=For DBH-genotype-by-condition interaction effects, we hypothesized that T-carriers would report less sadness to sad videos, in line with reports of reduced empathic responses in these individuals; further, we hypothesized that the neural expression of this effect would be reflected in diminished corticostriatal recruitment in T-carriers relative to the CC group during sad videos.
33-1	5725-5728	For	_	
33-2	5729-5754	DBH-genotype-by-condition	_	
33-3	5755-5766	interaction	_	
33-4	5767-5774	effects	_	
33-5	5774-5775	,	_	
33-6	5776-5778	we	_	
33-7	5779-5791	hypothesized	_	
33-8	5792-5796	that	_	
33-9	5797-5807	T-carriers	_	
33-10	5808-5813	would	_	
33-11	5814-5820	report	_	
33-12	5821-5825	less	_	
33-13	5826-5833	sadness	_	
33-14	5834-5836	to	_	
33-15	5837-5840	sad	_	
33-16	5841-5847	videos	_	
33-17	5847-5848	,	_	
33-18	5849-5851	in	_	
33-19	5852-5856	line	_	
33-20	5857-5861	with	_	
33-21	5862-5869	reports	_	
33-22	5870-5872	of	_	
33-23	5873-5880	reduced	_	
33-24	5881-5889	empathic	_	
33-25	5890-5899	responses	_	
33-26	5900-5902	in	_	
33-27	5903-5908	these	_	
33-28	5909-5920	individuals	_	
33-29	5920-5921	;	_	
33-30	5922-5929	further	_	
33-31	5929-5930	,	_	
33-32	5931-5933	we	_	
33-33	5934-5946	hypothesized	_	
33-34	5947-5951	that	_	
33-35	5952-5955	the	_	
33-36	5956-5962	neural	_	
33-37	5963-5973	expression	_	
33-38	5974-5976	of	_	
33-39	5977-5981	this	_	
33-40	5982-5988	effect	_	
33-41	5989-5994	would	_	
33-42	5995-5997	be	_	
33-43	5998-6007	reflected	_	
33-44	6008-6010	in	_	
33-45	6011-6021	diminished	_	
33-46	6022-6037	corticostriatal	_	
33-47	6038-6049	recruitment	_	
33-48	6050-6052	in	_	
33-49	6053-6063	T-carriers	_	
33-50	6064-6072	relative	_	
33-51	6073-6075	to	_	
33-52	6076-6079	the	_	
33-53	6080-6082	CC	_	
33-54	6083-6088	group	_	
33-55	6089-6095	during	_	
33-56	6096-6099	sad	_	
33-57	6100-6106	videos	_	
33-58	6106-6107	.	_	

#Text=Based on prior findings, we also expected group-by-condition interaction effects involving diminished ventromedial prefrontal cortex (vmPFC) and ventral striatum (VS) activity in the PG group during gambling videos.
34-1	6108-6113	Based	_	
34-2	6114-6116	on	_	
34-3	6117-6122	prior	_	
34-4	6123-6131	findings	_	
34-5	6131-6132	,	_	
34-6	6133-6135	we	_	
34-7	6136-6140	also	_	
34-8	6141-6149	expected	_	
34-9	6150-6168	group-by-condition	_	
34-10	6169-6180	interaction	_	
34-11	6181-6188	effects	_	
34-12	6189-6198	involving	_	
34-13	6199-6209	diminished	_	
34-14	6210-6222	ventromedial	_	
34-15	6223-6233	prefrontal	_	
34-16	6234-6240	cortex	_	
34-17	6241-6242	(	_	
34-18	6242-6247	vmPFC	_	
34-19	6247-6248	)	_	
34-20	6249-6252	and	_	
34-21	6253-6260	ventral	_	
34-22	6261-6269	striatum	_	
34-23	6270-6271	(	_	
34-24	6271-6273	VS	_	
34-25	6273-6274	)	_	
34-26	6275-6283	activity	_	
34-27	6284-6286	in	_	
34-28	6287-6290	the	_	
34-29	6291-6293	PG	_	
34-30	6294-6299	group	_	
34-31	6300-6306	during	_	
34-32	6307-6315	gambling	_	
34-33	6316-6322	videos	_	
34-34	6322-6323	.	_	

#Text=Methods and Materials
#Text=Participants
#Text=EA subjects, who provided fMRI and genetic data, were included from a larger sample of multi-ethnic individuals, whose data are reported elsewhere.
35-1	6324-6331	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
35-2	6332-6335	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
35-3	6336-6345	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
35-4	6346-6358	Participants	_	
35-5	6359-6361	EA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-6	6362-6370	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-7	6370-6371	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-8	6372-6375	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-9	6376-6384	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-10	6385-6389	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
35-11	6390-6393	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-12	6394-6401	genetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-13	6402-6406	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-14	6406-6407	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-15	6408-6412	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-16	6413-6421	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-17	6422-6426	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-18	6427-6428	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-19	6429-6435	larger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-20	6436-6442	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-21	6443-6445	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-22	6446-6458	multi-ethnic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-23	6459-6470	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-24	6470-6471	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-25	6472-6477	whose	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-26	6478-6482	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-27	6483-6486	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-28	6487-6495	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-29	6496-6505	elsewhere	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
35-30	6505-6506	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=To avoid potential genetic population stratification, only EA individuals were included: 18 individuals meeting PG criteria and 25 HC subjects.
36-1	6507-6509	To	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-2	6510-6515	avoid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-3	6516-6525	potential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-4	6526-6533	genetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-5	6534-6544	population	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-6	6545-6559	stratification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-7	6559-6560	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-8	6561-6565	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-9	6566-6568	EA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-10	6569-6580	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-11	6581-6585	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-12	6586-6594	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-13	6594-6595	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-14	6596-6598	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-15	6599-6610	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-16	6611-6618	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-17	6619-6621	PG	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling[8]	
36-18	6622-6630	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-19	6631-6634	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-20	6635-6637	25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-21	6638-6640	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
36-22	6641-6649	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-23	6649-6650	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=All subjects were native English speakers with no history of neurologic disorders or injury.
37-1	6651-6654	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-2	6655-6663	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-3	6664-6668	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-4	6669-6675	native	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-5	6676-6683	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-6	6684-6692	speakers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-7	6693-6697	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-8	6698-6700	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-9	6701-6708	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-10	6709-6711	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-11	6712-6722	neurologic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-12	6723-6732	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-13	6733-6735	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-14	6736-6742	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-15	6742-6743	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=A structured clinical interview determined that PG subjects met DSM-IV criteria for PG as the primary diagnosis and that HC subjects had no axis-I disorders except possible nicotine dependence (ND; one ND subject in the HC group).
38-1	6744-6745	A	_	
38-2	6746-6756	structured	_	
38-3	6757-6765	clinical	_	
38-4	6766-6775	interview	_	
38-5	6776-6786	determined	_	
38-6	6787-6791	that	_	
38-7	6792-6794	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
38-8	6795-6803	subjects	_	
38-9	6804-6807	met	_	
38-10	6808-6814	DSM-IV	_	
38-11	6815-6823	criteria	_	
38-12	6824-6827	for	_	
38-13	6828-6830	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
38-14	6831-6833	as	_	
38-15	6834-6837	the	_	
38-16	6838-6845	primary	_	
38-17	6846-6855	diagnosis	_	
38-18	6856-6859	and	_	
38-19	6860-6864	that	_	
38-20	6865-6867	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
38-21	6868-6876	subjects	_	
38-22	6877-6880	had	_	
38-23	6881-6883	no	_	
38-24	6884-6890	axis-I	_	
38-25	6891-6900	disorders	_	
38-26	6901-6907	except	_	
38-27	6908-6916	possible	_	
38-28	6917-6925	nicotine	_	
38-29	6926-6936	dependence	_	
38-30	6937-6938	(	_	
38-31	6938-6940	ND	_	
38-32	6940-6941	;	_	
38-33	6942-6945	one	_	
38-34	6946-6948	ND	_	
38-35	6949-6956	subject	_	
38-36	6957-6959	in	_	
38-37	6960-6963	the	_	
38-38	6964-6966	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
38-39	6967-6972	group	_	
38-40	6972-6973	)	_	
38-41	6973-6974	.	_	

#Text=Detailed participant characteristics including PG comorbidity with other psychiatric disorders are described in Supplementary Material I, with demographic information provided in Table 1 (including information on use of the Barratt impulsiveness scale (BIS-11) and South Oaks Gambling Screen (SOGS) and Supplementary Material II).
39-1	6975-6983	Detailed	_	
39-2	6984-6995	participant	_	
39-3	6996-7011	characteristics	_	
39-4	7012-7021	including	_	
39-5	7022-7024	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
39-6	7025-7036	comorbidity	_	
39-7	7037-7041	with	_	
39-8	7042-7047	other	_	
39-9	7048-7059	psychiatric	_	
39-10	7060-7069	disorders	_	
39-11	7070-7073	are	_	
39-12	7074-7083	described	_	
39-13	7084-7086	in	_	
39-14	7087-7100	Supplementary	_	
39-15	7101-7109	Material	_	
39-16	7110-7111	I	_	
39-17	7111-7112	,	_	
39-18	7113-7117	with	_	
39-19	7118-7129	demographic	_	
39-20	7130-7141	information	_	
39-21	7142-7150	provided	_	
39-22	7151-7153	in	_	
39-23	7154-7159	Table	_	
39-24	7159-7160	 	_	
39-25	7160-7161	1	_	
39-26	7162-7163	(	_	
39-27	7163-7172	including	_	
39-28	7173-7184	information	_	
39-29	7185-7187	on	_	
39-30	7188-7191	use	_	
39-31	7192-7194	of	_	
39-32	7195-7198	the	_	
39-33	7199-7206	Barratt	_	
39-34	7207-7220	impulsiveness	_	
39-35	7221-7226	scale	_	
39-36	7227-7228	(	_	
39-37	7228-7231	BIS	_	
39-38	7231-7232	-	_	
39-39	7232-7234	11	_	
39-40	7234-7235	)	_	
39-41	7236-7239	and	_	
39-42	7240-7245	South	_	
39-43	7246-7250	Oaks	_	
39-44	7251-7259	Gambling	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
39-45	7260-7266	Screen	_	
39-46	7267-7268	(	_	
39-47	7268-7272	SOGS	_	
39-48	7272-7273	)	_	
39-49	7274-7277	and	_	
39-50	7278-7291	Supplementary	_	
39-51	7292-7300	Material	_	
39-52	7301-7303	II	_	
39-53	7303-7304	)	_	
39-54	7304-7305	.	_	

#Text=Subject characteristics
#Text=(A)\tPG\tHC\tp-value\t\t \tSample size\t18\t25\t\t\t \tSex, male (%)\t13 (72.2%)\t15 (60.0%)\t.613\t\t \tAge (mean ± SD)\t36.6 ± 12.0\t30.0 ± 11.4\t.079\t\t \tEducation years\t13.8 ± 1.8\t14.6 ± 2.2\t.242\t\t \tFTND\t1.7 ± 2.8\t.1 ± .6\t.038*\t\t \tSouth Oaks Gambling Screen Score\t12.5 ± 3.5\t.08 ± .3\t2.1 × 10−11*\t\t \tBIS-11 total score\t71.7 ± 13.6\t54.6 ± 8.4\t7.5 × 10−5*\t\t \t\t \t\tCC\tT-carrier\t\t\t \t(B) DBH genotype\tCount (%)\tCount (%)\tTotal\tp-value\t \t\t \tPG\t9 (50.0)\t9 (50.0)\t18\t.937\t \tHC\t11 (44.0)\t14 (56.0)\t25\t\t \tMale\t13 (46.4)\t15 (53.6)\t28\t∼1\t \tFemale\t7 (46.7)\t8 (53.3)\t15\t\t \tBIS-11 total score\t58.3 ± 9.6\t65.3 ± 16.2\t\t.093\t \tSad video–Emotional intensity\t6.88 ± 1.7\t5.52 ± 2.3\t\t.035*\t \t
#Text=Note.
40-1	7306-7313	Subject	_	
40-2	7314-7329	characteristics	_	
40-3	7330-7331	(	_	
40-4	7331-7332	A	_	
40-5	7332-7333	)	_	
40-6	7334-7336	PG	_	
40-7	7337-7339	HC	_	
40-8	7340-7347	p-value	_	
40-9	7351-7357	Sample	_	
40-10	7358-7362	size	_	
40-11	7363-7365	18	_	
40-12	7366-7368	25	_	
40-13	7373-7376	Sex	_	
40-14	7376-7377	,	_	
40-15	7378-7382	male	_	
40-16	7383-7384	(	_	
40-17	7384-7385	%	_	
40-18	7385-7386	)	_	
40-19	7387-7389	13	_	
40-20	7390-7391	(	_	
40-21	7391-7396	72.2%	_	
40-22	7396-7397	)	_	
40-23	7398-7400	15	_	
40-24	7401-7402	(	_	
40-25	7402-7407	60.0%	_	
40-26	7407-7408	)	_	
40-27	7409-7413	.613	_	
40-28	7417-7420	Age	_	
40-29	7421-7422	(	_	
40-30	7422-7426	mean	_	
40-31	7427-7428	±	_	
40-32	7429-7431	SD	_	
40-33	7431-7432	)	_	
40-34	7433-7437	36.6	_	
40-35	7438-7439	±	_	
40-36	7440-7444	12.0	_	
40-37	7445-7449	30.0	_	
40-38	7450-7451	±	_	
40-39	7452-7456	11.4	_	
40-40	7457-7461	.079	_	
40-41	7465-7474	Education	_	
40-42	7475-7480	years	_	
40-43	7481-7485	13.8	_	
40-44	7486-7487	±	_	
40-45	7488-7491	1.8	_	
40-46	7492-7496	14.6	_	
40-47	7497-7498	±	_	
40-48	7499-7502	2.2	_	
40-49	7503-7507	.242	_	
40-50	7511-7515	FTND	_	
40-51	7516-7519	1.7	_	
40-52	7520-7521	±	_	
40-53	7522-7525	2.8	_	
40-54	7526-7528	.1	_	
40-55	7529-7530	±	_	
40-56	7531-7533	.6	_	
40-57	7534-7538	.038	_	
40-58	7538-7539	*	_	
40-59	7543-7548	South	_	
40-60	7549-7553	Oaks	_	
40-61	7554-7562	Gambling	_	
40-62	7563-7569	Screen	_	
40-63	7570-7575	Score	_	
40-64	7576-7580	12.5	_	
40-65	7581-7582	±	_	
40-66	7583-7586	3.5	_	
40-67	7587-7590	.08	_	
40-68	7591-7592	±	_	
40-69	7593-7595	.3	_	
40-70	7596-7599	2.1	_	
40-71	7600-7601	×	_	
40-72	7602-7604	10	_	
40-73	7604-7605	−	_	
40-74	7605-7607	11	_	
40-75	7607-7608	*	_	
40-76	7612-7615	BIS	_	
40-77	7615-7616	-	_	
40-78	7616-7618	11	_	
40-79	7619-7624	total	_	
40-80	7625-7630	score	_	
40-81	7631-7635	71.7	_	
40-82	7636-7637	±	_	
40-83	7638-7642	13.6	_	
40-84	7643-7647	54.6	_	
40-85	7648-7649	±	_	
40-86	7650-7653	8.4	_	
40-87	7654-7657	7.5	_	
40-88	7658-7659	×	_	
40-89	7660-7662	10	_	
40-90	7662-7663	−	_	
40-91	7663-7664	5	_	
40-92	7664-7665	*	_	
40-93	7673-7675	CC	_	
40-94	7676-7685	T-carrier	_	
40-95	7690-7691	(	_	
40-96	7691-7692	B	_	
40-97	7692-7693	)	_	
40-98	7694-7697	DBH	_	
40-99	7698-7706	genotype	_	
40-100	7707-7712	Count	_	
40-101	7713-7714	(	_	
40-102	7714-7715	%	_	
40-103	7715-7716	)	_	
40-104	7717-7722	Count	_	
40-105	7723-7724	(	_	
40-106	7724-7725	%	_	
40-107	7725-7726	)	_	
40-108	7727-7732	Total	_	
40-109	7733-7740	p-value	_	
40-110	7746-7748	PG	_	
40-111	7749-7750	9	_	
40-112	7751-7752	(	_	
40-113	7752-7756	50.0	_	
40-114	7756-7757	)	_	
40-115	7758-7759	9	_	
40-116	7760-7761	(	_	
40-117	7761-7765	50.0	_	
40-118	7765-7766	)	_	
40-119	7767-7769	18	_	
40-120	7770-7774	.937	_	
40-121	7777-7779	HC	_	
40-122	7780-7782	11	_	
40-123	7783-7784	(	_	
40-124	7784-7788	44.0	_	
40-125	7788-7789	)	_	
40-126	7790-7792	14	_	
40-127	7793-7794	(	_	
40-128	7794-7798	56.0	_	
40-129	7798-7799	)	_	
40-130	7800-7802	25	_	
40-131	7806-7810	Male	_	
40-132	7811-7813	13	_	
40-133	7814-7815	(	_	
40-134	7815-7819	46.4	_	
40-135	7819-7820	)	_	
40-136	7821-7823	15	_	
40-137	7824-7825	(	_	
40-138	7825-7829	53.6	_	
40-139	7829-7830	)	_	
40-140	7831-7833	28	_	
40-141	7834-7835	∼	_	
40-142	7835-7836	1	_	
40-143	7839-7845	Female	_	
40-144	7846-7847	7	_	
40-145	7848-7849	(	_	
40-146	7849-7853	46.7	_	
40-147	7853-7854	)	_	
40-148	7855-7856	8	_	
40-149	7857-7858	(	_	
40-150	7858-7862	53.3	_	
40-151	7862-7863	)	_	
40-152	7864-7866	15	_	
40-153	7870-7873	BIS	_	
40-154	7873-7874	-	_	
40-155	7874-7876	11	_	
40-156	7877-7882	total	_	
40-157	7883-7888	score	_	
40-158	7889-7893	58.3	_	
40-159	7894-7895	±	_	
40-160	7896-7899	9.6	_	
40-161	7900-7904	65.3	_	
40-162	7905-7906	±	_	
40-163	7907-7911	16.2	_	
40-164	7913-7917	.093	_	
40-165	7920-7923	Sad	_	
40-166	7924-7939	video–Emotional	_	
40-167	7940-7949	intensity	_	
40-168	7950-7954	6.88	_	
40-169	7955-7956	±	_	
40-170	7957-7960	1.7	_	
40-171	7961-7965	5.52	_	
40-172	7966-7967	±	_	
40-173	7968-7971	2.3	_	
40-174	7973-7977	.035	_	
40-175	7977-7978	*	_	
40-176	7982-7986	Note	_	
40-177	7986-7987	.	_	

#Text=BIS-11, Barratt impulsiveness scale, version 11; FTND, Fagerstrom test for nicotine dependence; PG, pathological gambling; HC, healthy comparison.
#Text=p < .05.
41-1	7988-7991	BIS	_	
41-2	7991-7992	-	_	
41-3	7992-7994	11	_	
41-4	7994-7995	,	_	
41-5	7996-8003	Barratt	_	
41-6	8004-8017	impulsiveness	_	
41-7	8018-8023	scale	_	
41-8	8023-8024	,	_	
41-9	8025-8032	version	_	
41-10	8033-8035	11	_	
41-11	8035-8036	;	_	
41-12	8037-8041	FTND	_	
41-13	8041-8042	,	_	
41-14	8043-8053	Fagerstrom	_	
41-15	8054-8058	test	_	
41-16	8059-8062	for	_	
41-17	8063-8071	nicotine	_	
41-18	8072-8082	dependence	_	
41-19	8082-8083	;	_	
41-20	8084-8086	PG	_	
41-21	8086-8087	,	_	
41-22	8088-8100	pathological	_	
41-23	8101-8109	gambling	_	
41-24	8109-8110	;	_	
41-25	8111-8113	HC	_	
41-26	8113-8114	,	_	
41-27	8115-8122	healthy	_	
41-28	8123-8133	comparison	_	
41-29	8133-8134	.	_	
41-30	8135-8136	p	_	
41-31	8137-8138	<	_	
41-32	8139-8142	.05	_	
41-33	8142-8143	.	_	

#Text=Genotyping
#Text=DNA was extracted from whole blood.
42-1	8144-8154	Genotyping	_	
42-2	8155-8158	DNA	_	
42-3	8159-8162	was	_	
42-4	8163-8172	extracted	_	
42-5	8173-8177	from	_	
42-6	8178-8183	whole	_	
42-7	8184-8189	blood	_	
42-8	8189-8190	.	_	

#Text=The SNP rs1611115 was genotyped for all subjects by a fluorogenic 5’ nuclease assay of the TaqMan method using the ABI PRISM 7900 Sequence Detection System (ABI, Foster City, CA).
43-1	8191-8194	The	_	
43-2	8195-8198	SNP	_	
43-3	8199-8208	rs1611115	_	
43-4	8209-8212	was	_	
43-5	8213-8222	genotyped	_	
43-6	8223-8226	for	_	
43-7	8227-8230	all	_	
43-8	8231-8239	subjects	_	
43-9	8240-8242	by	_	
43-10	8243-8244	a	_	
43-11	8245-8256	fluorogenic	_	
43-12	8257-8258	5	_	
43-13	8258-8259	’	_	
43-14	8260-8268	nuclease	_	
43-15	8269-8274	assay	_	
43-16	8275-8277	of	_	
43-17	8278-8281	the	_	
43-18	8282-8288	TaqMan	_	
43-19	8289-8295	method	_	
43-20	8296-8301	using	_	
43-21	8302-8305	the	_	
43-22	8306-8309	ABI	_	
43-23	8310-8315	PRISM	_	
43-24	8316-8320	7900	_	
43-25	8321-8329	Sequence	_	
43-26	8330-8339	Detection	_	
43-27	8340-8346	System	_	
43-28	8347-8348	(	_	
43-29	8348-8351	ABI	_	
43-30	8351-8352	,	_	
43-31	8353-8359	Foster	_	
43-32	8360-8364	City	_	
43-33	8364-8365	,	_	
43-34	8366-8368	CA	_	
43-35	8368-8369	)	_	
43-36	8369-8370	.	_	

#Text=No discrepancy was detected between the duplicates for one PG subject, one HC subject, and one control Centre d’Etude du Polymorphisme Humain (representative of the EA population) in the quality control of genotyping procedures.
44-1	8371-8373	No	_	
44-2	8374-8385	discrepancy	_	
44-3	8386-8389	was	_	
44-4	8390-8398	detected	_	
44-5	8399-8406	between	_	
44-6	8407-8410	the	_	
44-7	8411-8421	duplicates	_	
44-8	8422-8425	for	_	
44-9	8426-8429	one	_	
44-10	8430-8432	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
44-11	8433-8440	subject	_	
44-12	8440-8441	,	_	
44-13	8442-8445	one	_	
44-14	8446-8448	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
44-15	8449-8456	subject	_	
44-16	8456-8457	,	_	
44-17	8458-8461	and	_	
44-18	8462-8465	one	_	
44-19	8466-8473	control	_	
44-20	8474-8480	Centre	_	
44-21	8481-8482	d	_	
44-22	8482-8483	’	_	
44-23	8483-8488	Etude	_	
44-24	8489-8491	du	_	
44-25	8492-8505	Polymorphisme	_	
44-26	8506-8512	Humain	_	
44-27	8513-8514	(	_	
44-28	8514-8528	representative	_	
44-29	8529-8531	of	_	
44-30	8532-8535	the	_	
44-31	8536-8538	EA	_	
44-32	8539-8549	population	_	
44-33	8549-8550	)	_	
44-34	8551-8553	in	_	
44-35	8554-8557	the	_	
44-36	8558-8565	quality	_	
44-37	8566-8573	control	_	
44-38	8574-8576	of	_	
44-39	8577-8587	genotyping	_	
44-40	8588-8598	procedures	_	
44-41	8598-8599	.	_	

#Text=Genotypes were in Hardy–Weinberg equilibrium for the PG, HC, and combined PG and HC groups (all p > .05).
45-1	8600-8609	Genotypes	_	
45-2	8610-8614	were	_	
45-3	8615-8617	in	_	
45-4	8618-8632	Hardy–Weinberg	_	
45-5	8633-8644	equilibrium	_	
45-6	8645-8648	for	_	
45-7	8649-8652	the	_	
45-8	8653-8655	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
45-9	8655-8656	,	_	
45-10	8657-8659	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
45-11	8659-8660	,	_	
45-12	8661-8664	and	_	
45-13	8665-8673	combined	_	
45-14	8674-8676	PG	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling	
45-15	8677-8680	and	_	
45-16	8681-8683	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
45-17	8684-8690	groups	_	
45-18	8691-8692	(	_	
45-19	8692-8695	all	_	
45-20	8696-8697	p	_	
45-21	8698-8699	>	_	
45-22	8700-8703	.05	_	
45-23	8703-8704	)	_	
45-24	8704-8705	.	_	

#Text=Experimental task
#Text=Participants viewed six videos in random and counterbalanced order (see Supplementary Material III), including two videos each related to gambling, sad and cocaine scenarios in which actors depict each specific scenario.
46-1	8706-8718	Experimental	_	
46-2	8719-8723	task	_	
46-3	8724-8736	Participants	_	
46-4	8737-8743	viewed	_	
46-5	8744-8747	six	_	
46-6	8748-8754	videos	_	
46-7	8755-8757	in	_	
46-8	8758-8764	random	_	
46-9	8765-8768	and	_	
46-10	8769-8784	counterbalanced	_	
46-11	8785-8790	order	_	
46-12	8791-8792	(	_	
46-13	8792-8795	see	_	
46-14	8796-8809	Supplementary	_	
46-15	8810-8818	Material	_	
46-16	8819-8822	III	_	
46-17	8822-8823	)	_	
46-18	8823-8824	,	_	
46-19	8825-8834	including	_	
46-20	8835-8838	two	_	
46-21	8839-8845	videos	_	
46-22	8846-8850	each	_	
46-23	8851-8858	related	_	
46-24	8859-8861	to	_	
46-25	8862-8870	gambling	_	
46-26	8870-8871	,	_	
46-27	8872-8875	sad	_	
46-28	8876-8879	and	_	
46-29	8880-8887	cocaine	_	
46-30	8888-8897	scenarios	_	
46-31	8898-8900	in	_	
46-32	8901-8906	which	_	
46-33	8907-8913	actors	_	
46-34	8914-8920	depict	_	
46-35	8921-8925	each	_	
46-36	8926-8934	specific	_	
46-37	8935-8943	scenario	_	
46-38	8943-8944	.	_	

#Text=The detailed scenarios are previously described, with further descriptions in Supplementary Material IV.
47-1	8945-8948	The	_	
47-2	8949-8957	detailed	_	
47-3	8958-8967	scenarios	_	
47-4	8968-8971	are	_	
47-5	8972-8982	previously	_	
47-6	8983-8992	described	_	
47-7	8992-8993	,	_	
47-8	8994-8998	with	_	
47-9	8999-9006	further	_	
47-10	9007-9019	descriptions	_	
47-11	9020-9022	in	_	
47-12	9023-9036	Supplementary	_	
47-13	9037-9045	Material	_	
47-14	9046-9048	IV	_	
47-15	9048-9049	.	_	

#Text=Subjective responses to videos were recorded on a scale of 0–10 and involved rating emotional intensity, gambling urges, and drug cravings.
48-1	9050-9060	Subjective	_	
48-2	9061-9070	responses	_	
48-3	9071-9073	to	_	
48-4	9074-9080	videos	_	
48-5	9081-9085	were	_	
48-6	9086-9094	recorded	_	
48-7	9095-9097	on	_	
48-8	9098-9099	a	_	
48-9	9100-9105	scale	_	
48-10	9106-9108	of	_	
48-11	9109-9110	0	_	
48-12	9110-9111	–	_	
48-13	9111-9113	10	_	
48-14	9114-9117	and	_	
48-15	9118-9126	involved	_	
48-16	9127-9133	rating	_	
48-17	9134-9143	emotional	_	
48-18	9144-9153	intensity	_	
48-19	9153-9154	,	_	
48-20	9155-9163	gambling	_	
48-21	9164-9169	urges	_	
48-22	9169-9170	,	_	
48-23	9171-9174	and	_	
48-24	9175-9179	drug	_	
48-25	9180-9188	cravings	_	
48-26	9188-9189	.	_	

#Text=Image acquisition
#Text=Images were obtained using a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T2*-sensitive gradient-recalled single-shot echo-planar pulse sequence.
49-1	9190-9195	Image	_	
49-2	9196-9207	acquisition	_	
49-3	9208-9214	Images	_	
49-4	9215-9219	were	_	
49-5	9220-9228	obtained	_	
49-6	9229-9234	using	_	
49-7	9235-9236	a	_	
49-8	9237-9238	3	_	
49-9	9238-9239	-	_	
49-10	9239-9240	T	_	
49-11	9241-9248	Siemens	_	
49-12	9249-9253	Trio	_	
49-13	9254-9257	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
49-14	9258-9264	system	_	
49-15	9265-9273	equipped	_	
49-16	9274-9278	with	_	
49-17	9279-9280	a	_	
49-18	9281-9289	standard	_	
49-19	9290-9300	quadrature	_	
49-20	9301-9305	head	_	
49-21	9306-9310	coil	_	
49-22	9310-9311	,	_	
49-23	9312-9317	using	_	
49-24	9318-9320	T2	_	
49-25	9320-9321	*	_	
49-26	9321-9322	-	_	
49-27	9322-9331	sensitive	_	
49-28	9332-9349	gradient-recalled	_	
49-29	9350-9361	single-shot	_	
49-30	9362-9373	echo-planar	_	
49-31	9374-9379	pulse	_	
49-32	9380-9388	sequence	_	
49-33	9388-9389	.	_	

#Text=Subjects were positioned in the coil and head movements were restrained using foam pillows.
50-1	9390-9398	Subjects	_	
50-2	9399-9403	were	_	
50-3	9404-9414	positioned	_	
50-4	9415-9417	in	_	
50-5	9418-9421	the	_	
50-6	9422-9426	coil	_	
50-7	9427-9430	and	_	
50-8	9431-9435	head	_	
50-9	9436-9445	movements	_	
50-10	9446-9450	were	_	
50-11	9451-9461	restrained	_	
50-12	9462-9467	using	_	
50-13	9468-9472	foam	_	
50-14	9473-9480	pillows	_	
50-15	9480-9481	.	_	

#Text=Anatomical images at the functional slice locations were next obtained with spin-echo imaging in the axial plane parallel to the anterior-commissure/posterior-commissure (AC–PC) line with repetition time (TR) = 300 ms, echo time (TE) = 2.47 ms, bandwidth = 300 Hz/pixel, flip angle (FA) = 60°, field of view = 220 × 220 mm, matrix = 256 × 256, 25 slices with slice thickness = 5 mm and no gap.
51-1	9482-9492	Anatomical	_	
51-2	9493-9499	images	_	
51-3	9500-9502	at	_	
51-4	9503-9506	the	_	
51-5	9507-9517	functional	_	
51-6	9518-9523	slice	_	
51-7	9524-9533	locations	_	
51-8	9534-9538	were	_	
51-9	9539-9543	next	_	
51-10	9544-9552	obtained	_	
51-11	9553-9557	with	_	
51-12	9558-9567	spin-echo	_	
51-13	9568-9575	imaging	_	
51-14	9576-9578	in	_	
51-15	9579-9582	the	_	
51-16	9583-9588	axial	_	
51-17	9589-9594	plane	_	
51-18	9595-9603	parallel	_	
51-19	9604-9606	to	_	
51-20	9607-9610	the	_	
51-21	9611-9630	anterior-commissure	_	
51-22	9630-9631	/	_	
51-23	9631-9651	posterior-commissure	_	
51-24	9652-9653	(	_	
51-25	9653-9658	AC–PC	_	
51-26	9658-9659	)	_	
51-27	9660-9664	line	_	
51-28	9665-9669	with	_	
51-29	9670-9680	repetition	_	
51-30	9681-9685	time	_	
51-31	9686-9687	(	_	
51-32	9687-9689	TR	_	
51-33	9689-9690	)	_	
51-34	9691-9692	=	_	
51-35	9693-9696	300	_	
51-36	9697-9699	ms	_	
51-37	9699-9700	,	_	
51-38	9701-9705	echo	_	
51-39	9706-9710	time	_	
51-40	9711-9712	(	_	
51-41	9712-9714	TE	_	
51-42	9714-9715	)	_	
51-43	9716-9717	=	_	
51-44	9718-9722	2.47	_	
51-45	9723-9725	ms	_	
51-46	9725-9726	,	_	
51-47	9727-9736	bandwidth	_	
51-48	9737-9738	=	_	
51-49	9739-9742	300	_	
51-50	9743-9745	Hz	_	
51-51	9745-9746	/	_	
51-52	9746-9751	pixel	_	
51-53	9751-9752	,	_	
51-54	9753-9757	flip	_	
51-55	9758-9763	angle	_	
51-56	9764-9765	(	_	
51-57	9765-9767	FA	_	
51-58	9767-9768	)	_	
51-59	9769-9770	=	_	
51-60	9771-9773	60	_	
51-61	9773-9774	°	_	
51-62	9774-9775	,	_	
51-63	9776-9781	field	_	
51-64	9782-9784	of	_	
51-65	9785-9789	view	_	
51-66	9790-9791	=	_	
51-67	9792-9795	220	_	
51-68	9796-9797	×	_	
51-69	9798-9801	220	_	
51-70	9802-9804	mm	_	
51-71	9804-9805	,	_	
51-72	9806-9812	matrix	_	
51-73	9813-9814	=	_	
51-74	9815-9818	256	_	
51-75	9819-9820	×	_	
51-76	9821-9824	256	_	
51-77	9824-9825	,	_	
51-78	9826-9828	25	_	
51-79	9829-9835	slices	_	
51-80	9836-9840	with	_	
51-81	9841-9846	slice	_	
51-82	9847-9856	thickness	_	
51-83	9857-9858	=	_	
51-84	9859-9860	5	_	
51-85	9861-9863	mm	_	
51-86	9864-9867	and	_	
51-87	9868-9870	no	_	
51-88	9871-9874	gap	_	
51-89	9874-9875	.	_	

#Text=Functional blood-oxygen-level-dependent (BOLD) signals were then acquired with a single-shot gradient echo-planar-imaging sequence.
52-1	9876-9886	Functional	_	
52-2	9887-9915	blood-oxygen-level-dependent	_	
52-3	9916-9917	(	_	
52-4	9917-9921	BOLD	_	
52-5	9921-9922	)	_	
52-6	9923-9930	signals	_	
52-7	9931-9935	were	_	
52-8	9936-9940	then	_	
52-9	9941-9949	acquired	_	
52-10	9950-9954	with	_	
52-11	9955-9956	a	_	
52-12	9957-9968	single-shot	_	
52-13	9969-9977	gradient	_	
52-14	9978-9997	echo-planar-imaging	_	
52-15	9998-10006	sequence	_	
52-16	10006-10007	.	_	

#Text=Twenty-five axial slices parallel to the AC–PC line covering the whole brain were acquired with TR =1500 ms, TE = 27 ms, bandwidth = 2520 Hz/pixel, FA =60°, field of view = 220 × 220 mm, matrix = 64 × 64, 25 slices with slice thickness = 5 mm and no gap.
53-1	10008-10019	Twenty-five	_	
53-2	10020-10025	axial	_	
53-3	10026-10032	slices	_	
53-4	10033-10041	parallel	_	
53-5	10042-10044	to	_	
53-6	10045-10048	the	_	
53-7	10049-10054	AC–PC	_	
53-8	10055-10059	line	_	
53-9	10060-10068	covering	_	
53-10	10069-10072	the	_	
53-11	10073-10078	whole	_	
53-12	10079-10084	brain	_	
53-13	10085-10089	were	_	
53-14	10090-10098	acquired	_	
53-15	10099-10103	with	_	
53-16	10104-10106	TR	_	
53-17	10107-10108	=	_	
53-18	10108-10112	1500	_	
53-19	10113-10115	ms	_	
53-20	10115-10116	,	_	
53-21	10117-10119	TE	_	
53-22	10120-10121	=	_	
53-23	10122-10124	27	_	
53-24	10125-10127	ms	_	
53-25	10127-10128	,	_	
53-26	10129-10138	bandwidth	_	
53-27	10139-10140	=	_	
53-28	10141-10145	2520	_	
53-29	10146-10148	Hz	_	
53-30	10148-10149	/	_	
53-31	10149-10154	pixel	_	
53-32	10154-10155	,	_	
53-33	10156-10158	FA	_	
53-34	10159-10160	=	_	
53-35	10160-10162	60	_	
53-36	10162-10163	°	_	
53-37	10163-10164	,	_	
53-38	10165-10170	field	_	
53-39	10171-10173	of	_	
53-40	10174-10178	view	_	
53-41	10179-10180	=	_	
53-42	10181-10184	220	_	
53-43	10185-10186	×	_	
53-44	10187-10190	220	_	
53-45	10191-10193	mm	_	
53-46	10193-10194	,	_	
53-47	10195-10201	matrix	_	
53-48	10202-10203	=	_	
53-49	10204-10206	64	_	
53-50	10207-10208	×	_	
53-51	10209-10211	64	_	
53-52	10211-10212	,	_	
53-53	10213-10215	25	_	
53-54	10216-10222	slices	_	
53-55	10223-10227	with	_	
53-56	10228-10233	slice	_	
53-57	10234-10243	thickness	_	
53-58	10244-10245	=	_	
53-59	10246-10247	5	_	
53-60	10248-10250	mm	_	
53-61	10251-10254	and	_	
53-62	10255-10257	no	_	
53-63	10258-10261	gap	_	
53-64	10261-10262	.	_	

#Text=Six fMRI runs (two per condition) were acquired.
54-1	10263-10266	Six	_	
54-2	10267-10271	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
54-3	10272-10276	runs	_	
54-4	10277-10278	(	_	
54-5	10278-10281	two	_	
54-6	10282-10285	per	_	
54-7	10286-10295	condition	_	
54-8	10295-10296	)	_	
54-9	10297-10301	were	_	
54-10	10302-10310	acquired	_	
54-11	10310-10311	.	_	

#Text=Following functional imaging, high-resolution 3-D Magnetization-Prepared Rapid-Gradient Echo (MPRAGE) data (TR = 2530 ms; TE = 3.34 ms; bandwidth = 180 Hz/pixel; FA = 7°; slice thickness = 1 mm; field of view = 256 × 256 mm; matrix =256 × 256) were acquired for multi-subject registration.
55-1	10312-10321	Following	_	
55-2	10322-10332	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[10]	
55-3	10333-10340	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[10]	
55-4	10340-10341	,	_	
55-5	10342-10357	high-resolution	_	
55-6	10358-10359	3	_	
55-7	10359-10360	-	_	
55-8	10360-10361	D	_	
55-9	10362-10384	Magnetization-Prepared	_	
55-10	10385-10399	Rapid-Gradient	_	
55-11	10400-10404	Echo	_	
55-12	10405-10406	(	_	
55-13	10406-10412	MPRAGE	_	
55-14	10412-10413	)	_	
55-15	10414-10418	data	_	
55-16	10419-10420	(	_	
55-17	10420-10422	TR	_	
55-18	10423-10424	=	_	
55-19	10425-10429	2530	_	
55-20	10430-10432	ms	_	
55-21	10432-10433	;	_	
55-22	10434-10436	TE	_	
55-23	10437-10438	=	_	
55-24	10439-10443	3.34	_	
55-25	10444-10446	ms	_	
55-26	10446-10447	;	_	
55-27	10448-10457	bandwidth	_	
55-28	10458-10459	=	_	
55-29	10460-10463	180	_	
55-30	10464-10466	Hz	_	
55-31	10466-10467	/	_	
55-32	10467-10472	pixel	_	
55-33	10472-10473	;	_	
55-34	10474-10476	FA	_	
55-35	10477-10478	=	_	
55-36	10479-10480	7	_	
55-37	10480-10481	°	_	
55-38	10481-10482	;	_	
55-39	10483-10488	slice	_	
55-40	10489-10498	thickness	_	
55-41	10499-10500	=	_	
55-42	10501-10502	1	_	
55-43	10503-10505	mm	_	
55-44	10505-10506	;	_	
55-45	10507-10512	field	_	
55-46	10513-10515	of	_	
55-47	10516-10520	view	_	
55-48	10521-10522	=	_	
55-49	10523-10526	256	_	
55-50	10527-10528	×	_	
55-51	10529-10532	256	_	
55-52	10533-10535	mm	_	
55-53	10535-10536	;	_	
55-54	10537-10543	matrix	_	
55-55	10544-10545	=	_	
55-56	10545-10548	256	_	
55-57	10549-10550	×	_	
55-58	10551-10554	256	_	
55-59	10554-10555	)	_	
55-60	10556-10560	were	_	
55-61	10561-10569	acquired	_	
55-62	10570-10573	for	_	
55-63	10574-10587	multi-subject	_	
55-64	10588-10600	registration	_	
55-65	10600-10601	.	_	

#Text=Data analysis
#Text=Data were converted from Digital Imaging and Communication in Medicine (DICOM) format to ANALYZE format using XMedCon.
56-1	10602-10606	Data	_	
56-2	10607-10615	analysis	_	
56-3	10616-10620	Data	_	
56-4	10621-10625	were	_	
56-5	10626-10635	converted	_	
56-6	10636-10640	from	_	
56-7	10641-10648	Digital	_	
56-8	10649-10656	Imaging	_	
56-9	10657-10660	and	_	
56-10	10661-10674	Communication	_	
56-11	10675-10677	in	_	
56-12	10678-10686	Medicine	_	
56-13	10687-10688	(	_	
56-14	10688-10693	DICOM	_	
56-15	10693-10694	)	_	
56-16	10695-10701	format	_	
56-17	10702-10704	to	_	
56-18	10705-10712	ANALYZE	_	
56-19	10713-10719	format	_	
56-20	10720-10725	using	_	
56-21	10726-10733	XMedCon	_	
56-22	10733-10734	.	_	

#Text=The first six volumes of each functional series were discarded to enable signal to achieve steady-state equilibrium.
57-1	10735-10738	The	_	
57-2	10739-10744	first	_	
57-3	10745-10748	six	_	
57-4	10749-10756	volumes	_	
57-5	10757-10759	of	_	
57-6	10760-10764	each	_	
57-7	10765-10775	functional	_	
57-8	10776-10782	series	_	
57-9	10783-10787	were	_	
57-10	10788-10797	discarded	_	
57-11	10798-10800	to	_	
57-12	10801-10807	enable	_	
57-13	10808-10814	signal	_	
57-14	10815-10817	to	_	
57-15	10818-10825	achieve	_	
57-16	10826-10838	steady-state	_	
57-17	10839-10850	equilibrium	_	
57-18	10850-10851	.	_	

#Text=Functional images were first slice-time-corrected and then realigned (motion corrected) with the Statistical Parametric Mapping 5 algorithm (www.fil.ion.ucl.ac.uk/spm/software/spm5) for three translational directions (x, y, or z) and three possible rotations (pitch, yaw, or roll).
58-1	10852-10862	Functional	_	
58-2	10863-10869	images	_	
58-3	10870-10874	were	_	
58-4	10875-10880	first	_	
58-5	10881-10901	slice-time-corrected	_	
58-6	10902-10905	and	_	
58-7	10906-10910	then	_	
58-8	10911-10920	realigned	_	
58-9	10921-10922	(	_	
58-10	10922-10928	motion	_	
58-11	10929-10938	corrected	_	
58-12	10938-10939	)	_	
58-13	10940-10944	with	_	
58-14	10945-10948	the	_	
58-15	10949-10960	Statistical	_	
58-16	10961-10971	Parametric	_	
58-17	10972-10979	Mapping	_	
58-18	10980-10981	5	_	
58-19	10982-10991	algorithm	_	
58-20	10992-10993	(	_	
58-21	10993-11014	www.fil.ion.ucl.ac.uk	_	
58-22	11014-11015	/	_	
58-23	11015-11018	spm	_	
58-24	11018-11019	/	_	
58-25	11019-11027	software	_	
58-26	11027-11028	/	_	
58-27	11028-11032	spm5	_	
58-28	11032-11033	)	_	
58-29	11034-11037	for	_	
58-30	11038-11043	three	_	
58-31	11044-11057	translational	_	
58-32	11058-11068	directions	_	
58-33	11069-11070	(	_	
58-34	11070-11071	x	_	
58-35	11071-11072	,	_	
58-36	11073-11074	y	_	
58-37	11074-11075	,	_	
58-38	11076-11078	or	_	
58-39	11079-11080	z	_	
58-40	11080-11081	)	_	
58-41	11082-11085	and	_	
58-42	11086-11091	three	_	
58-43	11092-11100	possible	_	
58-44	11101-11110	rotations	_	
58-45	11111-11112	(	_	
58-46	11112-11117	pitch	_	
58-47	11117-11118	,	_	
58-48	11119-11122	yaw	_	
58-49	11122-11123	,	_	
58-50	11124-11126	or	_	
58-51	11127-11131	roll	_	
58-52	11131-11132	)	_	
58-53	11132-11133	.	_	

#Text=Trials with linear motion that had a displacement in excess of 2 mm or rotation in excess of 3° were rejected.
59-1	11134-11140	Trials	_	
59-2	11141-11145	with	_	
59-3	11146-11152	linear	_	
59-4	11153-11159	motion	_	
59-5	11160-11164	that	_	
59-6	11165-11168	had	_	
59-7	11169-11170	a	_	
59-8	11171-11183	displacement	_	
59-9	11184-11186	in	_	
59-10	11187-11193	excess	_	
59-11	11194-11196	of	_	
59-12	11197-11198	2	_	
59-13	11199-11201	mm	_	
59-14	11202-11204	or	_	
59-15	11205-11213	rotation	_	
59-16	11214-11216	in	_	
59-17	11217-11223	excess	_	
59-18	11224-11226	of	_	
59-19	11227-11228	3	_	
59-20	11228-11229	°	_	
59-21	11230-11234	were	_	
59-22	11235-11243	rejected	_	
59-23	11243-11244	.	_	

#Text=Corrected images were spatially smoothed by using a Gaussian filter with a full-width-at-half-maximum of 6.876 mm.
60-1	11245-11254	Corrected	_	
60-2	11255-11261	images	_	
60-3	11262-11266	were	_	
60-4	11267-11276	spatially	_	
60-5	11277-11285	smoothed	_	
60-6	11286-11288	by	_	
60-7	11289-11294	using	_	
60-8	11295-11296	a	_	
60-9	11297-11305	Gaussian	_	
60-10	11306-11312	filter	_	
60-11	11313-11317	with	_	
60-12	11318-11319	a	_	
60-13	11320-11346	full-width-at-half-maximum	_	
60-14	11347-11349	of	_	
60-15	11350-11355	6.876	_	
60-16	11356-11358	mm	_	
60-17	11358-11359	.	_	

#Text=Analysis-of-covariance (ANCOVA) approaches as described below controlled for covariates and analyzed signal change during the entire period of video-viewing relative to the combined pre- and post-baseline (see Supplementary Material X).
61-1	11360-11382	Analysis-of-covariance	_	
61-2	11383-11384	(	_	
61-3	11384-11390	ANCOVA	_	
61-4	11390-11391	)	_	
61-5	11392-11402	approaches	_	
61-6	11403-11405	as	_	
61-7	11406-11415	described	_	
61-8	11416-11421	below	_	
61-9	11422-11432	controlled	_	
61-10	11433-11436	for	_	
61-11	11437-11447	covariates	_	
61-12	11448-11451	and	_	
61-13	11452-11460	analyzed	_	
61-14	11461-11467	signal	_	
61-15	11468-11474	change	_	
61-16	11475-11481	during	_	
61-17	11482-11485	the	_	
61-18	11486-11492	entire	_	
61-19	11493-11499	period	_	
61-20	11500-11502	of	_	
61-21	11503-11516	video-viewing	_	
61-22	11517-11525	relative	_	
61-23	11526-11528	to	_	
61-24	11529-11532	the	_	
61-25	11533-11541	combined	_	
61-26	11542-11545	pre	_	
61-27	11545-11546	-	_	
61-28	11547-11550	and	_	
61-29	11551-11564	post-baseline	_	
61-30	11565-11566	(	_	
61-31	11566-11569	see	_	
61-32	11570-11583	Supplementary	_	
61-33	11584-11592	Material	_	
61-34	11593-11594	X	_	
61-35	11594-11595	)	_	
61-36	11595-11596	.	_	

#Text=Post hoc t-test comparisons were implemented to dissect what drived the effects identified in the ANCOVAs and examined the nature of the effects.
62-1	11597-11601	Post	_	
62-2	11602-11605	hoc	_	
62-3	11606-11612	t-test	_	
62-4	11613-11624	comparisons	_	
62-5	11625-11629	were	_	
62-6	11630-11641	implemented	_	
62-7	11642-11644	to	_	
62-8	11645-11652	dissect	_	
62-9	11653-11657	what	_	
62-10	11658-11664	drived	_	
62-11	11665-11668	the	_	
62-12	11669-11676	effects	_	
62-13	11677-11687	identified	_	
62-14	11688-11690	in	_	
62-15	11691-11694	the	_	
62-16	11695-11702	ANCOVAs	_	
62-17	11703-11706	and	_	
62-18	11707-11715	examined	_	
62-19	11716-11719	the	_	
62-20	11720-11726	nature	_	
62-21	11727-11729	of	_	
62-22	11730-11733	the	_	
62-23	11734-11741	effects	_	
62-24	11741-11742	.	_	

#Text=For subjective-response data, analyses of variance (ANOVAs) tested emotional/motivational ratings between the PG and HC groups.
63-1	11743-11746	For	_	
63-2	11747-11766	subjective-response	_	
63-3	11767-11771	data	_	
63-4	11771-11772	,	_	
63-5	11773-11781	analyses	_	
63-6	11782-11784	of	_	
63-7	11785-11793	variance	_	
63-8	11794-11795	(	_	
63-9	11795-11801	ANOVAs	_	
63-10	11801-11802	)	_	
63-11	11803-11809	tested	_	
63-12	11810-11819	emotional	_	
63-13	11819-11820	/	_	
63-14	11820-11832	motivational	_	
63-15	11833-11840	ratings	_	
63-16	11841-11848	between	_	
63-17	11849-11852	the	_	
63-18	11853-11855	PG	_	
63-19	11856-11859	and	_	
63-20	11860-11862	HC	_	
63-21	11863-11869	groups	_	
63-22	11869-11870	.	_	

#Text=ANOVAs tested DBH genotype differences for the sad condition.
64-1	11871-11877	ANOVAs	_	
64-2	11878-11884	tested	_	
64-3	11885-11888	DBH	_	
64-4	11889-11897	genotype	_	
64-5	11898-11909	differences	_	
64-6	11910-11913	for	_	
64-7	11914-11917	the	_	
64-8	11918-11921	sad	_	
64-9	11922-11931	condition	_	
64-10	11931-11932	.	_	

#Text=Analysis-of-covariance
#Text=Data were converted to AFNI format (http://afni.nimh.nih.gov) for ANCOVAs.
65-1	11933-11955	Analysis-of-covariance	_	
65-2	11956-11960	Data	_	
65-3	11961-11965	were	_	
65-4	11966-11975	converted	_	
65-5	11976-11978	to	_	
65-6	11979-11983	AFNI	_	
65-7	11984-11990	format	_	
65-8	11991-11992	(	_	
65-9	11992-11996	http	_	
65-10	11996-11997	:	_	
65-11	11997-11998	/	_	
65-12	11998-11999	/	_	
65-13	11999-12016	afni.nimh.nih.gov	_	
65-14	12016-12017	)	_	
65-15	12018-12021	for	_	
65-16	12022-12029	ANCOVAs	_	
65-17	12029-12030	.	_	

#Text=We applied a 2 × 2 × 3 ANCOVA with age adjustment involving two DBH genotypic groups (CC/T-carrier), two diagnostic groups (PG/HC), and three conditions (gambling, sad, and cocaine), in which subject was treated as a random factor using the GroupAna program from the AFNI MATLAB library (http://afni.nimh.nih.gov/afni/matlab/).
66-1	12031-12033	We	_	
66-2	12034-12041	applied	_	
66-3	12042-12043	a	_	
66-4	12044-12045	2	_	
66-5	12046-12047	×	_	
66-6	12048-12049	2	_	
66-7	12050-12051	×	_	
66-8	12052-12053	3	_	
66-9	12054-12060	ANCOVA	_	
66-10	12061-12065	with	_	
66-11	12066-12069	age	_	
66-12	12070-12080	adjustment	_	
66-13	12081-12090	involving	_	
66-14	12091-12094	two	_	
66-15	12095-12098	DBH	_	
66-16	12099-12108	genotypic	_	
66-17	12109-12115	groups	_	
66-18	12116-12117	(	_	
66-19	12117-12119	CC	_	
66-20	12119-12120	/	_	
66-21	12120-12129	T-carrier	_	
66-22	12129-12130	)	_	
66-23	12130-12131	,	_	
66-24	12132-12135	two	_	
66-25	12136-12146	diagnostic	_	
66-26	12147-12153	groups	_	
66-27	12154-12155	(	_	
66-28	12155-12157	PG	_	
66-29	12157-12158	/	_	
66-30	12158-12160	HC	_	
66-31	12160-12161	)	_	
66-32	12161-12162	,	_	
66-33	12163-12166	and	_	
66-34	12167-12172	three	_	
66-35	12173-12183	conditions	_	
66-36	12184-12185	(	_	
66-37	12185-12193	gambling	_	
66-38	12193-12194	,	_	
66-39	12195-12198	sad	_	
66-40	12198-12199	,	_	
66-41	12200-12203	and	_	
66-42	12204-12211	cocaine	_	
66-43	12211-12212	)	_	
66-44	12212-12213	,	_	
66-45	12214-12216	in	_	
66-46	12217-12222	which	_	
66-47	12223-12230	subject	_	
66-48	12231-12234	was	_	
66-49	12235-12242	treated	_	
66-50	12243-12245	as	_	
66-51	12246-12247	a	_	
66-52	12248-12254	random	_	
66-53	12255-12261	factor	_	
66-54	12262-12267	using	_	
66-55	12268-12271	the	_	
66-56	12272-12280	GroupAna	_	
66-57	12281-12288	program	_	
66-58	12289-12293	from	_	
66-59	12294-12297	the	_	
66-60	12298-12302	AFNI	_	
66-61	12303-12309	MATLAB	_	
66-62	12310-12317	library	_	
66-63	12318-12319	(	_	
66-64	12319-12323	http	_	
66-65	12323-12324	:	_	
66-66	12324-12325	/	_	
66-67	12325-12326	/	_	
66-68	12326-12343	afni.nimh.nih.gov	_	
66-69	12343-12344	/	_	
66-70	12344-12348	afni	_	
66-71	12348-12349	/	_	
66-72	12349-12355	matlab	_	
66-73	12355-12356	/	_	
66-74	12356-12357	)	_	
66-75	12357-12358	.	_	

#Text=Results were masked, converted back to ANALYZE format and viewed in Yale BioImage Suite (http://wwww.bioimagesuite.org).
67-1	12359-12366	Results	_	
67-2	12367-12371	were	_	
67-3	12372-12378	masked	_	
67-4	12378-12379	,	_	
67-5	12380-12389	converted	_	
67-6	12390-12394	back	_	
67-7	12395-12397	to	_	
67-8	12398-12405	ANALYZE	_	
67-9	12406-12412	format	_	
67-10	12413-12416	and	_	
67-11	12417-12423	viewed	_	
67-12	12424-12426	in	_	
67-13	12427-12431	Yale	_	
67-14	12432-12440	BioImage	_	
67-15	12441-12446	Suite	_	
67-16	12447-12448	(	_	
67-17	12448-12452	http	_	
67-18	12452-12453	:	_	
67-19	12453-12454	/	_	
67-20	12454-12455	/	_	
67-21	12455-12477	wwww.bioimagesuite.org	_	
67-22	12477-12478	)	_	
67-23	12478-12479	.	_	

#Text=Data were thresholded at a voxel level of p < .05, corrected for multiple comparisons by spatial extent of contiguous suprathresholded individual voxels at a family-wise-error-corrected (FWE corrected) threshold of p < .05.
68-1	12480-12484	Data	_	
68-2	12485-12489	were	_	
68-3	12490-12501	thresholded	_	
68-4	12502-12504	at	_	
68-5	12505-12506	a	_	
68-6	12507-12512	voxel	_	
68-7	12513-12518	level	_	
68-8	12519-12521	of	_	
68-9	12522-12523	p	_	
68-10	12524-12525	<	_	
68-11	12526-12529	.05	_	
68-12	12529-12530	,	_	
68-13	12531-12540	corrected	_	
68-14	12541-12544	for	_	
68-15	12545-12553	multiple	_	
68-16	12554-12565	comparisons	_	
68-17	12566-12568	by	_	
68-18	12569-12576	spatial	_	
68-19	12577-12583	extent	_	
68-20	12584-12586	of	_	
68-21	12587-12597	contiguous	_	
68-22	12598-12614	suprathresholded	_	
68-23	12615-12625	individual	_	
68-24	12626-12632	voxels	_	
68-25	12633-12635	at	_	
68-26	12636-12637	a	_	
68-27	12638-12665	family-wise-error-corrected	_	
68-28	12666-12667	(	_	
68-29	12667-12670	FWE	_	
68-30	12671-12680	corrected	_	
68-31	12680-12681	)	_	
68-32	12682-12691	threshold	_	
68-33	12692-12694	of	_	
68-34	12695-12696	p	_	
68-35	12697-12698	<	_	
68-36	12699-12702	.05	_	
68-37	12702-12703	.	_	

#Text=In a Monte-Carlo simulation using AFNI (applying a smoothing kernel of 6.876 mm and a connection radius of 6.97 mm on 3.44 mm × 3.44 mm × 5 mm voxels), an activation volume of 311 voxels (8402 µl) satisfied the FWE-corrected p < .05 threshold.
69-1	12704-12706	In	_	
69-2	12707-12708	a	_	
69-3	12709-12720	Monte-Carlo	_	
69-4	12721-12731	simulation	_	
69-5	12732-12737	using	_	
69-6	12738-12742	AFNI	_	
69-7	12743-12744	(	_	
69-8	12744-12752	applying	_	
69-9	12753-12754	a	_	
69-10	12755-12764	smoothing	_	
69-11	12765-12771	kernel	_	
69-12	12772-12774	of	_	
69-13	12775-12780	6.876	_	
69-14	12781-12783	mm	_	
69-15	12784-12787	and	_	
69-16	12788-12789	a	_	
69-17	12790-12800	connection	_	
69-18	12801-12807	radius	_	
69-19	12808-12810	of	_	
69-20	12811-12815	6.97	_	
69-21	12816-12818	mm	_	
69-22	12819-12821	on	_	
69-23	12822-12826	3.44	_	
69-24	12827-12829	mm	_	
69-25	12830-12831	×	_	
69-26	12832-12836	3.44	_	
69-27	12837-12839	mm	_	
69-28	12840-12841	×	_	
69-29	12842-12843	5	_	
69-30	12844-12846	mm	_	
69-31	12847-12853	voxels	_	
69-32	12853-12854	)	_	
69-33	12854-12855	,	_	
69-34	12856-12858	an	_	
69-35	12859-12869	activation	_	
69-36	12870-12876	volume	_	
69-37	12877-12879	of	_	
69-38	12880-12883	311	_	
69-39	12884-12890	voxels	_	
69-40	12891-12892	(	_	
69-41	12892-12896	8402	_	
69-42	12897-12899	µl	_	
69-43	12899-12900	)	_	
69-44	12901-12910	satisfied	_	
69-45	12911-12914	the	_	
69-46	12915-12928	FWE-corrected	_	
69-47	12929-12930	p	_	
69-48	12931-12932	<	_	
69-49	12933-12936	.05	_	
69-50	12937-12946	threshold	_	
69-51	12946-12947	.	_	

#Text=Ethics
#Text=The investigation was carried out in accordance with the latest version of the Declaration of Helsinki; the protocol was approved by the Yale Human Investigation Committee.
70-1	12948-12954	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-2	12955-12958	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-3	12959-12972	investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-4	12973-12976	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-5	12977-12984	carried	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-6	12985-12988	out	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-7	12989-12991	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-8	12992-13002	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-9	13003-13007	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-10	13008-13011	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-11	13012-13018	latest	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-12	13019-13026	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-13	13027-13029	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-14	13030-13033	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-15	13034-13045	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-16	13046-13048	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-17	13049-13057	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-18	13057-13058	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-19	13059-13062	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-20	13063-13071	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-21	13072-13075	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-22	13076-13084	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-23	13085-13087	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-24	13088-13091	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-25	13092-13096	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-26	13097-13102	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-27	13103-13116	Investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-28	13117-13126	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
70-29	13126-13127	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=All subjects were recruited through advertisements and provided written informed consent after the nature of the procedures had been fully explained.
71-1	13128-13131	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-2	13132-13140	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-3	13141-13145	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-4	13146-13155	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-5	13156-13163	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-6	13164-13178	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-7	13179-13182	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-8	13183-13191	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-9	13192-13199	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-10	13200-13208	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-11	13209-13216	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-12	13217-13222	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-13	13223-13226	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-14	13227-13233	nature	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-15	13234-13236	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-16	13237-13240	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-17	13241-13251	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-18	13252-13255	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-19	13256-13260	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-20	13261-13266	fully	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-21	13267-13276	explained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
71-22	13276-13277	.	_	

#Text=Results
#Text=Diagnostic group differences
#Text=The PG group (versus HC group) was more impulsive (p = 7.5 × 10−5) and demonstrated greater problem-gambling severity on the SOGS (p = 2.1 × 10−11).
72-1	13278-13285	Results	_	
72-2	13286-13296	Diagnostic	_	
72-3	13297-13302	group	_	
72-4	13303-13314	differences	_	
72-5	13315-13318	The	_	
72-6	13319-13321	PG	_	
72-7	13322-13327	group	_	
72-8	13328-13329	(	_	
72-9	13329-13335	versus	_	
72-10	13336-13338	HC	_	
72-11	13339-13344	group	_	
72-12	13344-13345	)	_	
72-13	13346-13349	was	_	
72-14	13350-13354	more	_	
72-15	13355-13364	impulsive	_	
72-16	13365-13366	(	_	
72-17	13366-13367	p	_	
72-18	13368-13369	=	_	
72-19	13370-13373	7.5	_	
72-20	13374-13375	×	_	
72-21	13376-13378	10	_	
72-22	13378-13379	−	_	
72-23	13379-13380	5	_	
72-24	13380-13381	)	_	
72-25	13382-13385	and	_	
72-26	13386-13398	demonstrated	_	
72-27	13399-13406	greater	_	
72-28	13407-13423	problem-gambling	_	
72-29	13424-13432	severity	_	
72-30	13433-13435	on	_	
72-31	13436-13439	the	_	
72-32	13440-13444	SOGS	_	
72-33	13445-13446	(	_	
72-34	13446-13447	p	_	
72-35	13448-13449	=	_	
72-36	13450-13453	2.1	_	
72-37	13454-13455	×	_	
72-38	13456-13458	10	_	
72-39	13458-13459	−	_	
72-40	13459-13461	11	_	
72-41	13461-13462	)	_	
72-42	13462-13463	.	_	

#Text=Genotype distribution
#Text=No between-group differences in genotypic distributions of SNP rs1611115 were observed between PG and HC subjects (p > .05) or between male and female subjects (p > .05) (Table 1B).
73-1	13464-13472	Genotype	_	
73-2	13473-13485	distribution	_	
73-3	13486-13488	No	_	
73-4	13489-13502	between-group	_	
73-5	13503-13514	differences	_	
73-6	13515-13517	in	_	
73-7	13518-13527	genotypic	_	
73-8	13528-13541	distributions	_	
73-9	13542-13544	of	_	
73-10	13545-13548	SNP	_	
73-11	13549-13558	rs1611115	_	
73-12	13559-13563	were	_	
73-13	13564-13572	observed	_	
73-14	13573-13580	between	_	
73-15	13581-13583	PG	_	
73-16	13584-13587	and	_	
73-17	13588-13590	HC	_	
73-18	13591-13599	subjects	_	
73-19	13600-13601	(	_	
73-20	13601-13602	p	_	
73-21	13603-13604	>	_	
73-22	13605-13608	.05	_	
73-23	13608-13609	)	_	
73-24	13610-13612	or	_	
73-25	13613-13620	between	_	
73-26	13621-13625	male	_	
73-27	13626-13629	and	_	
73-28	13630-13636	female	_	
73-29	13637-13645	subjects	_	
73-30	13646-13647	(	_	
73-31	13647-13648	p	_	
73-32	13649-13650	>	_	
73-33	13651-13654	.05	_	
73-34	13654-13655	)	_	
73-35	13656-13657	(	_	
73-36	13657-13662	Table	_	
73-37	13662-13663	 	_	
73-38	13663-13665	1B	_	
73-39	13665-13666	)	_	
73-40	13666-13667	.	_	

#Text=Modestly higher impulsivity scores in T-carriers relative to CC individuals did not reach significance (p = .093).
74-1	13668-13676	Modestly	_	
74-2	13677-13683	higher	_	
74-3	13684-13695	impulsivity	_	
74-4	13696-13702	scores	_	
74-5	13703-13705	in	_	
74-6	13706-13716	T-carriers	_	
74-7	13717-13725	relative	_	
74-8	13726-13728	to	_	
74-9	13729-13731	CC	_	
74-10	13732-13743	individuals	_	
74-11	13744-13747	did	_	
74-12	13748-13751	not	_	
74-13	13752-13757	reach	_	
74-14	13758-13770	significance	_	
74-15	13771-13772	(	_	
74-16	13772-13773	p	_	
74-17	13774-13775	=	_	
74-18	13776-13780	.093	_	
74-19	13780-13781	)	_	
74-20	13781-13782	.	_	

#Text=Brain activations elicited by videos
#Text=Significant two-way interaction effects emerged for DBH-genotype-by-condition (Figure 1A) and group-by-condition (Figure 1C) analyses (see Supplementary Material VI for additional activation maps).
75-1	13783-13788	Brain	_	
75-2	13789-13800	activations	_	
75-3	13801-13809	elicited	_	
75-4	13810-13812	by	_	
75-5	13813-13819	videos	_	
75-6	13820-13831	Significant	_	
75-7	13832-13839	two-way	_	
75-8	13840-13851	interaction	_	
75-9	13852-13859	effects	_	
75-10	13860-13867	emerged	_	
75-11	13868-13871	for	_	
75-12	13872-13897	DBH-genotype-by-condition	_	
75-13	13898-13899	(	_	
75-14	13899-13905	Figure	_	
75-15	13905-13906	 	_	
75-16	13906-13908	1A	_	
75-17	13908-13909	)	_	
75-18	13910-13913	and	_	
75-19	13914-13932	group-by-condition	_	
75-20	13933-13934	(	_	
75-21	13934-13940	Figure	_	
75-22	13940-13941	 	_	
75-23	13941-13943	1C	_	
75-24	13943-13944	)	_	
75-25	13945-13953	analyses	_	
75-26	13954-13955	(	_	
75-27	13955-13958	see	_	
75-28	13959-13972	Supplementary	_	
75-29	13973-13981	Material	_	
75-30	13982-13984	VI	_	
75-31	13985-13988	for	_	
75-32	13989-13999	additional	_	
75-33	14000-14010	activation	_	
75-34	14011-14015	maps	_	
75-35	14015-14016	)	_	
75-36	14016-14017	.	_	

#Text=No activations in group-by-DBH-genotype and group-by-DBH-genotype-by-condition interactions survived whole-brain correction.
76-1	14018-14020	No	_	
76-2	14021-14032	activations	_	
76-3	14033-14035	in	_	
76-4	14036-14057	group-by-DBH-genotype	_	
76-5	14058-14061	and	_	
76-6	14062-14096	group-by-DBH-genotype-by-condition	_	
76-7	14097-14109	interactions	_	
76-8	14110-14118	survived	_	
76-9	14119-14130	whole-brain	_	
76-10	14131-14141	correction	_	
76-11	14141-14142	.	_	

#Text=Main effects of DBH genotype and condition on brain activation were identified; main effects of group did not survive whole-brain correction.
77-1	14143-14147	Main	_	
77-2	14148-14155	effects	_	
77-3	14156-14158	of	_	
77-4	14159-14162	DBH	_	
77-5	14163-14171	genotype	_	
77-6	14172-14175	and	_	
77-7	14176-14185	condition	_	
77-8	14186-14188	on	_	
77-9	14189-14194	brain	_	
77-10	14195-14205	activation	_	
77-11	14206-14210	were	_	
77-12	14211-14221	identified	_	
77-13	14221-14222	;	_	
77-14	14223-14227	main	_	
77-15	14228-14235	effects	_	
77-16	14236-14238	of	_	
77-17	14239-14244	group	_	
77-18	14245-14248	did	_	
77-19	14249-14252	not	_	
77-20	14253-14260	survive	_	
77-21	14261-14272	whole-brain	_	
77-22	14273-14283	correction	_	
77-23	14283-14284	.	_	

#Text=Extracted BOLD-signal changes from the identified regions were used to understand the nature of the significant effects, as described below.
78-1	14285-14294	Extracted	_	
78-2	14295-14306	BOLD-signal	_	
78-3	14307-14314	changes	_	
78-4	14315-14319	from	_	
78-5	14320-14323	the	_	
78-6	14324-14334	identified	_	
78-7	14335-14342	regions	_	
78-8	14343-14347	were	_	
78-9	14348-14352	used	_	
78-10	14353-14355	to	_	
78-11	14356-14366	understand	_	
78-12	14367-14370	the	_	
78-13	14371-14377	nature	_	
78-14	14378-14380	of	_	
78-15	14381-14384	the	_	
78-16	14385-14396	significant	_	
78-17	14397-14404	effects	_	
78-18	14404-14405	,	_	
78-19	14406-14408	as	_	
78-20	14409-14418	described	_	
78-21	14419-14424	below	_	
78-22	14424-14425	.	_	

#Text=Activation maps displaying interactive effects of DBH genotype, condition and diagnostic group.
79-1	14426-14436	Activation	_	
79-2	14437-14441	maps	_	
79-3	14442-14452	displaying	_	
79-4	14453-14464	interactive	_	
79-5	14465-14472	effects	_	
79-6	14473-14475	of	_	
79-7	14476-14479	DBH	_	
79-8	14480-14488	genotype	_	
79-9	14488-14489	,	_	
79-10	14490-14499	condition	_	
79-11	14500-14503	and	_	
79-12	14504-14514	diagnostic	_	
79-13	14515-14520	group	_	
79-14	14520-14521	.	_	

#Text=The axial brain sections highlighting regions showing significant two-way interactions adjusted by age involving two genotypic groups (CC, T-carrier [shown as Tx]), two diagnostic groups (pathological gambling, healthy comparison, shortened as PG and HC, respectively) and three cue conditions (gambling, sad, and cocaine, shortened as Gam, Sad, and Coc, respectively) are shown.
80-1	14522-14525	The	_	
80-2	14526-14531	axial	_	
80-3	14532-14537	brain	_	
80-4	14538-14546	sections	_	
80-5	14547-14559	highlighting	_	
80-6	14560-14567	regions	_	
80-7	14568-14575	showing	_	
80-8	14576-14587	significant	_	
80-9	14588-14595	two-way	_	
80-10	14596-14608	interactions	_	
80-11	14609-14617	adjusted	_	
80-12	14618-14620	by	_	
80-13	14621-14624	age	_	
80-14	14625-14634	involving	_	
80-15	14635-14638	two	_	
80-16	14639-14648	genotypic	_	
80-17	14649-14655	groups	_	
80-18	14656-14657	(	_	
80-19	14657-14659	CC	_	
80-20	14659-14660	,	_	
80-21	14661-14670	T-carrier	_	
80-22	14671-14672	[	_	
80-23	14672-14677	shown	_	
80-24	14678-14680	as	_	
80-25	14681-14683	Tx	_	
80-26	14683-14684	]	_	
80-27	14684-14685	)	_	
80-28	14685-14686	,	_	
80-29	14687-14690	two	_	
80-30	14691-14701	diagnostic	_	
80-31	14702-14708	groups	_	
80-32	14709-14710	(	_	
80-33	14710-14722	pathological	_	
80-34	14723-14731	gambling	_	
80-35	14731-14732	,	_	
80-36	14733-14740	healthy	_	
80-37	14741-14751	comparison	_	
80-38	14751-14752	,	_	
80-39	14753-14762	shortened	_	
80-40	14763-14765	as	_	
80-41	14766-14768	PG	_	
80-42	14769-14772	and	_	
80-43	14773-14775	HC	_	
80-44	14775-14776	,	_	
80-45	14777-14789	respectively	_	
80-46	14789-14790	)	_	
80-47	14791-14794	and	_	
80-48	14795-14800	three	_	
80-49	14801-14804	cue	_	
80-50	14805-14815	conditions	_	
80-51	14816-14817	(	_	
80-52	14817-14825	gambling	_	
80-53	14825-14826	,	_	
80-54	14827-14830	sad	_	
80-55	14830-14831	,	_	
80-56	14832-14835	and	_	
80-57	14836-14843	cocaine	_	
80-58	14843-14844	,	_	
80-59	14845-14854	shortened	_	
80-60	14855-14857	as	_	
80-61	14858-14861	Gam	_	
80-62	14861-14862	,	_	
80-63	14863-14866	Sad	_	
80-64	14866-14867	,	_	
80-65	14868-14871	and	_	
80-66	14872-14875	Coc	_	
80-67	14875-14876	,	_	
80-68	14877-14889	respectively	_	
80-69	14889-14890	)	_	
80-70	14891-14894	are	_	
80-71	14895-14900	shown	_	
80-72	14900-14901	.	_	

#Text=The maps are thresholded at p < .05, with a family-wise-error correction.
81-1	14902-14905	The	_	
81-2	14906-14910	maps	_	
81-3	14911-14914	are	_	
81-4	14915-14926	thresholded	_	
81-5	14927-14929	at	_	
81-6	14930-14931	p	_	
81-7	14932-14933	<	_	
81-8	14934-14937	.05	_	
81-9	14937-14938	,	_	
81-10	14939-14943	with	_	
81-11	14944-14945	a	_	
81-12	14946-14963	family-wise-error	_	
81-13	14964-14974	correction	_	
81-14	14974-14975	.	_	

#Text=Talairach z levels are indicated (A, C).
82-1	14976-14985	Talairach	_	
82-2	14986-14987	z	_	
82-3	14988-14994	levels	_	
82-4	14995-14998	are	_	
82-5	14999-15008	indicated	_	
82-6	15009-15010	(	_	
82-7	15010-15011	A	_	
82-8	15011-15012	,	_	
82-9	15013-15014	C	_	
82-10	15014-15015	)	_	
82-11	15015-15016	.	_	

#Text=The bar on the right side of the Figures A and C indicates the strengths of identified interactions.
83-1	15017-15020	The	_	
83-2	15021-15024	bar	_	
83-3	15025-15027	on	_	
83-4	15028-15031	the	_	
83-5	15032-15037	right	_	
83-6	15038-15042	side	_	
83-7	15043-15045	of	_	
83-8	15046-15049	the	_	
83-9	15050-15057	Figures	_	
83-10	15058-15059	A	_	
83-11	15060-15063	and	_	
83-12	15064-15065	C	_	
83-13	15066-15075	indicates	_	
83-14	15076-15079	the	_	
83-15	15080-15089	strengths	_	
83-16	15090-15092	of	_	
83-17	15093-15103	identified	_	
83-18	15104-15116	interactions	_	
83-19	15116-15117	.	_	

#Text=Right side of the brain is shown on the left.
84-1	15118-15123	Right	_	
84-2	15124-15128	side	_	
84-3	15129-15131	of	_	
84-4	15132-15135	the	_	
84-5	15136-15141	brain	_	
84-6	15142-15144	is	_	
84-7	15145-15150	shown	_	
84-8	15151-15153	on	_	
84-9	15154-15157	the	_	
84-10	15158-15162	left	_	
84-11	15162-15163	.	_	

#Text=Indicated on the right (B and D) are extracted values of percentage signal changes according to respective interactions for genotype (CC, T-carrier [shown as Tx]), diagnostic group (PG, HC) or condition (gam, sad, and coc).
85-1	15164-15173	Indicated	_	
85-2	15174-15176	on	_	
85-3	15177-15180	the	_	
85-4	15181-15186	right	_	
85-5	15187-15188	(	_	
85-6	15188-15189	B	_	
85-7	15190-15193	and	_	
85-8	15194-15195	D	_	
85-9	15195-15196	)	_	
85-10	15197-15200	are	_	
85-11	15201-15210	extracted	_	
85-12	15211-15217	values	_	
85-13	15218-15220	of	_	
85-14	15221-15231	percentage	_	
85-15	15232-15238	signal	_	
85-16	15239-15246	changes	_	
85-17	15247-15256	according	_	
85-18	15257-15259	to	_	
85-19	15260-15270	respective	_	
85-20	15271-15283	interactions	_	
85-21	15284-15287	for	_	
85-22	15288-15296	genotype	_	
85-23	15297-15298	(	_	
85-24	15298-15300	CC	_	
85-25	15300-15301	,	_	
85-26	15302-15311	T-carrier	_	
85-27	15312-15313	[	_	
85-28	15313-15318	shown	_	
85-29	15319-15321	as	_	
85-30	15322-15324	Tx	_	
85-31	15324-15325	]	_	
85-32	15325-15326	)	_	
85-33	15326-15327	,	_	
85-34	15328-15338	diagnostic	_	
85-35	15339-15344	group	_	
85-36	15345-15346	(	_	
85-37	15346-15348	PG	_	
85-38	15348-15349	,	_	
85-39	15350-15352	HC	_	
85-40	15352-15353	)	_	
85-41	15354-15356	or	_	
85-42	15357-15366	condition	_	
85-43	15367-15368	(	_	
85-44	15368-15371	gam	_	
85-45	15371-15372	,	_	
85-46	15373-15376	sad	_	
85-47	15376-15377	,	_	
85-48	15378-15381	and	_	
85-49	15382-15385	coc	_	
85-50	15385-15386	)	_	
85-51	15386-15387	.	_	

#Text=Outliers of BOLD-signal are marked by circles; outlier evaluation by exclusion and retest; all the effects in the retests remained similar. mOFC = medial orbitofrontal cortex; vPFC = ventral prefrontal cortex.
86-1	15388-15396	Outliers	_	
86-2	15397-15399	of	_	
86-3	15400-15411	BOLD-signal	_	
86-4	15412-15415	are	_	
86-5	15416-15422	marked	_	
86-6	15423-15425	by	_	
86-7	15426-15433	circles	_	
86-8	15433-15434	;	_	
86-9	15435-15442	outlier	_	
86-10	15443-15453	evaluation	_	
86-11	15454-15456	by	_	
86-12	15457-15466	exclusion	_	
86-13	15467-15470	and	_	
86-14	15471-15477	retest	_	
86-15	15477-15478	;	_	
86-16	15479-15482	all	_	
86-17	15483-15486	the	_	
86-18	15487-15494	effects	_	
86-19	15495-15497	in	_	
86-20	15498-15501	the	_	
86-21	15502-15509	retests	_	
86-22	15510-15518	remained	_	
86-23	15519-15526	similar	_	
86-24	15526-15527	.	_	
86-25	15528-15532	mOFC	_	
86-26	15533-15534	=	_	
86-27	15535-15541	medial	_	
86-28	15542-15555	orbitofrontal	_	
86-29	15556-15562	cortex	_	
86-30	15562-15563	;	_	
86-31	15564-15568	vPFC	_	
86-32	15569-15570	=	_	
86-33	15571-15578	ventral	_	
86-34	15579-15589	prefrontal	_	
86-35	15590-15596	cortex	_	
86-36	15596-15597	.	_	

#Text=Cluster-a: Thalamus/putamen/caudate/insula/dorsal lateralprefrontal cortex/hippocampus/anterior cingulate/pars triangularis/superior temporal gyrus/primary sensory/primary motor.
87-1	15598-15607	Cluster-a	_	
87-2	15607-15608	:	_	
87-3	15609-15617	Thalamus	_	
87-4	15617-15618	/	_	
87-5	15618-15625	putamen	_	
87-6	15625-15626	/	_	
87-7	15626-15633	caudate	_	
87-8	15633-15634	/	_	
87-9	15634-15640	insula	_	
87-10	15640-15641	/	_	
87-11	15641-15647	dorsal	_	
87-12	15648-15665	lateralprefrontal	_	
87-13	15666-15672	cortex	_	
87-14	15672-15673	/	_	
87-15	15673-15684	hippocampus	_	
87-16	15684-15685	/	_	
87-17	15685-15693	anterior	_	
87-18	15694-15703	cingulate	_	
87-19	15703-15704	/	_	
87-20	15704-15708	pars	_	
87-21	15709-15721	triangularis	_	
87-22	15721-15722	/	_	
87-23	15722-15730	superior	_	
87-24	15731-15739	temporal	_	
87-25	15740-15745	gyrus	_	
87-26	15745-15746	/	_	
87-27	15746-15753	primary	_	
87-28	15754-15761	sensory	_	
87-29	15761-15762	/	_	
87-30	15762-15769	primary	_	
87-31	15770-15775	motor	_	
87-32	15775-15776	.	_	

#Text=Cluster-b: Frontal eye fields/dorsolateral prefrontal cortex/posterior cingulate
#Text=DBH-genotype-by-condition interaction
#Text=A DBH-genotype-by-condition interaction identified one cluster involving the bilateral thalamus and putamen extending to the left insula, hippocampus, caudate, dorsolateral prefrontal cortex (dlPFC), and anterior cingulate cortex (ACC) (Figure 1A and B; Cluster-a).
88-1	15777-15786	Cluster-b	_	
88-2	15786-15787	:	_	
88-3	15788-15795	Frontal	_	
88-4	15796-15799	eye	_	
88-5	15800-15806	fields	_	
88-6	15806-15807	/	_	
88-7	15807-15819	dorsolateral	_	
88-8	15820-15830	prefrontal	_	
88-9	15831-15837	cortex	_	
88-10	15837-15838	/	_	
88-11	15838-15847	posterior	_	
88-12	15848-15857	cingulate	_	
88-13	15858-15883	DBH-genotype-by-condition	_	
88-14	15884-15895	interaction	_	
88-15	15896-15897	A	_	
88-16	15898-15923	DBH-genotype-by-condition	_	
88-17	15924-15935	interaction	_	
88-18	15936-15946	identified	_	
88-19	15947-15950	one	_	
88-20	15951-15958	cluster	_	
88-21	15959-15968	involving	_	
88-22	15969-15972	the	_	
88-23	15973-15982	bilateral	_	
88-24	15983-15991	thalamus	_	
88-25	15992-15995	and	_	
88-26	15996-16003	putamen	_	
88-27	16004-16013	extending	_	
88-28	16014-16016	to	_	
88-29	16017-16020	the	_	
88-30	16021-16025	left	_	
88-31	16026-16032	insula	_	
88-32	16032-16033	,	_	
88-33	16034-16045	hippocampus	_	
88-34	16045-16046	,	_	
88-35	16047-16054	caudate	_	
88-36	16054-16055	,	_	
88-37	16056-16068	dorsolateral	_	
88-38	16069-16079	prefrontal	_	
88-39	16080-16086	cortex	_	
88-40	16087-16088	(	_	
88-41	16088-16093	dlPFC	_	
88-42	16093-16094	)	_	
88-43	16094-16095	,	_	
88-44	16096-16099	and	_	
88-45	16100-16108	anterior	_	
88-46	16109-16118	cingulate	_	
88-47	16119-16125	cortex	_	
88-48	16126-16127	(	_	
88-49	16127-16130	ACC	_	
88-50	16130-16131	)	_	
88-51	16132-16133	(	_	
88-52	16133-16139	Figure	_	
88-53	16139-16140	 	_	
88-54	16140-16142	1A	_	
88-55	16143-16146	and	_	
88-56	16147-16148	B	_	
88-57	16148-16149	;	_	
88-58	16150-16159	Cluster-a	_	
88-59	16159-16160	)	_	
88-60	16160-16161	.	_	

#Text=Another cluster involved the right dlPFC and posterior cingulate cortex (Figure 1A and B; Cluster-b; Table 2C).
89-1	16162-16169	Another	_	
89-2	16170-16177	cluster	_	
89-3	16178-16186	involved	_	
89-4	16187-16190	the	_	
89-5	16191-16196	right	_	
89-6	16197-16202	dlPFC	_	
89-7	16203-16206	and	_	
89-8	16207-16216	posterior	_	
89-9	16217-16226	cingulate	_	
89-10	16227-16233	cortex	_	
89-11	16234-16235	(	_	
89-12	16235-16241	Figure	_	
89-13	16241-16242	 	_	
89-14	16242-16244	1A	_	
89-15	16245-16248	and	_	
89-16	16249-16250	B	_	
89-17	16250-16251	;	_	
89-18	16252-16261	Cluster-b	_	
89-19	16261-16262	;	_	
89-20	16263-16268	Table	_	
89-21	16268-16269	 	_	
89-22	16269-16271	2C	_	
89-23	16271-16272	)	_	
89-24	16272-16273	.	_	

#Text=For both clusters, significant differences appear driven by greater activation in the DBH CC participants relative to T-carriers during the sad condition (p = .0087 and .041, respectively) but not during the other two conditions (Figure 1B).
90-1	16274-16277	For	_	
90-2	16278-16282	both	_	
90-3	16283-16291	clusters	_	
90-4	16291-16292	,	_	
90-5	16293-16304	significant	_	
90-6	16305-16316	differences	_	
90-7	16317-16323	appear	_	
90-8	16324-16330	driven	_	
90-9	16331-16333	by	_	
90-10	16334-16341	greater	_	
90-11	16342-16352	activation	_	
90-12	16353-16355	in	_	
90-13	16356-16359	the	_	
90-14	16360-16363	DBH	_	
90-15	16364-16366	CC	_	
90-16	16367-16379	participants	_	
90-17	16380-16388	relative	_	
90-18	16389-16391	to	_	
90-19	16392-16402	T-carriers	_	
90-20	16403-16409	during	_	
90-21	16410-16413	the	_	
90-22	16414-16417	sad	_	
90-23	16418-16427	condition	_	
90-24	16428-16429	(	_	
90-25	16429-16430	p	_	
90-26	16431-16432	=	_	
90-27	16433-16438	.0087	_	
90-28	16439-16442	and	_	
90-29	16443-16447	.041	_	
90-30	16447-16448	,	_	
90-31	16449-16461	respectively	_	
90-32	16461-16462	)	_	
90-33	16463-16466	but	_	
90-34	16467-16470	not	_	
90-35	16471-16477	during	_	
90-36	16478-16481	the	_	
90-37	16482-16487	other	_	
90-38	16488-16491	two	_	
90-39	16492-16502	conditions	_	
90-40	16503-16504	(	_	
90-41	16504-16510	Figure	_	
90-42	16510-16511	 	_	
90-43	16511-16513	1B	_	
90-44	16513-16514	)	_	
90-45	16514-16515	.	_	

#Text=Age-adjusted main and interactive effects of DBH genotype, condition and diagnostic group on regional brain activations
#Text=\tLeft/Right\tVolume mm3 (voxels)\tTalairach CenterMass (x, y, z)\tF-values Mean\tF-values Stdev\t \t(A) Main effect DBH genotype\t\t\t\t\t\t \t\t \tCerebellum_parahippocampus_hippocampus_fusiform\t\t35375 (1310)\t−9, −56, −22\t5.85\t1.56\t \tVentral striatum_orbital frontal cortex_anterior cingulate_rostrolateral prefrontal\t\t\t\t\t\t \tCortex_I nferior frontal gyrus_amygdala\t\t19055 (706)\t−8, 20, −6\t5.96\t1.72\t \tSubclusters: Ventral striatum\tL\t955 (35)\t−13, 0, −5\t6.45\t2.21\t \t Anterior cingulate\tL/R\t2301 (85)\t3, 32, 0\t5.09\t.88\t \t Amygdala\tL\t500 (19)\t−17, −7, −10\t6.04\t1.48\t \t Caudate\tL\t774 (29)\t−12, 14, 0\t5.63\t1.22\t \t Putamen\tL\t525 (19)\t−21, 7, −4\t5.67\t1.65\t \t vmPFC\tL/R\t5146 (191)\t−8, 13, −15\t6.72\t2.19\t \t\t \t(B) Main effect condition\t\t\t\t\t\t \t\t \tOccipital cortex_temporal gyrus_angular gyrus_fusiform gyrus_temporopolar area_thalamus_posteror cingulate_cerebellum\t\t249810 (9252)\t−1, −52, 4\t9.00\t6.52\t \tSubclusters: Thalamus\tL\t2089 (77)\t−11, −23, 3\t4.18\t.83\t \t Thalamus\tR\t563 (21)\t7, −23, 2\t3.76\t.48\t \t Posterior cingulate\tL/R\t4181 (155)\t−8, −55, 33\t4.82\t1.37\t \tAnterior cingulate cortex_anterior prefrontal cortex_orbitofrontal gyri_I nsula\t\t12983 (481)\t−9, 42, −6\t4.39\t1.18\t \tSubclusters: Insula\tL\t232 (9)\t−26, 20, 0\t3.66\t.40\t \t vmPFC\tL/R\t4151 (154)\t−8, 37, −20\t4.18\t1.03\t \t Anterior cingulate\tL/R\t1402 (52)\t−4, 39, 8\t4.58\t1.29\t \t Medial frontal gyrus\tL/R\t5907 (219)\t−8, 48, −4\t4.57\t1.27\t \t\t \t(C) DBH genotype X condition\t\t\t\t\t\t \t\t \tThalamus_putamen_caudate_I nsula_dlPFC_Hippocampus_anterior cingulate_pars triangularis_superior temporal gyrus_primary\t\t56708 (2100)\t−24, −1, 19\t4.30\t1.00\t \tSubclusters: Thalamus\tR\t2938 (109)\t11, −15, 7\t4.21\t.77\t \t Thalamus\tL\t2213 (82)\t−10, −16, 10\t4.11\t.84\t \t Putamen\tR\t280 (10)\t25, −1, 0\t3.68\t.41\t \t Putamen\tL\t1475 (55)\t−22, 2, 6\t4.28\t.87\t \t Insula\tL\t544 (20)\t−26, 16, 9\t4.12\t.65\t \t Hippocampus\tL\t905 (34)\t−28, −34, 0\t4.42\t.94\t \t Caudate\tL\t1181 (44)\t−14, 15, 13\t5.31\t1.71\t \t dlPFC\tL\t13771 (510)\t−30, 27, 20\t4.36\t1.00\t \t Anterior Cingulate\tL/R\t794 (29)\t−7, 21, 22\t3.76\t.54\t \tFrontal eye fields_dlPFC_posterior cingulate\tR\t8789 (326)\t17, 15, 28\t4.23\t1.00\t \tSubcluster: Posterior cingulate\tR\t409 (15)\t4, −18, 33\t4.17\t.82\t \t\t \t(D) Group X condition\t\t\t\t\t\t \t\t \tPutamen_caudate_thalamus_orbital frontal cortex_ventral striatum_anterior cingulate_insula_hypothalamus\t\t26068 (965)\t−1, 1, 3\t4.63\t1.50\t \tSubclusters: Putamen\tL\t2918 (108)\t−24, 0, 4\t5.17\t1.90\t \t Caudate\t\t1364 (51)\t14, 4, 13\t4.04\t.78\t \t Caudate\tL\t1449 (54)\t−13, 9, 7\t4.45\t1.04\t \t Thalamus\t\t1592 (59)\t9, −15, 9\t4.01\t.70\t \t Thalamus\tL\t717 (27)\t−8, −17, 6\t3.61\t.42\t \t Ventral Striatum\t\t2004 (74)\t10, 3, −2\t5.43\t1.93\t \t Ventral Striatum\tL\t1159 (43)\t −12, 1, −2\t5.55\t2.31\t \t Medial Orbital Frontal Cortex\tL/R\t474 (18)\t10, 11, −14\t4.37\t.98\t \t Lateral Orbital Frontal Cortex\tL/R\t2299 (85)\t24, 16, −10\t4.43\t1.04\t \t Insula\tL\t1208 (45)\t−33, −4, 13\t4.45\t.94\t \t
#Text=Note.
91-1	16516-16528	Age-adjusted	_	
91-2	16529-16533	main	_	
91-3	16534-16537	and	_	
91-4	16538-16549	interactive	_	
91-5	16550-16557	effects	_	
91-6	16558-16560	of	_	
91-7	16561-16564	DBH	_	
91-8	16565-16573	genotype	_	
91-9	16573-16574	,	_	
91-10	16575-16584	condition	_	
91-11	16585-16588	and	_	
91-12	16589-16599	diagnostic	_	
91-13	16600-16605	group	_	
91-14	16606-16608	on	_	
91-15	16609-16617	regional	_	
91-16	16618-16623	brain	_	
91-17	16624-16635	activations	_	
91-18	16637-16641	Left	_	
91-19	16641-16642	/	_	
91-20	16642-16647	Right	_	
91-21	16648-16654	Volume	_	
91-22	16655-16658	mm3	_	
91-23	16659-16660	(	_	
91-24	16660-16666	voxels	_	
91-25	16666-16667	)	_	
91-26	16668-16677	Talairach	_	
91-27	16678-16688	CenterMass	_	
91-28	16689-16690	(	_	
91-29	16690-16691	x	_	
91-30	16691-16692	,	_	
91-31	16693-16694	y	_	
91-32	16694-16695	,	_	
91-33	16696-16697	z	_	
91-34	16697-16698	)	_	
91-35	16699-16707	F-values	_	
91-36	16708-16712	Mean	_	
91-37	16713-16721	F-values	_	
91-38	16722-16727	Stdev	_	
91-39	16730-16731	(	_	
91-40	16731-16732	A	_	
91-41	16732-16733	)	_	
91-42	16734-16738	Main	_	
91-43	16739-16745	effect	_	
91-44	16746-16749	DBH	_	
91-45	16750-16758	genotype	_	
91-46	16769-16816	Cerebellum_parahippocampus_hippocampus_fusiform	_	
91-47	16818-16823	35375	_	
91-48	16824-16825	(	_	
91-49	16825-16829	1310	_	
91-50	16829-16830	)	_	
91-51	16831-16832	−	_	
91-52	16832-16833	9	_	
91-53	16833-16834	,	_	
91-54	16835-16836	−	_	
91-55	16836-16838	56	_	
91-56	16838-16839	,	_	
91-57	16840-16841	−	_	
91-58	16841-16843	22	_	
91-59	16844-16848	5.85	_	
91-60	16849-16853	1.56	_	
91-61	16856-16863	Ventral	_	
91-62	16864-16880	striatum_orbital	_	
91-63	16881-16888	frontal	_	
91-64	16889-16904	cortex_anterior	_	
91-65	16905-16928	cingulate_rostrolateral	_	
91-66	16929-16939	prefrontal	_	
91-67	16947-16955	Cortex_I	_	
91-68	16956-16963	nferior	_	
91-69	16964-16971	frontal	_	
91-70	16972-16986	gyrus_amygdala	_	
91-71	16988-16993	19055	_	
91-72	16994-16995	(	_	
91-73	16995-16998	706	_	
91-74	16998-16999	)	_	
91-75	17000-17001	−	_	
91-76	17001-17002	8	_	
91-77	17002-17003	,	_	
91-78	17004-17006	20	_	
91-79	17006-17007	,	_	
91-80	17008-17009	−	_	
91-81	17009-17010	6	_	
91-82	17011-17015	5.96	_	
91-83	17016-17020	1.72	_	
91-84	17023-17034	Subclusters	_	
91-85	17034-17035	:	_	
91-86	17036-17043	Ventral	_	
91-87	17044-17052	striatum	_	
91-88	17053-17054	L	_	
91-89	17055-17058	955	_	
91-90	17059-17060	(	_	
91-91	17060-17062	35	_	
91-92	17062-17063	)	_	
91-93	17064-17065	−	_	
91-94	17065-17067	13	_	
91-95	17067-17068	,	_	
91-96	17069-17070	0	_	
91-97	17070-17071	,	_	
91-98	17072-17073	−	_	
91-99	17073-17074	5	_	
91-100	17075-17079	6.45	_	
91-101	17080-17084	2.21	_	
91-102	17088-17096	Anterior	_	
91-103	17097-17106	cingulate	_	
91-104	17107-17108	L	_	
91-105	17108-17109	/	_	
91-106	17109-17110	R	_	
91-107	17111-17115	2301	_	
91-108	17116-17117	(	_	
91-109	17117-17119	85	_	
91-110	17119-17120	)	_	
91-111	17121-17122	3	_	
91-112	17122-17123	,	_	
91-113	17124-17126	32	_	
91-114	17126-17127	,	_	
91-115	17128-17129	0	_	
91-116	17130-17134	5.09	_	
91-117	17135-17138	.88	_	
91-118	17142-17150	Amygdala	_	
91-119	17151-17152	L	_	
91-120	17153-17156	500	_	
91-121	17157-17158	(	_	
91-122	17158-17160	19	_	
91-123	17160-17161	)	_	
91-124	17162-17163	−	_	
91-125	17163-17165	17	_	
91-126	17165-17166	,	_	
91-127	17167-17168	−	_	
91-128	17168-17169	7	_	
91-129	17169-17170	,	_	
91-130	17171-17172	−	_	
91-131	17172-17174	10	_	
91-132	17175-17179	6.04	_	
91-133	17180-17184	1.48	_	
91-134	17188-17195	Caudate	_	
91-135	17196-17197	L	_	
91-136	17198-17201	774	_	
91-137	17202-17203	(	_	
91-138	17203-17205	29	_	
91-139	17205-17206	)	_	
91-140	17207-17208	−	_	
91-141	17208-17210	12	_	
91-142	17210-17211	,	_	
91-143	17212-17214	14	_	
91-144	17214-17215	,	_	
91-145	17216-17217	0	_	
91-146	17218-17222	5.63	_	
91-147	17223-17227	1.22	_	
91-148	17231-17238	Putamen	_	
91-149	17239-17240	L	_	
91-150	17241-17244	525	_	
91-151	17245-17246	(	_	
91-152	17246-17248	19	_	
91-153	17248-17249	)	_	
91-154	17250-17251	−	_	
91-155	17251-17253	21	_	
91-156	17253-17254	,	_	
91-157	17255-17256	7	_	
91-158	17256-17257	,	_	
91-159	17258-17259	−	_	
91-160	17259-17260	4	_	
91-161	17261-17265	5.67	_	
91-162	17266-17270	1.65	_	
91-163	17274-17279	vmPFC	_	
91-164	17280-17281	L	_	
91-165	17281-17282	/	_	
91-166	17282-17283	R	_	
91-167	17284-17288	5146	_	
91-168	17289-17290	(	_	
91-169	17290-17293	191	_	
91-170	17293-17294	)	_	
91-171	17295-17296	−	_	
91-172	17296-17297	8	_	
91-173	17297-17298	,	_	
91-174	17299-17301	13	_	
91-175	17301-17302	,	_	
91-176	17303-17304	−	_	
91-177	17304-17306	15	_	
91-178	17307-17311	6.72	_	
91-179	17312-17316	2.19	_	
91-180	17322-17323	(	_	
91-181	17323-17324	B	_	
91-182	17324-17325	)	_	
91-183	17326-17330	Main	_	
91-184	17331-17337	effect	_	
91-185	17338-17347	condition	_	
91-186	17358-17367	Occipital	_	
91-187	17368-17383	cortex_temporal	_	
91-188	17384-17397	gyrus_angular	_	
91-189	17398-17412	gyrus_fusiform	_	
91-190	17413-17431	gyrus_temporopolar	_	
91-191	17432-17454	area_thalamus_posteror	_	
91-192	17455-17475	cingulate_cerebellum	_	
91-193	17477-17483	249810	_	
91-194	17484-17485	(	_	
91-195	17485-17489	9252	_	
91-196	17489-17490	)	_	
91-197	17491-17492	−	_	
91-198	17492-17493	1	_	
91-199	17493-17494	,	_	
91-200	17495-17496	−	_	
91-201	17496-17498	52	_	
91-202	17498-17499	,	_	
91-203	17500-17501	4	_	
91-204	17502-17506	9.00	_	
91-205	17507-17511	6.52	_	
91-206	17514-17525	Subclusters	_	
91-207	17525-17526	:	_	
91-208	17527-17535	Thalamus	_	
91-209	17536-17537	L	_	
91-210	17538-17542	2089	_	
91-211	17543-17544	(	_	
91-212	17544-17546	77	_	
91-213	17546-17547	)	_	
91-214	17548-17549	−	_	
91-215	17549-17551	11	_	
91-216	17551-17552	,	_	
91-217	17553-17554	−	_	
91-218	17554-17556	23	_	
91-219	17556-17557	,	_	
91-220	17558-17559	3	_	
91-221	17560-17564	4.18	_	
91-222	17565-17568	.83	_	
91-223	17572-17580	Thalamus	_	
91-224	17581-17582	R	_	
91-225	17583-17586	563	_	
91-226	17587-17588	(	_	
91-227	17588-17590	21	_	
91-228	17590-17591	)	_	
91-229	17592-17593	7	_	
91-230	17593-17594	,	_	
91-231	17595-17596	−	_	
91-232	17596-17598	23	_	
91-233	17598-17599	,	_	
91-234	17600-17601	2	_	
91-235	17602-17606	3.76	_	
91-236	17607-17610	.48	_	
91-237	17614-17623	Posterior	_	
91-238	17624-17633	cingulate	_	
91-239	17634-17635	L	_	
91-240	17635-17636	/	_	
91-241	17636-17637	R	_	
91-242	17638-17642	4181	_	
91-243	17643-17644	(	_	
91-244	17644-17647	155	_	
91-245	17647-17648	)	_	
91-246	17649-17650	−	_	
91-247	17650-17651	8	_	
91-248	17651-17652	,	_	
91-249	17653-17654	−	_	
91-250	17654-17656	55	_	
91-251	17656-17657	,	_	
91-252	17658-17660	33	_	
91-253	17661-17665	4.82	_	
91-254	17666-17670	1.37	_	
91-255	17673-17681	Anterior	_	
91-256	17682-17691	cingulate	_	
91-257	17692-17707	cortex_anterior	_	
91-258	17708-17718	prefrontal	_	
91-259	17719-17739	cortex_orbitofrontal	_	
91-260	17740-17746	gyri_I	_	
91-261	17747-17752	nsula	_	
91-262	17754-17759	12983	_	
91-263	17760-17761	(	_	
91-264	17761-17764	481	_	
91-265	17764-17765	)	_	
91-266	17766-17767	−	_	
91-267	17767-17768	9	_	
91-268	17768-17769	,	_	
91-269	17770-17772	42	_	
91-270	17772-17773	,	_	
91-271	17774-17775	−	_	
91-272	17775-17776	6	_	
91-273	17777-17781	4.39	_	
91-274	17782-17786	1.18	_	
91-275	17789-17800	Subclusters	_	
91-276	17800-17801	:	_	
91-277	17802-17808	Insula	_	
91-278	17809-17810	L	_	
91-279	17811-17814	232	_	
91-280	17815-17816	(	_	
91-281	17816-17817	9	_	
91-282	17817-17818	)	_	
91-283	17819-17820	−	_	
91-284	17820-17822	26	_	
91-285	17822-17823	,	_	
91-286	17824-17826	20	_	
91-287	17826-17827	,	_	
91-288	17828-17829	0	_	
91-289	17830-17834	3.66	_	
91-290	17835-17838	.40	_	
91-291	17842-17847	vmPFC	_	
91-292	17848-17849	L	_	
91-293	17849-17850	/	_	
91-294	17850-17851	R	_	
91-295	17852-17856	4151	_	
91-296	17857-17858	(	_	
91-297	17858-17861	154	_	
91-298	17861-17862	)	_	
91-299	17863-17864	−	_	
91-300	17864-17865	8	_	
91-301	17865-17866	,	_	
91-302	17867-17869	37	_	
91-303	17869-17870	,	_	
91-304	17871-17872	−	_	
91-305	17872-17874	20	_	
91-306	17875-17879	4.18	_	
91-307	17880-17884	1.03	_	
91-308	17888-17896	Anterior	_	
91-309	17897-17906	cingulate	_	
91-310	17907-17908	L	_	
91-311	17908-17909	/	_	
91-312	17909-17910	R	_	
91-313	17911-17915	1402	_	
91-314	17916-17917	(	_	
91-315	17917-17919	52	_	
91-316	17919-17920	)	_	
91-317	17921-17922	−	_	
91-318	17922-17923	4	_	
91-319	17923-17924	,	_	
91-320	17925-17927	39	_	
91-321	17927-17928	,	_	
91-322	17929-17930	8	_	
91-323	17931-17935	4.58	_	
91-324	17936-17940	1.29	_	
91-325	17944-17950	Medial	_	
91-326	17951-17958	frontal	_	
91-327	17959-17964	gyrus	_	
91-328	17965-17966	L	_	
91-329	17966-17967	/	_	
91-330	17967-17968	R	_	
91-331	17969-17973	5907	_	
91-332	17974-17975	(	_	
91-333	17975-17978	219	_	
91-334	17978-17979	)	_	
91-335	17980-17981	−	_	
91-336	17981-17982	8	_	
91-337	17982-17983	,	_	
91-338	17984-17986	48	_	
91-339	17986-17987	,	_	
91-340	17988-17989	−	_	
91-341	17989-17990	4	_	
91-342	17991-17995	4.57	_	
91-343	17996-18000	1.27	_	
91-344	18006-18007	(	_	
91-345	18007-18008	C	_	
91-346	18008-18009	)	_	
91-347	18010-18013	DBH	_	
91-348	18014-18022	genotype	_	
91-349	18023-18024	X	_	
91-350	18025-18034	condition	_	
91-351	18045-18071	Thalamus_putamen_caudate_I	_	
91-352	18072-18104	nsula_dlPFC_Hippocampus_anterior	_	
91-353	18105-18119	cingulate_pars	_	
91-354	18120-18141	triangularis_superior	_	
91-355	18142-18150	temporal	_	
91-356	18151-18164	gyrus_primary	_	
91-357	18166-18171	56708	_	
91-358	18172-18173	(	_	
91-359	18173-18177	2100	_	
91-360	18177-18178	)	_	
91-361	18179-18180	−	_	
91-362	18180-18182	24	_	
91-363	18182-18183	,	_	
91-364	18184-18185	−	_	
91-365	18185-18186	1	_	
91-366	18186-18187	,	_	
91-367	18188-18190	19	_	
91-368	18191-18195	4.30	_	
91-369	18196-18200	1.00	_	
91-370	18203-18214	Subclusters	_	
91-371	18214-18215	:	_	
91-372	18216-18224	Thalamus	_	
91-373	18225-18226	R	_	
91-374	18227-18231	2938	_	
91-375	18232-18233	(	_	
91-376	18233-18236	109	_	
91-377	18236-18237	)	_	
91-378	18238-18240	11	_	
91-379	18240-18241	,	_	
91-380	18242-18243	−	_	
91-381	18243-18245	15	_	
91-382	18245-18246	,	_	
91-383	18247-18248	7	_	
91-384	18249-18253	4.21	_	
91-385	18254-18257	.77	_	
91-386	18261-18269	Thalamus	_	
91-387	18270-18271	L	_	
91-388	18272-18276	2213	_	
91-389	18277-18278	(	_	
91-390	18278-18280	82	_	
91-391	18280-18281	)	_	
91-392	18282-18283	−	_	
91-393	18283-18285	10	_	
91-394	18285-18286	,	_	
91-395	18287-18288	−	_	
91-396	18288-18290	16	_	
91-397	18290-18291	,	_	
91-398	18292-18294	10	_	
91-399	18295-18299	4.11	_	
91-400	18300-18303	.84	_	
91-401	18307-18314	Putamen	_	
91-402	18315-18316	R	_	
91-403	18317-18320	280	_	
91-404	18321-18322	(	_	
91-405	18322-18324	10	_	
91-406	18324-18325	)	_	
91-407	18326-18328	25	_	
91-408	18328-18329	,	_	
91-409	18330-18331	−	_	
91-410	18331-18332	1	_	
91-411	18332-18333	,	_	
91-412	18334-18335	0	_	
91-413	18336-18340	3.68	_	
91-414	18341-18344	.41	_	
91-415	18348-18355	Putamen	_	
91-416	18356-18357	L	_	
91-417	18358-18362	1475	_	
91-418	18363-18364	(	_	
91-419	18364-18366	55	_	
91-420	18366-18367	)	_	
91-421	18368-18369	−	_	
91-422	18369-18371	22	_	
91-423	18371-18372	,	_	
91-424	18373-18374	2	_	
91-425	18374-18375	,	_	
91-426	18376-18377	6	_	
91-427	18378-18382	4.28	_	
91-428	18383-18386	.87	_	
91-429	18390-18396	Insula	_	
91-430	18397-18398	L	_	
91-431	18399-18402	544	_	
91-432	18403-18404	(	_	
91-433	18404-18406	20	_	
91-434	18406-18407	)	_	
91-435	18408-18409	−	_	
91-436	18409-18411	26	_	
91-437	18411-18412	,	_	
91-438	18413-18415	16	_	
91-439	18415-18416	,	_	
91-440	18417-18418	9	_	
91-441	18419-18423	4.12	_	
91-442	18424-18427	.65	_	
91-443	18431-18442	Hippocampus	_	
91-444	18443-18444	L	_	
91-445	18445-18448	905	_	
91-446	18449-18450	(	_	
91-447	18450-18452	34	_	
91-448	18452-18453	)	_	
91-449	18454-18455	−	_	
91-450	18455-18457	28	_	
91-451	18457-18458	,	_	
91-452	18459-18460	−	_	
91-453	18460-18462	34	_	
91-454	18462-18463	,	_	
91-455	18464-18465	0	_	
91-456	18466-18470	4.42	_	
91-457	18471-18474	.94	_	
91-458	18478-18485	Caudate	_	
91-459	18486-18487	L	_	
91-460	18488-18492	1181	_	
91-461	18493-18494	(	_	
91-462	18494-18496	44	_	
91-463	18496-18497	)	_	
91-464	18498-18499	−	_	
91-465	18499-18501	14	_	
91-466	18501-18502	,	_	
91-467	18503-18505	15	_	
91-468	18505-18506	,	_	
91-469	18507-18509	13	_	
91-470	18510-18514	5.31	_	
91-471	18515-18519	1.71	_	
91-472	18523-18528	dlPFC	_	
91-473	18529-18530	L	_	
91-474	18531-18536	13771	_	
91-475	18537-18538	(	_	
91-476	18538-18541	510	_	
91-477	18541-18542	)	_	
91-478	18543-18544	−	_	
91-479	18544-18546	30	_	
91-480	18546-18547	,	_	
91-481	18548-18550	27	_	
91-482	18550-18551	,	_	
91-483	18552-18554	20	_	
91-484	18555-18559	4.36	_	
91-485	18560-18564	1.00	_	
91-486	18568-18576	Anterior	_	
91-487	18577-18586	Cingulate	_	
91-488	18587-18588	L	_	
91-489	18588-18589	/	_	
91-490	18589-18590	R	_	
91-491	18591-18594	794	_	
91-492	18595-18596	(	_	
91-493	18596-18598	29	_	
91-494	18598-18599	)	_	
91-495	18600-18601	−	_	
91-496	18601-18602	7	_	
91-497	18602-18603	,	_	
91-498	18604-18606	21	_	
91-499	18606-18607	,	_	
91-500	18608-18610	22	_	
91-501	18611-18615	3.76	_	
91-502	18616-18619	.54	_	
91-503	18622-18629	Frontal	_	
91-504	18630-18633	eye	_	
91-505	18634-18656	fields_dlPFC_posterior	_	
91-506	18657-18666	cingulate	_	
91-507	18667-18668	R	_	
91-508	18669-18673	8789	_	
91-509	18674-18675	(	_	
91-510	18675-18678	326	_	
91-511	18678-18679	)	_	
91-512	18680-18682	17	_	
91-513	18682-18683	,	_	
91-514	18684-18686	15	_	
91-515	18686-18687	,	_	
91-516	18688-18690	28	_	
91-517	18691-18695	4.23	_	
91-518	18696-18700	1.00	_	
91-519	18703-18713	Subcluster	_	
91-520	18713-18714	:	_	
91-521	18715-18724	Posterior	_	
91-522	18725-18734	cingulate	_	
91-523	18735-18736	R	_	
91-524	18737-18740	409	_	
91-525	18741-18742	(	_	
91-526	18742-18744	15	_	
91-527	18744-18745	)	_	
91-528	18746-18747	4	_	
91-529	18747-18748	,	_	
91-530	18749-18750	−	_	
91-531	18750-18752	18	_	
91-532	18752-18753	,	_	
91-533	18754-18756	33	_	
91-534	18757-18761	4.17	_	
91-535	18762-18765	.82	_	
91-536	18771-18772	(	_	
91-537	18772-18773	D	_	
91-538	18773-18774	)	_	
91-539	18775-18780	Group	_	
91-540	18781-18782	X	_	
91-541	18783-18792	condition	_	
91-542	18803-18835	Putamen_caudate_thalamus_orbital	_	
91-543	18836-18843	frontal	_	
91-544	18844-18858	cortex_ventral	_	
91-545	18859-18876	striatum_anterior	_	
91-546	18877-18906	cingulate_insula_hypothalamus	_	
91-547	18908-18913	26068	_	
91-548	18914-18915	(	_	
91-549	18915-18918	965	_	
91-550	18918-18919	)	_	
91-551	18920-18921	−	_	
91-552	18921-18922	1	_	
91-553	18922-18923	,	_	
91-554	18924-18925	1	_	
91-555	18925-18926	,	_	
91-556	18927-18928	3	_	
91-557	18929-18933	4.63	_	
91-558	18934-18938	1.50	_	
91-559	18941-18952	Subclusters	_	
91-560	18952-18953	:	_	
91-561	18954-18961	Putamen	_	
91-562	18962-18963	L	_	
91-563	18964-18968	2918	_	
91-564	18969-18970	(	_	
91-565	18970-18973	108	_	
91-566	18973-18974	)	_	
91-567	18975-18976	−	_	
91-568	18976-18978	24	_	
91-569	18978-18979	,	_	
91-570	18980-18981	0	_	
91-571	18981-18982	,	_	
91-572	18983-18984	4	_	
91-573	18985-18989	5.17	_	
91-574	18990-18994	1.90	_	
91-575	18998-19005	Caudate	_	
91-576	19007-19011	1364	_	
91-577	19012-19013	(	_	
91-578	19013-19015	51	_	
91-579	19015-19016	)	_	
91-580	19017-19019	14	_	
91-581	19019-19020	,	_	
91-582	19021-19022	4	_	
91-583	19022-19023	,	_	
91-584	19024-19026	13	_	
91-585	19027-19031	4.04	_	
91-586	19032-19035	.78	_	
91-587	19039-19046	Caudate	_	
91-588	19047-19048	L	_	
91-589	19049-19053	1449	_	
91-590	19054-19055	(	_	
91-591	19055-19057	54	_	
91-592	19057-19058	)	_	
91-593	19059-19060	−	_	
91-594	19060-19062	13	_	
91-595	19062-19063	,	_	
91-596	19064-19065	9	_	
91-597	19065-19066	,	_	
91-598	19067-19068	7	_	
91-599	19069-19073	4.45	_	
91-600	19074-19078	1.04	_	
91-601	19082-19090	Thalamus	_	
91-602	19092-19096	1592	_	
91-603	19097-19098	(	_	
91-604	19098-19100	59	_	
91-605	19100-19101	)	_	
91-606	19102-19103	9	_	
91-607	19103-19104	,	_	
91-608	19105-19106	−	_	
91-609	19106-19108	15	_	
91-610	19108-19109	,	_	
91-611	19110-19111	9	_	
91-612	19112-19116	4.01	_	
91-613	19117-19120	.70	_	
91-614	19124-19132	Thalamus	_	
91-615	19133-19134	L	_	
91-616	19135-19138	717	_	
91-617	19139-19140	(	_	
91-618	19140-19142	27	_	
91-619	19142-19143	)	_	
91-620	19144-19145	−	_	
91-621	19145-19146	8	_	
91-622	19146-19147	,	_	
91-623	19148-19149	−	_	
91-624	19149-19151	17	_	
91-625	19151-19152	,	_	
91-626	19153-19154	6	_	
91-627	19155-19159	3.61	_	
91-628	19160-19163	.42	_	
91-629	19167-19174	Ventral	_	
91-630	19175-19183	Striatum	_	
91-631	19185-19189	2004	_	
91-632	19190-19191	(	_	
91-633	19191-19193	74	_	
91-634	19193-19194	)	_	
91-635	19195-19197	10	_	
91-636	19197-19198	,	_	
91-637	19199-19200	3	_	
91-638	19200-19201	,	_	
91-639	19202-19203	−	_	
91-640	19203-19204	2	_	
91-641	19205-19209	5.43	_	
91-642	19210-19214	1.93	_	
91-643	19218-19225	Ventral	_	
91-644	19226-19234	Striatum	_	
91-645	19235-19236	L	_	
91-646	19237-19241	1159	_	
91-647	19242-19243	(	_	
91-648	19243-19245	43	_	
91-649	19245-19246	)	_	
91-650	19248-19249	−	_	
91-651	19249-19251	12	_	
91-652	19251-19252	,	_	
91-653	19253-19254	1	_	
91-654	19254-19255	,	_	
91-655	19256-19257	−	_	
91-656	19257-19258	2	_	
91-657	19259-19263	5.55	_	
91-658	19264-19268	2.31	_	
91-659	19272-19278	Medial	_	
91-660	19279-19286	Orbital	_	
91-661	19287-19294	Frontal	_	
91-662	19295-19301	Cortex	_	
91-663	19302-19303	L	_	
91-664	19303-19304	/	_	
91-665	19304-19305	R	_	
91-666	19306-19309	474	_	
91-667	19310-19311	(	_	
91-668	19311-19313	18	_	
91-669	19313-19314	)	_	
91-670	19315-19317	10	_	
91-671	19317-19318	,	_	
91-672	19319-19321	11	_	
91-673	19321-19322	,	_	
91-674	19323-19324	−	_	
91-675	19324-19326	14	_	
91-676	19327-19331	4.37	_	
91-677	19332-19335	.98	_	
91-678	19339-19346	Lateral	_	
91-679	19347-19354	Orbital	_	
91-680	19355-19362	Frontal	_	
91-681	19363-19369	Cortex	_	
91-682	19370-19371	L	_	
91-683	19371-19372	/	_	
91-684	19372-19373	R	_	
91-685	19374-19378	2299	_	
91-686	19379-19380	(	_	
91-687	19380-19382	85	_	
91-688	19382-19383	)	_	
91-689	19384-19386	24	_	
91-690	19386-19387	,	_	
91-691	19388-19390	16	_	
91-692	19390-19391	,	_	
91-693	19392-19393	−	_	
91-694	19393-19395	10	_	
91-695	19396-19400	4.43	_	
91-696	19401-19405	1.04	_	
91-697	19409-19415	Insula	_	
91-698	19416-19417	L	_	
91-699	19418-19422	1208	_	
91-700	19423-19424	(	_	
91-701	19424-19426	45	_	
91-702	19426-19427	)	_	
91-703	19428-19429	−	_	
91-704	19429-19431	33	_	
91-705	19431-19432	,	_	
91-706	19433-19434	−	_	
91-707	19434-19435	4	_	
91-708	19435-19436	,	_	
91-709	19437-19439	13	_	
91-710	19440-19444	4.45	_	
91-711	19445-19448	.94	_	
91-712	19452-19456	Note	_	
91-713	19456-19457	.	_	

#Text=All the main and interactive effects were detected with an uncorrected threshold of p < .05 and familywise error (FWE)-corrected with c = 311 except the main effect of condition with an uncorrected threshold of p < .005 and c = 311 FWE-corrected.
92-1	19458-19461	All	_	
92-2	19462-19465	the	_	
92-3	19466-19470	main	_	
92-4	19471-19474	and	_	
92-5	19475-19486	interactive	_	
92-6	19487-19494	effects	_	
92-7	19495-19499	were	_	
92-8	19500-19508	detected	_	
92-9	19509-19513	with	_	
92-10	19514-19516	an	_	
92-11	19517-19528	uncorrected	_	
92-12	19529-19538	threshold	_	
92-13	19539-19541	of	_	
92-14	19542-19543	p	_	
92-15	19544-19545	<	_	
92-16	19546-19549	.05	_	
92-17	19550-19553	and	_	
92-18	19554-19564	familywise	_	
92-19	19565-19570	error	_	
92-20	19571-19572	(	_	
92-21	19572-19575	FWE	_	
92-22	19575-19576	)	_	
92-23	19576-19577	-	_	
92-24	19577-19586	corrected	_	
92-25	19587-19591	with	_	
92-26	19592-19593	c	_	
92-27	19594-19595	=	_	
92-28	19596-19599	311	_	
92-29	19600-19606	except	_	
92-30	19607-19610	the	_	
92-31	19611-19615	main	_	
92-32	19616-19622	effect	_	
92-33	19623-19625	of	_	
92-34	19626-19635	condition	_	
92-35	19636-19640	with	_	
92-36	19641-19643	an	_	
92-37	19644-19655	uncorrected	_	
92-38	19656-19665	threshold	_	
92-39	19666-19668	of	_	
92-40	19669-19670	p	_	
92-41	19671-19672	<	_	
92-42	19673-19677	.005	_	
92-43	19678-19681	and	_	
92-44	19682-19683	c	_	
92-45	19684-19685	=	_	
92-46	19686-19689	311	_	
92-47	19690-19703	FWE-corrected	_	
92-48	19703-19704	.	_	

#Text=Brain regions starting with “R” or “L” indicate right and left, respectively.
93-1	19705-19710	Brain	_	
93-2	19711-19718	regions	_	
93-3	19719-19727	starting	_	
93-4	19728-19732	with	_	
93-5	19733-19734	“	_	
93-6	19734-19735	R	_	
93-7	19735-19736	”	_	
93-8	19737-19739	or	_	
93-9	19740-19741	“	_	
93-10	19741-19742	L	_	
93-11	19742-19743	”	_	
93-12	19744-19752	indicate	_	
93-13	19753-19758	right	_	
93-14	19759-19762	and	_	
93-15	19763-19767	left	_	
93-16	19767-19768	,	_	
93-17	19769-19781	respectively	_	
93-18	19781-19782	.	_	

#Text=Group-by-condition interaction
#Text=A group-by-condition interaction occurred in a ventral striatal cluster extending to the medial and lateral orbitofrontal cortex (OFC), thalamus, caudate, left insula, and left putamen (Figure 1C and Table 2D).
94-1	19783-19801	Group-by-condition	_	
94-2	19802-19813	interaction	_	
94-3	19814-19815	A	_	
94-4	19816-19834	group-by-condition	_	
94-5	19835-19846	interaction	_	
94-6	19847-19855	occurred	_	
94-7	19856-19858	in	_	
94-8	19859-19860	a	_	
94-9	19861-19868	ventral	_	
94-10	19869-19877	striatal	_	
94-11	19878-19885	cluster	_	
94-12	19886-19895	extending	_	
94-13	19896-19898	to	_	
94-14	19899-19902	the	_	
94-15	19903-19909	medial	_	
94-16	19910-19913	and	_	
94-17	19914-19921	lateral	_	
94-18	19922-19935	orbitofrontal	_	
94-19	19936-19942	cortex	_	
94-20	19943-19944	(	_	
94-21	19944-19947	OFC	_	
94-22	19947-19948	)	_	
94-23	19948-19949	,	_	
94-24	19950-19958	thalamus	_	
94-25	19958-19959	,	_	
94-26	19960-19967	caudate	_	
94-27	19967-19968	,	_	
94-28	19969-19973	left	_	
94-29	19974-19980	insula	_	
94-30	19980-19981	,	_	
94-31	19982-19985	and	_	
94-32	19986-19990	left	_	
94-33	19991-19998	putamen	_	
94-34	19999-20000	(	_	
94-35	20000-20006	Figure	_	
94-36	20006-20007	 	_	
94-37	20007-20009	1C	_	
94-38	20010-20013	and	_	
94-39	20014-20019	Table	_	
94-40	20019-20020	 	_	
94-41	20020-20022	2D	_	
94-42	20022-20023	)	_	
94-43	20023-20024	.	_	

#Text=Relative to the HC group, the PG group demonstrated significantly greater recruitment during the cocaine condition (p = .0098), less activation during the sad condition (p = .031), and no difference during the gambling condition (p = .24; Figure 1D).
95-1	20025-20033	Relative	_	
95-2	20034-20036	to	_	
95-3	20037-20040	the	_	
95-4	20041-20043	HC	_	
95-5	20044-20049	group	_	
95-6	20049-20050	,	_	
95-7	20051-20054	the	_	
95-8	20055-20057	PG	_	
95-9	20058-20063	group	_	
95-10	20064-20076	demonstrated	_	
95-11	20077-20090	significantly	_	
95-12	20091-20098	greater	_	
95-13	20099-20110	recruitment	_	
95-14	20111-20117	during	_	
95-15	20118-20121	the	_	
95-16	20122-20129	cocaine	_	
95-17	20130-20139	condition	_	
95-18	20140-20141	(	_	
95-19	20141-20142	p	_	
95-20	20143-20144	=	_	
95-21	20145-20150	.0098	_	
95-22	20150-20151	)	_	
95-23	20151-20152	,	_	
95-24	20153-20157	less	_	
95-25	20158-20168	activation	_	
95-26	20169-20175	during	_	
95-27	20176-20179	the	_	
95-28	20180-20183	sad	_	
95-29	20184-20193	condition	_	
95-30	20194-20195	(	_	
95-31	20195-20196	p	_	
95-32	20197-20198	=	_	
95-33	20199-20203	.031	_	
95-34	20203-20204	)	_	
95-35	20204-20205	,	_	
95-36	20206-20209	and	_	
95-37	20210-20212	no	_	
95-38	20213-20223	difference	_	
95-39	20224-20230	during	_	
95-40	20231-20234	the	_	
95-41	20235-20243	gambling	_	
95-42	20244-20253	condition	_	
95-43	20254-20255	(	_	
95-44	20255-20256	p	_	
95-45	20257-20258	=	_	
95-46	20259-20262	.24	_	
95-47	20262-20263	;	_	
95-48	20264-20270	Figure	_	
95-49	20270-20271	 	_	
95-50	20271-20273	1D	_	
95-51	20273-20274	)	_	
95-52	20274-20275	.	_	

#Text=Main effects of DBH genotype
#Text=A main DBH-genotype effect demonstrated greater CC group activity in the left VS extending to the OFC, ACC, amygdala, caudate, putamen, and vmPFC (Table 2A and Figure 2A), relative to the T-carriers (Figure 2B, Cluster-a).
96-1	20276-20280	Main	_	
96-2	20281-20288	effects	_	
96-3	20289-20291	of	_	
96-4	20292-20295	DBH	_	
96-5	20296-20304	genotype	_	
96-6	20305-20306	A	_	
96-7	20307-20311	main	_	
96-8	20312-20324	DBH-genotype	_	
96-9	20325-20331	effect	_	
96-10	20332-20344	demonstrated	_	
96-11	20345-20352	greater	_	
96-12	20353-20355	CC	_	
96-13	20356-20361	group	_	
96-14	20362-20370	activity	_	
96-15	20371-20373	in	_	
96-16	20374-20377	the	_	
96-17	20378-20382	left	_	
96-18	20383-20385	VS	_	
96-19	20386-20395	extending	_	
96-20	20396-20398	to	_	
96-21	20399-20402	the	_	
96-22	20403-20406	OFC	_	
96-23	20406-20407	,	_	
96-24	20408-20411	ACC	_	
96-25	20411-20412	,	_	
96-26	20413-20421	amygdala	_	
96-27	20421-20422	,	_	
96-28	20423-20430	caudate	_	
96-29	20430-20431	,	_	
96-30	20432-20439	putamen	_	
96-31	20439-20440	,	_	
96-32	20441-20444	and	_	
96-33	20445-20450	vmPFC	_	
96-34	20451-20452	(	_	
96-35	20452-20457	Table	_	
96-36	20457-20458	 	_	
96-37	20458-20460	2A	_	
96-38	20461-20464	and	_	
96-39	20465-20471	Figure	_	
96-40	20471-20472	 	_	
96-41	20472-20474	2A	_	
96-42	20474-20475	)	_	
96-43	20475-20476	,	_	
96-44	20477-20485	relative	_	
96-45	20486-20488	to	_	
96-46	20489-20492	the	_	
96-47	20493-20503	T-carriers	_	
96-48	20504-20505	(	_	
96-49	20505-20511	Figure	_	
96-50	20511-20512	 	_	
96-51	20512-20514	2B	_	
96-52	20514-20515	,	_	
96-53	20516-20525	Cluster-a	_	
96-54	20525-20526	)	_	
96-55	20526-20527	.	_	

#Text=Another cluster extended from the cerebellum to the hippocampus and also displayed relatively greater activity in the CC versus T-carrier groups (Figure 2B, Cluster-b).
97-1	20528-20535	Another	_	
97-2	20536-20543	cluster	_	
97-3	20544-20552	extended	_	
97-4	20553-20557	from	_	
97-5	20558-20561	the	_	
97-6	20562-20572	cerebellum	_	
97-7	20573-20575	to	_	
97-8	20576-20579	the	_	
97-9	20580-20591	hippocampus	_	
97-10	20592-20595	and	_	
97-11	20596-20600	also	_	
97-12	20601-20610	displayed	_	
97-13	20611-20621	relatively	_	
97-14	20622-20629	greater	_	
97-15	20630-20638	activity	_	
97-16	20639-20641	in	_	
97-17	20642-20645	the	_	
97-18	20646-20648	CC	_	
97-19	20649-20655	versus	_	
97-20	20656-20665	T-carrier	_	
97-21	20666-20672	groups	_	
97-22	20673-20674	(	_	
97-23	20674-20680	Figure	_	
97-24	20680-20681	 	_	
97-25	20681-20683	2B	_	
97-26	20683-20684	,	_	
97-27	20685-20694	Cluster-b	_	
97-28	20694-20695	)	_	
97-29	20695-20696	.	_	

#Text=Main effects of DBH genotype and condition.
98-1	20697-20701	Main	_	
98-2	20702-20709	effects	_	
98-3	20710-20712	of	_	
98-4	20713-20716	DBH	_	
98-5	20717-20725	genotype	_	
98-6	20726-20729	and	_	
98-7	20730-20739	condition	_	
98-8	20739-20740	.	_	

#Text=Axial brain sections highlighting regions showing significant main effects of DBH genotype (A) and condition (C) with age adjustment are shown.
99-1	20741-20746	Axial	_	
99-2	20747-20752	brain	_	
99-3	20753-20761	sections	_	
99-4	20762-20774	highlighting	_	
99-5	20775-20782	regions	_	
99-6	20783-20790	showing	_	
99-7	20791-20802	significant	_	
99-8	20803-20807	main	_	
99-9	20808-20815	effects	_	
99-10	20816-20818	of	_	
99-11	20819-20822	DBH	_	
99-12	20823-20831	genotype	_	
99-13	20832-20833	(	_	
99-14	20833-20834	A	_	
99-15	20834-20835	)	_	
99-16	20836-20839	and	_	
99-17	20840-20849	condition	_	
99-18	20850-20851	(	_	
99-19	20851-20852	C	_	
99-20	20852-20853	)	_	
99-21	20854-20858	with	_	
99-22	20859-20862	age	_	
99-23	20863-20873	adjustment	_	
99-24	20874-20877	are	_	
99-25	20878-20883	shown	_	
99-26	20883-20884	.	_	

#Text=The maps are thresholded at p < .05, with a family-wise-error correction.
100-1	20885-20888	The	_	
100-2	20889-20893	maps	_	
100-3	20894-20897	are	_	
100-4	20898-20909	thresholded	_	
100-5	20910-20912	at	_	
100-6	20913-20914	p	_	
100-7	20915-20916	<	_	
100-8	20917-20920	.05	_	
100-9	20920-20921	,	_	
100-10	20922-20926	with	_	
100-11	20927-20928	a	_	
100-12	20929-20946	family-wise-error	_	
100-13	20947-20957	correction	_	
100-14	20957-20958	.	_	

#Text=Talairach z of slices levels are indicated.
101-1	20959-20968	Talairach	_	
101-2	20969-20970	z	_	
101-3	20971-20973	of	_	
101-4	20974-20980	slices	_	
101-5	20981-20987	levels	_	
101-6	20988-20991	are	_	
101-7	20992-21001	indicated	_	
101-8	21001-21002	.	_	

#Text=The bar on the right side of the Figures A and C indicates the strengths of effects.
102-1	21003-21006	The	_	
102-2	21007-21010	bar	_	
102-3	21011-21013	on	_	
102-4	21014-21017	the	_	
102-5	21018-21023	right	_	
102-6	21024-21028	side	_	
102-7	21029-21031	of	_	
102-8	21032-21035	the	_	
102-9	21036-21043	Figures	_	
102-10	21044-21045	A	_	
102-11	21046-21049	and	_	
102-12	21050-21051	C	_	
102-13	21052-21061	indicates	_	
102-14	21062-21065	the	_	
102-15	21066-21075	strengths	_	
102-16	21076-21078	of	_	
102-17	21079-21086	effects	_	
102-18	21086-21087	.	_	

#Text=Right side of the brain is shown on the left.
103-1	21088-21093	Right	_	
103-2	21094-21098	side	_	
103-3	21099-21101	of	_	
103-4	21102-21105	the	_	
103-5	21106-21111	brain	_	
103-6	21112-21114	is	_	
103-7	21115-21120	shown	_	
103-8	21121-21123	on	_	
103-9	21124-21127	the	_	
103-10	21128-21132	left	_	
103-11	21132-21133	.	_	

#Text=Indicated on the right are extracted values of percentage signal change according to (B) genotype (CC, T-carrier) or (D) condition (gambling, sad, and cocaine).
104-1	21134-21143	Indicated	_	
104-2	21144-21146	on	_	
104-3	21147-21150	the	_	
104-4	21151-21156	right	_	
104-5	21157-21160	are	_	
104-6	21161-21170	extracted	_	
104-7	21171-21177	values	_	
104-8	21178-21180	of	_	
104-9	21181-21191	percentage	_	
104-10	21192-21198	signal	_	
104-11	21199-21205	change	_	
104-12	21206-21215	according	_	
104-13	21216-21218	to	_	
104-14	21219-21220	(	_	
104-15	21220-21221	B	_	
104-16	21221-21222	)	_	
104-17	21223-21231	genotype	_	
104-18	21232-21233	(	_	
104-19	21233-21235	CC	_	
104-20	21235-21236	,	_	
104-21	21237-21246	T-carrier	_	
104-22	21246-21247	)	_	
104-23	21248-21250	or	_	
104-24	21251-21252	(	_	
104-25	21252-21253	D	_	
104-26	21253-21254	)	_	
104-27	21255-21264	condition	_	
104-28	21265-21266	(	_	
104-29	21266-21274	gambling	_	
104-30	21274-21275	,	_	
104-31	21276-21279	sad	_	
104-32	21279-21280	,	_	
104-33	21281-21284	and	_	
104-34	21285-21292	cocaine	_	
104-35	21292-21293	)	_	
104-36	21293-21294	.	_	

#Text=Outliers of BOLD-signal are marked by circles; outlier evaluation by exclusion and retest; all the effects in the retests remained similar.
105-1	21295-21303	Outliers	_	
105-2	21304-21306	of	_	
105-3	21307-21318	BOLD-signal	_	
105-4	21319-21322	are	_	
105-5	21323-21329	marked	_	
105-6	21330-21332	by	_	
105-7	21333-21340	circles	_	
105-8	21340-21341	;	_	
105-9	21342-21349	outlier	_	
105-10	21350-21360	evaluation	_	
105-11	21361-21363	by	_	
105-12	21364-21373	exclusion	_	
105-13	21374-21377	and	_	
105-14	21378-21384	retest	_	
105-15	21384-21385	;	_	
105-16	21386-21389	all	_	
105-17	21390-21393	the	_	
105-18	21394-21401	effects	_	
105-19	21402-21404	in	_	
105-20	21405-21408	the	_	
105-21	21409-21416	retests	_	
105-22	21417-21425	remained	_	
105-23	21426-21433	similar	_	
105-24	21433-21434	.	_	

#Text=Cluster-a: ventral striatum/orbital frontal cortex/anterior cingulate/rostrolateral prefrontal cortex/inferior frontal gyrus/amygdala.
106-1	21435-21444	Cluster-a	_	
106-2	21444-21445	:	_	
106-3	21446-21453	ventral	_	
106-4	21454-21462	striatum	_	
106-5	21462-21463	/	_	
106-6	21463-21470	orbital	_	
106-7	21471-21478	frontal	_	
106-8	21479-21485	cortex	_	
106-9	21485-21486	/	_	
106-10	21486-21494	anterior	_	
106-11	21495-21504	cingulate	_	
106-12	21504-21505	/	_	
106-13	21505-21518	rostrolateral	_	
106-14	21519-21529	prefrontal	_	
106-15	21530-21536	cortex	_	
106-16	21536-21537	/	_	
106-17	21537-21545	inferior	_	
106-18	21546-21553	frontal	_	
106-19	21554-21559	gyrus	_	
106-20	21559-21560	/	_	
106-21	21560-21568	amygdala	_	
106-22	21568-21569	.	_	

#Text=Cluster-b: Cerebellum/parahippocampus/hippocampus/Fusiform.
107-1	21570-21579	Cluster-b	_	
107-2	21579-21580	:	_	
107-3	21581-21591	Cerebellum	_	
107-4	21591-21592	/	_	
107-5	21592-21607	parahippocampus	_	
107-6	21607-21608	/	_	
107-7	21608-21619	hippocampus	_	
107-8	21619-21620	/	_	
107-9	21620-21628	Fusiform	_	
107-10	21628-21629	.	_	

#Text=Cluster-c: Occipital cortex/temporal gyrus/angular gyrus/fusiform gyrus/temporopolar area/thalamus/posteror cingulate/cerebellum.
108-1	21630-21639	Cluster-c	_	
108-2	21639-21640	:	_	
108-3	21641-21650	Occipital	_	
108-4	21651-21657	cortex	_	
108-5	21657-21658	/	_	
108-6	21658-21666	temporal	_	
108-7	21667-21672	gyrus	_	
108-8	21672-21673	/	_	
108-9	21673-21680	angular	_	
108-10	21681-21686	gyrus	_	
108-11	21686-21687	/	_	
108-12	21687-21695	fusiform	_	
108-13	21696-21701	gyrus	_	
108-14	21701-21702	/	_	
108-15	21702-21714	temporopolar	_	
108-16	21715-21719	area	_	
108-17	21719-21720	/	_	
108-18	21720-21728	thalamus	_	
108-19	21728-21729	/	_	
108-20	21729-21737	posteror	_	
108-21	21738-21747	cingulate	_	
108-22	21747-21748	/	_	
108-23	21748-21758	cerebellum	_	
108-24	21758-21759	.	_	

#Text=Cluster-d: Anterior cingulate cortex/anterior prefrontal cortex/orbitofrontal gyri/insula
#Text=Main effects of condition
#Text=A main condition effect recruited the bilateral thalamus extending to the posterior cingulate and appeared to be driven by greater activation to the gambling versus cocaine (p = 1.62 × 10−5) and gambling versus sad (p = .0067) conditions, with no difference in the cocaine versus sad condition (p = .10) (Figure 2D, Cluster-c).
109-1	21760-21769	Cluster-d	_	
109-2	21769-21770	:	_	
109-3	21771-21779	Anterior	_	
109-4	21780-21789	cingulate	_	
109-5	21790-21796	cortex	_	
109-6	21796-21797	/	_	
109-7	21797-21805	anterior	_	
109-8	21806-21816	prefrontal	_	
109-9	21817-21823	cortex	_	
109-10	21823-21824	/	_	
109-11	21824-21837	orbitofrontal	_	
109-12	21838-21842	gyri	_	
109-13	21842-21843	/	_	
109-14	21843-21849	insula	_	
109-15	21850-21854	Main	_	
109-16	21855-21862	effects	_	
109-17	21863-21865	of	_	
109-18	21866-21875	condition	_	
109-19	21876-21877	A	_	
109-20	21878-21882	main	_	
109-21	21883-21892	condition	_	
109-22	21893-21899	effect	_	
109-23	21900-21909	recruited	_	
109-24	21910-21913	the	_	
109-25	21914-21923	bilateral	_	
109-26	21924-21932	thalamus	_	
109-27	21933-21942	extending	_	
109-28	21943-21945	to	_	
109-29	21946-21949	the	_	
109-30	21950-21959	posterior	_	
109-31	21960-21969	cingulate	_	
109-32	21970-21973	and	_	
109-33	21974-21982	appeared	_	
109-34	21983-21985	to	_	
109-35	21986-21988	be	_	
109-36	21989-21995	driven	_	
109-37	21996-21998	by	_	
109-38	21999-22006	greater	_	
109-39	22007-22017	activation	_	
109-40	22018-22020	to	_	
109-41	22021-22024	the	_	
109-42	22025-22033	gambling	_	
109-43	22034-22040	versus	_	
109-44	22041-22048	cocaine	_	
109-45	22049-22050	(	_	
109-46	22050-22051	p	_	
109-47	22052-22053	=	_	
109-48	22054-22058	1.62	_	
109-49	22059-22060	×	_	
109-50	22061-22063	10	_	
109-51	22063-22064	−	_	
109-52	22064-22065	5	_	
109-53	22065-22066	)	_	
109-54	22067-22070	and	_	
109-55	22071-22079	gambling	_	
109-56	22080-22086	versus	_	
109-57	22087-22090	sad	_	
109-58	22091-22092	(	_	
109-59	22092-22093	p	_	
109-60	22094-22095	=	_	
109-61	22096-22101	.0067	_	
109-62	22101-22102	)	_	
109-63	22103-22113	conditions	_	
109-64	22113-22114	,	_	
109-65	22115-22119	with	_	
109-66	22120-22122	no	_	
109-67	22123-22133	difference	_	
109-68	22134-22136	in	_	
109-69	22137-22140	the	_	
109-70	22141-22148	cocaine	_	
109-71	22149-22155	versus	_	
109-72	22156-22159	sad	_	
109-73	22160-22169	condition	_	
109-74	22170-22171	(	_	
109-75	22171-22172	p	_	
109-76	22173-22174	=	_	
109-77	22175-22178	.10	_	
109-78	22178-22179	)	_	
109-79	22180-22181	(	_	
109-80	22181-22187	Figure	_	
109-81	22187-22188	 	_	
109-82	22188-22190	2D	_	
109-83	22190-22191	,	_	
109-84	22192-22201	Cluster-c	_	
109-85	22201-22202	)	_	
109-86	22202-22203	.	_	

#Text=Another cluster extending from the vmPFC to the ACC and medial frontal gyrus (Table 2B and Figure 2C) appeared to be driven by decreased activation in the cocaine versus gambling (p = .0021) and cocaine versus sad (p = .00094) conditions, with no difference in the gambling versus sad conditions (p = .57) (Figure 2D, Cluster-d).
110-1	22204-22211	Another	_	
110-2	22212-22219	cluster	_	
110-3	22220-22229	extending	_	
110-4	22230-22234	from	_	
110-5	22235-22238	the	_	
110-6	22239-22244	vmPFC	_	
110-7	22245-22247	to	_	
110-8	22248-22251	the	_	
110-9	22252-22255	ACC	_	
110-10	22256-22259	and	_	
110-11	22260-22266	medial	_	
110-12	22267-22274	frontal	_	
110-13	22275-22280	gyrus	_	
110-14	22281-22282	(	_	
110-15	22282-22287	Table	_	
110-16	22287-22288	 	_	
110-17	22288-22290	2B	_	
110-18	22291-22294	and	_	
110-19	22295-22301	Figure	_	
110-20	22301-22302	 	_	
110-21	22302-22304	2C	_	
110-22	22304-22305	)	_	
110-23	22306-22314	appeared	_	
110-24	22315-22317	to	_	
110-25	22318-22320	be	_	
110-26	22321-22327	driven	_	
110-27	22328-22330	by	_	
110-28	22331-22340	decreased	_	
110-29	22341-22351	activation	_	
110-30	22352-22354	in	_	
110-31	22355-22358	the	_	
110-32	22359-22366	cocaine	_	
110-33	22367-22373	versus	_	
110-34	22374-22382	gambling	_	
110-35	22383-22384	(	_	
110-36	22384-22385	p	_	
110-37	22386-22387	=	_	
110-38	22388-22393	.0021	_	
110-39	22393-22394	)	_	
110-40	22395-22398	and	_	
110-41	22399-22406	cocaine	_	
110-42	22407-22413	versus	_	
110-43	22414-22417	sad	_	
110-44	22418-22419	(	_	
110-45	22419-22420	p	_	
110-46	22421-22422	=	_	
110-47	22423-22429	.00094	_	
110-48	22429-22430	)	_	
110-49	22431-22441	conditions	_	
110-50	22441-22442	,	_	
110-51	22443-22447	with	_	
110-52	22448-22450	no	_	
110-53	22451-22461	difference	_	
110-54	22462-22464	in	_	
110-55	22465-22468	the	_	
110-56	22469-22477	gambling	_	
110-57	22478-22484	versus	_	
110-58	22485-22488	sad	_	
110-59	22489-22499	conditions	_	
110-60	22500-22501	(	_	
110-61	22501-22502	p	_	
110-62	22503-22504	=	_	
110-63	22505-22508	.57	_	
110-64	22508-22509	)	_	
110-65	22510-22511	(	_	
110-66	22511-22517	Figure	_	
110-67	22517-22518	 	_	
110-68	22518-22520	2D	_	
110-69	22520-22521	,	_	
110-70	22522-22531	Cluster-d	_	
110-71	22531-22532	)	_	
110-72	22532-22533	.	_	

#Text=Potential effects of outliers of BOLD-signal changes, as depicted in Figures 1 and 2, were evaluated by exclusion and retest; all the effects in the retests remained similar.
111-1	22534-22543	Potential	_	
111-2	22544-22551	effects	_	
111-3	22552-22554	of	_	
111-4	22555-22563	outliers	_	
111-5	22564-22566	of	_	
111-6	22567-22578	BOLD-signal	_	
111-7	22579-22586	changes	_	
111-8	22586-22587	,	_	
111-9	22588-22590	as	_	
111-10	22591-22599	depicted	_	
111-11	22600-22602	in	_	
111-12	22603-22610	Figures	_	
111-13	22610-22611	 	_	
111-14	22611-22612	1	_	
111-15	22613-22616	and	_	
111-16	22617-22618	2	_	
111-17	22618-22619	,	_	
111-18	22620-22624	were	_	
111-19	22625-22634	evaluated	_	
111-20	22635-22637	by	_	
111-21	22638-22647	exclusion	_	
111-22	22648-22651	and	_	
111-23	22652-22658	retest	_	
111-24	22658-22659	;	_	
111-25	22660-22663	all	_	
111-26	22664-22667	the	_	
111-27	22668-22675	effects	_	
111-28	22676-22678	in	_	
111-29	22679-22682	the	_	
111-30	22683-22690	retests	_	
111-31	22691-22699	remained	_	
111-32	22700-22707	similar	_	
111-33	22707-22708	.	_	

#Text=Main effects of DBH genotype and condition remained strong.
112-1	22709-22713	Main	_	
112-2	22714-22721	effects	_	
112-3	22722-22724	of	_	
112-4	22725-22728	DBH	_	
112-5	22729-22737	genotype	_	
112-6	22738-22741	and	_	
112-7	22742-22751	condition	_	
112-8	22752-22760	remained	_	
112-9	22761-22767	strong	_	
112-10	22767-22768	.	_	

#Text=Effects of DBH-genotype-by-condition kept the striatal cluster (p = .012) and the cluster with the posterior cingulate cortex was in marginal significance (p = .074), and both appeared to be driven by the sad condition.
113-1	22769-22776	Effects	_	
113-2	22777-22779	of	_	
113-3	22780-22805	DBH-genotype-by-condition	_	
113-4	22806-22810	kept	_	
113-5	22811-22814	the	_	
113-6	22815-22823	striatal	_	
113-7	22824-22831	cluster	_	
113-8	22832-22833	(	_	
113-9	22833-22834	p	_	
113-10	22835-22836	=	_	
113-11	22837-22841	.012	_	
113-12	22841-22842	)	_	
113-13	22843-22846	and	_	
113-14	22847-22850	the	_	
113-15	22851-22858	cluster	_	
113-16	22859-22863	with	_	
113-17	22864-22867	the	_	
113-18	22868-22877	posterior	_	
113-19	22878-22887	cingulate	_	
113-20	22888-22894	cortex	_	
113-21	22895-22898	was	_	
113-22	22899-22901	in	_	
113-23	22902-22910	marginal	_	
113-24	22911-22923	significance	_	
113-25	22924-22925	(	_	
113-26	22925-22926	p	_	
113-27	22927-22928	=	_	
113-28	22929-22933	.074	_	
113-29	22933-22934	)	_	
113-30	22934-22935	,	_	
113-31	22936-22939	and	_	
113-32	22940-22944	both	_	
113-33	22945-22953	appeared	_	
113-34	22954-22956	to	_	
113-35	22957-22959	be	_	
113-36	22960-22966	driven	_	
113-37	22967-22969	by	_	
113-38	22970-22973	the	_	
113-39	22974-22977	sad	_	
113-40	22978-22987	condition	_	
113-41	22987-22988	.	_	

#Text=Effects of group-by-condition for the PG group relative to the HC group demonstrated similar results, which reflected greater recruitment during the cocaine condition (p = .016), less recruitment during the sad condition (p = .09), and no difference during the gambling condition (p > .4).
114-1	22989-22996	Effects	_	
114-2	22997-22999	of	_	
114-3	23000-23018	group-by-condition	_	
114-4	23019-23022	for	_	
114-5	23023-23026	the	_	
114-6	23027-23029	PG	_	
114-7	23030-23035	group	_	
114-8	23036-23044	relative	_	
114-9	23045-23047	to	_	
114-10	23048-23051	the	_	
114-11	23052-23054	HC	_	
114-12	23055-23060	group	_	
114-13	23061-23073	demonstrated	_	
114-14	23074-23081	similar	_	
114-15	23082-23089	results	_	
114-16	23089-23090	,	_	
114-17	23091-23096	which	_	
114-18	23097-23106	reflected	_	
114-19	23107-23114	greater	_	
114-20	23115-23126	recruitment	_	
114-21	23127-23133	during	_	
114-22	23134-23137	the	_	
114-23	23138-23145	cocaine	_	
114-24	23146-23155	condition	_	
114-25	23156-23157	(	_	
114-26	23157-23158	p	_	
114-27	23159-23160	=	_	
114-28	23161-23165	.016	_	
114-29	23165-23166	)	_	
114-30	23166-23167	,	_	
114-31	23168-23172	less	_	
114-32	23173-23184	recruitment	_	
114-33	23185-23191	during	_	
114-34	23192-23195	the	_	
114-35	23196-23199	sad	_	
114-36	23200-23209	condition	_	
114-37	23210-23211	(	_	
114-38	23211-23212	p	_	
114-39	23213-23214	=	_	
114-40	23215-23218	.09	_	
114-41	23218-23219	)	_	
114-42	23219-23220	,	_	
114-43	23221-23224	and	_	
114-44	23225-23227	no	_	
114-45	23228-23238	difference	_	
114-46	23239-23245	during	_	
114-47	23246-23249	the	_	
114-48	23250-23258	gambling	_	
114-49	23259-23268	condition	_	
114-50	23269-23270	(	_	
114-51	23270-23271	p	_	
114-52	23272-23273	>	_	
114-53	23274-23276	.4	_	
114-54	23276-23277	)	_	
114-55	23277-23278	.	_	

#Text=Subjective responses
#Text=The subjective response ratings to the videos, involving ratings of emotional intensity, gambling urges, and drug cravings, are summarized by comparisons of the diagnostic groups (Table 3) and the genotype groups for the sad condition (Table 1B).
115-1	23279-23289	Subjective	_	
115-2	23290-23299	responses	_	
115-3	23300-23303	The	_	
115-4	23304-23314	subjective	_	
115-5	23315-23323	response	_	
115-6	23324-23331	ratings	_	
115-7	23332-23334	to	_	
115-8	23335-23338	the	_	
115-9	23339-23345	videos	_	
115-10	23345-23346	,	_	
115-11	23347-23356	involving	_	
115-12	23357-23364	ratings	_	
115-13	23365-23367	of	_	
115-14	23368-23377	emotional	_	
115-15	23378-23387	intensity	_	
115-16	23387-23388	,	_	
115-17	23389-23397	gambling	_	
115-18	23398-23403	urges	_	
115-19	23403-23404	,	_	
115-20	23405-23408	and	_	
115-21	23409-23413	drug	_	
115-22	23414-23422	cravings	_	
115-23	23422-23423	,	_	
115-24	23424-23427	are	_	
115-25	23428-23438	summarized	_	
115-26	23439-23441	by	_	
115-27	23442-23453	comparisons	_	
115-28	23454-23456	of	_	
115-29	23457-23460	the	_	
115-30	23461-23471	diagnostic	_	
115-31	23472-23478	groups	_	
115-32	23479-23480	(	_	
115-33	23480-23485	Table	_	
115-34	23485-23486	 	_	
115-35	23486-23487	3	_	
115-36	23487-23488	)	_	
115-37	23489-23492	and	_	
115-38	23493-23496	the	_	
115-39	23497-23505	genotype	_	
115-40	23506-23512	groups	_	
115-41	23513-23516	for	_	
115-42	23517-23520	the	_	
115-43	23521-23524	sad	_	
115-44	23525-23534	condition	_	
115-45	23535-23536	(	_	
115-46	23536-23541	Table	_	
115-47	23541-23542	 	_	
115-48	23542-23544	1B	_	
115-49	23544-23545	)	_	
115-50	23545-23546	.	_	

#Text=The T-carriers responded to the sad videos with less subjective sadness (p = .035, Table 1B).
116-1	23547-23550	The	_	
116-2	23551-23561	T-carriers	_	
116-3	23562-23571	responded	_	
116-4	23572-23574	to	_	
116-5	23575-23578	the	_	
116-6	23579-23582	sad	_	
116-7	23583-23589	videos	_	
116-8	23590-23594	with	_	
116-9	23595-23599	less	_	
116-10	23600-23610	subjective	_	
116-11	23611-23618	sadness	_	
116-12	23619-23620	(	_	
116-13	23620-23621	p	_	
116-14	23622-23623	=	_	
116-15	23624-23628	.035	_	
116-16	23628-23629	,	_	
116-17	23630-23635	Table	_	
116-18	23635-23636	 	_	
116-19	23636-23638	1B	_	
116-20	23638-23639	)	_	
116-21	23639-23640	.	_	

#Text=More detailed descriptions regarding the subjective responses of the PG versus HC groups are presented in Supplementary Material VII.
117-1	23641-23645	More	_	
117-2	23646-23654	detailed	_	
117-3	23655-23667	descriptions	_	
117-4	23668-23677	regarding	_	
117-5	23678-23681	the	_	
117-6	23682-23692	subjective	_	
117-7	23693-23702	responses	_	
117-8	23703-23705	of	_	
117-9	23706-23709	the	_	
117-10	23710-23712	PG	_	
117-11	23713-23719	versus	_	
117-12	23720-23722	HC	_	
117-13	23723-23729	groups	_	
117-14	23730-23733	are	_	
117-15	23734-23743	presented	_	
117-16	23744-23746	in	_	
117-17	23747-23760	Supplementary	_	
117-18	23761-23769	Material	_	
117-19	23770-23773	VII	_	
117-20	23773-23774	.	_	

#Text=In comparison to the T-carriers, CC participants demonstrated stronger correlations between brain activations and subjective emotional intensity in response to the sad videos in a cluster extending from the parietal cortex (including inferior parietal lobule) to the inferior occipital gyrus (whole-brain correction p < .05; Supplementary Material VII, Figure S3).
118-1	23775-23777	In	_	
118-2	23778-23788	comparison	_	
118-3	23789-23791	to	_	
118-4	23792-23795	the	_	
118-5	23796-23806	T-carriers	_	
118-6	23806-23807	,	_	
118-7	23808-23810	CC	_	
118-8	23811-23823	participants	_	
118-9	23824-23836	demonstrated	_	
118-10	23837-23845	stronger	_	
118-11	23846-23858	correlations	_	
118-12	23859-23866	between	_	
118-13	23867-23872	brain	_	
118-14	23873-23884	activations	_	
118-15	23885-23888	and	_	
118-16	23889-23899	subjective	_	
118-17	23900-23909	emotional	_	
118-18	23910-23919	intensity	_	
118-19	23920-23922	in	_	
118-20	23923-23931	response	_	
118-21	23932-23934	to	_	
118-22	23935-23938	the	_	
118-23	23939-23942	sad	_	
118-24	23943-23949	videos	_	
118-25	23950-23952	in	_	
118-26	23953-23954	a	_	
118-27	23955-23962	cluster	_	
118-28	23963-23972	extending	_	
118-29	23973-23977	from	_	
118-30	23978-23981	the	_	
118-31	23982-23990	parietal	_	
118-32	23991-23997	cortex	_	
118-33	23998-23999	(	_	
118-34	23999-24008	including	_	
118-35	24009-24017	inferior	_	
118-36	24018-24026	parietal	_	
118-37	24027-24033	lobule	_	
118-38	24033-24034	)	_	
118-39	24035-24037	to	_	
118-40	24038-24041	the	_	
118-41	24042-24050	inferior	_	
118-42	24051-24060	occipital	_	
118-43	24061-24066	gyrus	_	
118-44	24067-24068	(	_	
118-45	24068-24079	whole-brain	_	
118-46	24080-24090	correction	_	
118-47	24091-24092	p	_	
118-48	24093-24094	<	_	
118-49	24095-24098	.05	_	
118-50	24098-24099	;	_	
118-51	24100-24113	Supplementary	_	
118-52	24114-24122	Material	_	
118-53	24123-24126	VII	_	
118-54	24126-24127	,	_	
118-55	24128-24134	Figure	_	
118-56	24135-24137	S3	_	
118-57	24137-24138	)	_	
118-58	24138-24139	.	_	

#Text=Subjective responses to the tape viewing
#Text=Videotape condition\tSubjective responses\tPG mean [SD]\tHC mean [SD]\tPG versus HC p-values\t \tGambling\tEmotional intensity\t7.89 [1.27]\t4.78 [2.17]\t<.00001*\t \tGambling\tGamble urge\t7.53 [1.97]\t1.16 [.40]\t<.00001*\t \tGambling\tDrugs urge\t1.28 [.55]\t1 [0]\t.046\t \tSad\tEmotional intensity\t7.25 [2.01]\t5.36 [1.93]\t.0038*\t \tSad\tGamble urge\t3.33 [2.66]\t1 [0]\t.0017*\t \tSad\tDrugs urge\t1.11 [.32]\t1 [0]\t.163\t \tCocaine\tEmotional intensity\t6.97 [2.38]\t4.74 [2.18]\t.0034*\t \tCocaine\tGamble urge\t3.28 [2.71]\t1.04 [.20]\t.0028*\t \tCocaine\tDrugs urge\t1.94 [1.85]\t1.08 [.28]\t.066\t \t
#Text=Note.
119-1	24140-24150	Subjective	_	
119-2	24151-24160	responses	_	
119-3	24161-24163	to	_	
119-4	24164-24167	the	_	
119-5	24168-24172	tape	_	
119-6	24173-24180	viewing	_	
119-7	24181-24190	Videotape	_	
119-8	24191-24200	condition	_	
119-9	24201-24211	Subjective	_	
119-10	24212-24221	responses	_	
119-11	24222-24224	PG	_	
119-12	24225-24229	mean	_	
119-13	24230-24231	[	_	
119-14	24231-24233	SD	_	
119-15	24233-24234	]	_	
119-16	24235-24237	HC	_	
119-17	24238-24242	mean	_	
119-18	24243-24244	[	_	
119-19	24244-24246	SD	_	
119-20	24246-24247	]	_	
119-21	24248-24250	PG	_	
119-22	24251-24257	versus	_	
119-23	24258-24260	HC	_	
119-24	24261-24269	p-values	_	
119-25	24272-24280	Gambling	_	
119-26	24281-24290	Emotional	_	
119-27	24291-24300	intensity	_	
119-28	24301-24305	7.89	_	
119-29	24306-24307	[	_	
119-30	24307-24311	1.27	_	
119-31	24311-24312	]	_	
119-32	24313-24317	4.78	_	
119-33	24318-24319	[	_	
119-34	24319-24323	2.17	_	
119-35	24323-24324	]	_	
119-36	24325-24326	<	_	
119-37	24326-24332	.00001	_	
119-38	24332-24333	*	_	
119-39	24336-24344	Gambling	_	
119-40	24345-24351	Gamble	_	
119-41	24352-24356	urge	_	
119-42	24357-24361	7.53	_	
119-43	24362-24363	[	_	
119-44	24363-24367	1.97	_	
119-45	24367-24368	]	_	
119-46	24369-24373	1.16	_	
119-47	24374-24375	[	_	
119-48	24375-24378	.40	_	
119-49	24378-24379	]	_	
119-50	24380-24381	<	_	
119-51	24381-24387	.00001	_	
119-52	24387-24388	*	_	
119-53	24391-24399	Gambling	_	
119-54	24400-24405	Drugs	_	
119-55	24406-24410	urge	_	
119-56	24411-24415	1.28	_	
119-57	24416-24417	[	_	
119-58	24417-24420	.55	_	
119-59	24420-24421	]	_	
119-60	24422-24423	1	_	
119-61	24424-24425	[	_	
119-62	24425-24426	0	_	
119-63	24426-24427	]	_	
119-64	24428-24432	.046	_	
119-65	24435-24438	Sad	_	
119-66	24439-24448	Emotional	_	
119-67	24449-24458	intensity	_	
119-68	24459-24463	7.25	_	
119-69	24464-24465	[	_	
119-70	24465-24469	2.01	_	
119-71	24469-24470	]	_	
119-72	24471-24475	5.36	_	
119-73	24476-24477	[	_	
119-74	24477-24481	1.93	_	
119-75	24481-24482	]	_	
119-76	24483-24488	.0038	_	
119-77	24488-24489	*	_	
119-78	24492-24495	Sad	_	
119-79	24496-24502	Gamble	_	
119-80	24503-24507	urge	_	
119-81	24508-24512	3.33	_	
119-82	24513-24514	[	_	
119-83	24514-24518	2.66	_	
119-84	24518-24519	]	_	
119-85	24520-24521	1	_	
119-86	24522-24523	[	_	
119-87	24523-24524	0	_	
119-88	24524-24525	]	_	
119-89	24526-24531	.0017	_	
119-90	24531-24532	*	_	
119-91	24535-24538	Sad	_	
119-92	24539-24544	Drugs	_	
119-93	24545-24549	urge	_	
119-94	24550-24554	1.11	_	
119-95	24555-24556	[	_	
119-96	24556-24559	.32	_	
119-97	24559-24560	]	_	
119-98	24561-24562	1	_	
119-99	24563-24564	[	_	
119-100	24564-24565	0	_	
119-101	24565-24566	]	_	
119-102	24567-24571	.163	_	
119-103	24574-24581	Cocaine	_	
119-104	24582-24591	Emotional	_	
119-105	24592-24601	intensity	_	
119-106	24602-24606	6.97	_	
119-107	24607-24608	[	_	
119-108	24608-24612	2.38	_	
119-109	24612-24613	]	_	
119-110	24614-24618	4.74	_	
119-111	24619-24620	[	_	
119-112	24620-24624	2.18	_	
119-113	24624-24625	]	_	
119-114	24626-24631	.0034	_	
119-115	24631-24632	*	_	
119-116	24635-24642	Cocaine	_	
119-117	24643-24649	Gamble	_	
119-118	24650-24654	urge	_	
119-119	24655-24659	3.28	_	
119-120	24660-24661	[	_	
119-121	24661-24665	2.71	_	
119-122	24665-24666	]	_	
119-123	24667-24671	1.04	_	
119-124	24672-24673	[	_	
119-125	24673-24676	.20	_	
119-126	24676-24677	]	_	
119-127	24678-24683	.0028	_	
119-128	24683-24684	*	_	
119-129	24687-24694	Cocaine	_	
119-130	24695-24700	Drugs	_	
119-131	24701-24705	urge	_	
119-132	24706-24710	1.94	_	
119-133	24711-24712	[	_	
119-134	24712-24716	1.85	_	
119-135	24716-24717	]	_	
119-136	24718-24722	1.08	_	
119-137	24723-24724	[	_	
119-138	24724-24727	.28	_	
119-139	24727-24728	]	_	
119-140	24729-24733	.066	_	
119-141	24737-24741	Note	_	
119-142	24741-24742	.	_	

#Text=Multiple comparison was adjusted by Bonferroni correction.
120-1	24743-24751	Multiple	_	
120-2	24752-24762	comparison	_	
120-3	24763-24766	was	_	
120-4	24767-24775	adjusted	_	
120-5	24776-24778	by	_	
120-6	24779-24789	Bonferroni	_	
120-7	24790-24800	correction	_	
120-8	24800-24801	.	_	

#Text=The significance threshold was set at .05/9 = .00556 by taking into the account that three subjective responses were tested for each of the three scenarios for each subject.
121-1	24802-24805	The	_	
121-2	24806-24818	significance	_	
121-3	24819-24828	threshold	_	
121-4	24829-24832	was	_	
121-5	24833-24836	set	_	
121-6	24837-24839	at	_	
121-7	24840-24843	.05	_	
121-8	24843-24844	/	_	
121-9	24844-24845	9	_	
121-10	24846-24847	=	_	
121-11	24848-24854	.00556	_	
121-12	24855-24857	by	_	
121-13	24858-24864	taking	_	
121-14	24865-24869	into	_	
121-15	24870-24873	the	_	
121-16	24874-24881	account	_	
121-17	24882-24886	that	_	
121-18	24887-24892	three	_	
121-19	24893-24903	subjective	_	
121-20	24904-24913	responses	_	
121-21	24914-24918	were	_	
121-22	24919-24925	tested	_	
121-23	24926-24929	for	_	
121-24	24930-24934	each	_	
121-25	24935-24937	of	_	
121-26	24938-24941	the	_	
121-27	24942-24947	three	_	
121-28	24948-24957	scenarios	_	
121-29	24958-24961	for	_	
121-30	24962-24966	each	_	
121-31	24967-24974	subject	_	
121-32	24974-24975	.	_	

#Text=SD = 0 reflected the same rating for all of the responses in the subgroup analyzed.
#Text=p < .00556.
122-1	24976-24978	SD	_	
122-2	24979-24980	=	_	
122-3	24981-24982	0	_	
122-4	24983-24992	reflected	_	
122-5	24993-24996	the	_	
122-6	24997-25001	same	_	
122-7	25002-25008	rating	_	
122-8	25009-25012	for	_	
122-9	25013-25016	all	_	
122-10	25017-25019	of	_	
122-11	25020-25023	the	_	
122-12	25024-25033	responses	_	
122-13	25034-25036	in	_	
122-14	25037-25040	the	_	
122-15	25041-25049	subgroup	_	
122-16	25050-25058	analyzed	_	
122-17	25058-25059	.	_	
122-18	25060-25061	p	_	
122-19	25062-25063	<	_	
122-20	25064-25070	.00556	_	
122-21	25070-25071	.	_	

#Text=Discussion
#Text=This first study investigating DBH genetic influences on brain activity found that the functional T allele in DBH SNP rs1611115, which reduces the conversion of dopamine to norepinephrine, corresponds with different BOLD-signal changes in responses to gambling, drug or sad cues in individuals with and without PG.
123-1	25072-25082	Discussion	_	
123-2	25083-25087	This	_	
123-3	25088-25093	first	_	
123-4	25094-25099	study	_	
123-5	25100-25113	investigating	_	
123-6	25114-25117	DBH	_	
123-7	25118-25125	genetic	_	
123-8	25126-25136	influences	_	
123-9	25137-25139	on	_	
123-10	25140-25145	brain	_	
123-11	25146-25154	activity	_	
123-12	25155-25160	found	_	
123-13	25161-25165	that	_	
123-14	25166-25169	the	_	
123-15	25170-25180	functional	_	
123-16	25181-25182	T	_	
123-17	25183-25189	allele	_	
123-18	25190-25192	in	_	
123-19	25193-25196	DBH	_	
123-20	25197-25200	SNP	_	
123-21	25201-25210	rs1611115	_	
123-22	25210-25211	,	_	
123-23	25212-25217	which	_	
123-24	25218-25225	reduces	_	
123-25	25226-25229	the	_	
123-26	25230-25240	conversion	_	
123-27	25241-25243	of	_	
123-28	25244-25252	dopamine	_	
123-29	25253-25255	to	_	
123-30	25256-25270	norepinephrine	_	
123-31	25270-25271	,	_	
123-32	25272-25283	corresponds	_	
123-33	25284-25288	with	_	
123-34	25289-25298	different	_	
123-35	25299-25310	BOLD-signal	_	
123-36	25311-25318	changes	_	
123-37	25319-25321	in	_	
123-38	25322-25331	responses	_	
123-39	25332-25334	to	_	
123-40	25335-25343	gambling	_	
123-41	25343-25344	,	_	
123-42	25345-25349	drug	_	
123-43	25350-25352	or	_	
123-44	25353-25356	sad	_	
123-45	25357-25361	cues	_	
123-46	25362-25364	in	_	
123-47	25365-25376	individuals	_	
123-48	25377-25381	with	_	
123-49	25382-25385	and	_	
123-50	25386-25393	without	_	
123-51	25394-25396	PG	_	
123-52	25396-25397	.	_	

#Text=A main effect of genotype was observed with respect to responses to the videotapes in the amygdala, vmPFC, and striatal areas, and a DBH-genotype-by-condition, as well as group-by-condition interactions, implicated corticostriatal-limbic regions.
124-1	25398-25399	A	_	
124-2	25400-25404	main	_	
124-3	25405-25411	effect	_	
124-4	25412-25414	of	_	
124-5	25415-25423	genotype	_	
124-6	25424-25427	was	_	
124-7	25428-25436	observed	_	
124-8	25437-25441	with	_	
124-9	25442-25449	respect	_	
124-10	25450-25452	to	_	
124-11	25453-25462	responses	_	
124-12	25463-25465	to	_	
124-13	25466-25469	the	_	
124-14	25470-25480	videotapes	_	
124-15	25481-25483	in	_	
124-16	25484-25487	the	_	
124-17	25488-25496	amygdala	_	
124-18	25496-25497	,	_	
124-19	25498-25503	vmPFC	_	
124-20	25503-25504	,	_	
124-21	25505-25508	and	_	
124-22	25509-25517	striatal	_	
124-23	25518-25523	areas	_	
124-24	25523-25524	,	_	
124-25	25525-25528	and	_	
124-26	25529-25530	a	_	
124-27	25531-25556	DBH-genotype-by-condition	_	
124-28	25556-25557	,	_	
124-29	25558-25560	as	_	
124-30	25561-25565	well	_	
124-31	25566-25568	as	_	
124-32	25569-25587	group-by-condition	_	
124-33	25588-25600	interactions	_	
124-34	25600-25601	,	_	
124-35	25602-25612	implicated	_	
124-36	25613-25635	corticostriatal-limbic	_	
124-37	25636-25643	regions	_	
124-38	25643-25644	.	_	

#Text=DBH genotype was also linked to subjective responses to the sad videotapes.
125-1	25645-25648	DBH	_	
125-2	25649-25657	genotype	_	
125-3	25658-25661	was	_	
125-4	25662-25666	also	_	
125-5	25667-25673	linked	_	
125-6	25674-25676	to	_	
125-7	25677-25687	subjective	_	
125-8	25688-25697	responses	_	
125-9	25698-25700	to	_	
125-10	25701-25704	the	_	
125-11	25705-25708	sad	_	
125-12	25709-25719	videotapes	_	
125-13	25719-25720	.	_	

#Text=The finding of DBH effects across diagnostic groupings is consistent with transdiagnostic research efforts (e.g., research domain criteria).
126-1	25721-25724	The	_	
126-2	25725-25732	finding	_	
126-3	25733-25735	of	_	
126-4	25736-25739	DBH	_	
126-5	25740-25747	effects	_	
126-6	25748-25754	across	_	
126-7	25755-25765	diagnostic	_	
126-8	25766-25775	groupings	_	
126-9	25776-25778	is	_	
126-10	25779-25789	consistent	_	
126-11	25790-25794	with	_	
126-12	25795-25810	transdiagnostic	_	
126-13	25811-25819	research	_	
126-14	25820-25827	efforts	_	
126-15	25828-25829	(	_	
126-16	25829-25832	e.g	_	
126-17	25832-25833	.	_	
126-18	25833-25834	,	_	
126-19	25834-25835	 	_	
126-20	25835-25843	research	_	
126-21	25844-25850	domain	_	
126-22	25851-25859	criteria	_	
126-23	25859-25860	)	_	
126-24	25860-25861	.	_	

#Text=Finally, cue-condition differences were found in occipital and temporal cortices and ventral prefrontal cortical regions.
127-1	25862-25869	Finally	_	
127-2	25869-25870	,	_	
127-3	25871-25884	cue-condition	_	
127-4	25885-25896	differences	_	
127-5	25897-25901	were	_	
127-6	25902-25907	found	_	
127-7	25908-25910	in	_	
127-8	25911-25920	occipital	_	
127-9	25921-25924	and	_	
127-10	25925-25933	temporal	_	
127-11	25934-25942	cortices	_	
127-12	25943-25946	and	_	
127-13	25947-25954	ventral	_	
127-14	25955-25965	prefrontal	_	
127-15	25966-25974	cortical	_	
127-16	25975-25982	regions	_	
127-17	25982-25983	.	_	

#Text=These findings, particularly the novel DBH-related findings, suggest an important role for dopamine and norepinephrine in subjective sadness and brain correlates of emotional regulation, impulse control, and motivational processes.
128-1	25984-25989	These	_	
128-2	25990-25998	findings	_	
128-3	25998-25999	,	_	
128-4	26000-26012	particularly	_	
128-5	26013-26016	the	_	
128-6	26017-26022	novel	_	
128-7	26023-26034	DBH-related	_	
128-8	26035-26043	findings	_	
128-9	26043-26044	,	_	
128-10	26045-26052	suggest	_	
128-11	26053-26055	an	_	
128-12	26056-26065	important	_	
128-13	26066-26070	role	_	
128-14	26071-26074	for	_	
128-15	26075-26083	dopamine	_	
128-16	26084-26087	and	_	
128-17	26088-26102	norepinephrine	_	
128-18	26103-26105	in	_	
128-19	26106-26116	subjective	_	
128-20	26117-26124	sadness	_	
128-21	26125-26128	and	_	
128-22	26129-26134	brain	_	
128-23	26135-26145	correlates	_	
128-24	26146-26148	of	_	
128-25	26149-26158	emotional	_	
128-26	26159-26169	regulation	_	
128-27	26169-26170	,	_	
128-28	26171-26178	impulse	_	
128-29	26179-26186	control	_	
128-30	26186-26187	,	_	
128-31	26188-26191	and	_	
128-32	26192-26204	motivational	_	
128-33	26205-26214	processes	_	
128-34	26214-26215	.	_	

#Text=Subjective responses
#Text=Subjective responses to the videos provide a validity check (i.e., specificity of responsiveness as designed) and are consistent with previous studies reporting stronger gambling-urge responses during the gambling-cue condition in the PG group and for cue-specificity as in the larger sample.
129-1	26216-26226	Subjective	_	
129-2	26227-26236	responses	_	
129-3	26237-26247	Subjective	_	
129-4	26248-26257	responses	_	
129-5	26258-26260	to	_	
129-6	26261-26264	the	_	
129-7	26265-26271	videos	_	
129-8	26272-26279	provide	_	
129-9	26280-26281	a	_	
129-10	26282-26290	validity	_	
129-11	26291-26296	check	_	
129-12	26297-26298	(	_	
129-13	26298-26301	i.e	_	
129-14	26301-26302	.	_	
129-15	26302-26303	,	_	
129-16	26304-26315	specificity	_	
129-17	26316-26318	of	_	
129-18	26319-26333	responsiveness	_	
129-19	26334-26336	as	_	
129-20	26337-26345	designed	_	
129-21	26345-26346	)	_	
129-22	26347-26350	and	_	
129-23	26351-26354	are	_	
129-24	26355-26365	consistent	_	
129-25	26366-26370	with	_	
129-26	26371-26379	previous	_	
129-27	26380-26387	studies	_	
129-28	26388-26397	reporting	_	
129-29	26398-26406	stronger	_	
129-30	26407-26420	gambling-urge	_	
129-31	26421-26430	responses	_	
129-32	26431-26437	during	_	
129-33	26438-26441	the	_	
129-34	26442-26454	gambling-cue	_	
129-35	26455-26464	condition	_	
129-36	26465-26467	in	_	
129-37	26468-26471	the	_	
129-38	26472-26474	PG	_	
129-39	26475-26480	group	_	
129-40	26481-26484	and	_	
129-41	26485-26488	for	_	
129-42	26489-26504	cue-specificity	_	
129-43	26505-26507	as	_	
129-44	26508-26510	in	_	
129-45	26511-26514	the	_	
129-46	26515-26521	larger	_	
129-47	26522-26528	sample	_	
129-48	26528-26529	.	_	

#Text=Interestingly, the PG group also reported stronger gambling urges to the sad and cocaine-cue conditions, suggesting that other states (dysphoric, drug-cue-related) may trigger gambling urges; alternatively, persistent baseline gambling urges may endure across conditions in the PG group.
130-1	26530-26543	Interestingly	_	
130-2	26543-26544	,	_	
130-3	26545-26548	the	_	
130-4	26549-26551	PG	_	
130-5	26552-26557	group	_	
130-6	26558-26562	also	_	
130-7	26563-26571	reported	_	
130-8	26572-26580	stronger	_	
130-9	26581-26589	gambling	_	
130-10	26590-26595	urges	_	
130-11	26596-26598	to	_	
130-12	26599-26602	the	_	
130-13	26603-26606	sad	_	
130-14	26607-26610	and	_	
130-15	26611-26622	cocaine-cue	_	
130-16	26623-26633	conditions	_	
130-17	26633-26634	,	_	
130-18	26635-26645	suggesting	_	
130-19	26646-26650	that	_	
130-20	26651-26656	other	_	
130-21	26657-26663	states	_	
130-22	26664-26665	(	_	
130-23	26665-26674	dysphoric	_	
130-24	26674-26675	,	_	
130-25	26676-26692	drug-cue-related	_	
130-26	26692-26693	)	_	
130-27	26694-26697	may	_	
130-28	26698-26705	trigger	_	
130-29	26706-26714	gambling	_	
130-30	26715-26720	urges	_	
130-31	26720-26721	;	_	
130-32	26722-26735	alternatively	_	
130-33	26735-26736	,	_	
130-34	26737-26747	persistent	_	
130-35	26748-26756	baseline	_	
130-36	26757-26765	gambling	_	
130-37	26766-26771	urges	_	
130-38	26772-26775	may	_	
130-39	26776-26782	endure	_	
130-40	26783-26789	across	_	
130-41	26790-26800	conditions	_	
130-42	26801-26803	in	_	
130-43	26804-26807	the	_	
130-44	26808-26810	PG	_	
130-45	26811-26816	group	_	
130-46	26816-26817	.	_	

#Text=Main effect of DBH genotype
#Text=Collapsed across diagnostic groups and video conditions, the increased recruitment by the CC relative to the T-carrier subjects in dopaminergic projection sites suggests that greater conversion of dopamine to norepinephrine may relate to increased corticostriatal-limbic activation in regions implicated in emotional regulation, motivation, executive and cognitive functions, and impulse control, among other processes.
131-1	26818-26822	Main	_	
131-2	26823-26829	effect	_	
131-3	26830-26832	of	_	
131-4	26833-26836	DBH	_	
131-5	26837-26845	genotype	_	
131-6	26846-26855	Collapsed	_	
131-7	26856-26862	across	_	
131-8	26863-26873	diagnostic	_	
131-9	26874-26880	groups	_	
131-10	26881-26884	and	_	
131-11	26885-26890	video	_	
131-12	26891-26901	conditions	_	
131-13	26901-26902	,	_	
131-14	26903-26906	the	_	
131-15	26907-26916	increased	_	
131-16	26917-26928	recruitment	_	
131-17	26929-26931	by	_	
131-18	26932-26935	the	_	
131-19	26936-26938	CC	_	
131-20	26939-26947	relative	_	
131-21	26948-26950	to	_	
131-22	26951-26954	the	_	
131-23	26955-26964	T-carrier	_	
131-24	26965-26973	subjects	_	
131-25	26974-26976	in	_	
131-26	26977-26989	dopaminergic	_	
131-27	26990-27000	projection	_	
131-28	27001-27006	sites	_	
131-29	27007-27015	suggests	_	
131-30	27016-27020	that	_	
131-31	27021-27028	greater	_	
131-32	27029-27039	conversion	_	
131-33	27040-27042	of	_	
131-34	27043-27051	dopamine	_	
131-35	27052-27054	to	_	
131-36	27055-27069	norepinephrine	_	
131-37	27070-27073	may	_	
131-38	27074-27080	relate	_	
131-39	27081-27083	to	_	
131-40	27084-27093	increased	_	
131-41	27094-27116	corticostriatal-limbic	_	
131-42	27117-27127	activation	_	
131-43	27128-27130	in	_	
131-44	27131-27138	regions	_	
131-45	27139-27149	implicated	_	
131-46	27150-27152	in	_	
131-47	27153-27162	emotional	_	
131-48	27163-27173	regulation	_	
131-49	27173-27174	,	_	
131-50	27175-27185	motivation	_	
131-51	27185-27186	,	_	
131-52	27187-27196	executive	_	
131-53	27197-27200	and	_	
131-54	27201-27210	cognitive	_	
131-55	27211-27220	functions	_	
131-56	27220-27221	,	_	
131-57	27222-27225	and	_	
131-58	27226-27233	impulse	_	
131-59	27234-27241	control	_	
131-60	27241-27242	,	_	
131-61	27243-27248	among	_	
131-62	27249-27254	other	_	
131-63	27255-27264	processes	_	
131-64	27264-27265	.	_	

#Text=Given the links between DBH activity and addiction characteristics, manipulating the balance between dopamine and norepinephrine could prove an effective treatment strategy for multiple neuropsychiatric disorders.
132-1	27266-27271	Given	_	
132-2	27272-27275	the	_	
132-3	27276-27281	links	_	
132-4	27282-27289	between	_	
132-5	27290-27293	DBH	_	
132-6	27294-27302	activity	_	
132-7	27303-27306	and	_	
132-8	27307-27316	addiction	_	
132-9	27317-27332	characteristics	_	
132-10	27332-27333	,	_	
132-11	27334-27346	manipulating	_	
132-12	27347-27350	the	_	
132-13	27351-27358	balance	_	
132-14	27359-27366	between	_	
132-15	27367-27375	dopamine	_	
132-16	27376-27379	and	_	
132-17	27380-27394	norepinephrine	_	
132-18	27395-27400	could	_	
132-19	27401-27406	prove	_	
132-20	27407-27409	an	_	
132-21	27410-27419	effective	_	
132-22	27420-27429	treatment	_	
132-23	27430-27438	strategy	_	
132-24	27439-27442	for	_	
132-25	27443-27451	multiple	_	
132-26	27452-27468	neuropsychiatric	_	
132-27	27469-27478	disorders	_	
132-28	27478-27479	.	_	

#Text=For example, the drug disulfiram is effective in the treatment of alcohol and CD, possibly through effects on craving.
133-1	27480-27483	For	_	
133-2	27484-27491	example	_	
133-3	27491-27492	,	_	
133-4	27493-27496	the	_	
133-5	27497-27501	drug	_	
133-6	27502-27512	disulfiram	_	
133-7	27513-27515	is	_	
133-8	27516-27525	effective	_	
133-9	27526-27528	in	_	
133-10	27529-27532	the	_	
133-11	27533-27542	treatment	_	
133-12	27543-27545	of	_	
133-13	27546-27553	alcohol	_	
133-14	27554-27557	and	_	
133-15	27558-27560	CD	_	
133-16	27560-27561	,	_	
133-17	27562-27570	possibly	_	
133-18	27571-27578	through	_	
133-19	27579-27586	effects	_	
133-20	27587-27589	on	_	
133-21	27590-27597	craving	_	
133-22	27597-27598	.	_	

#Text=DBH inhibition by disulfiram may reduce craving via increasing dopamine levels and decreasing norepinephrine levels.
134-1	27599-27602	DBH	_	
134-2	27603-27613	inhibition	_	
134-3	27614-27616	by	_	
134-4	27617-27627	disulfiram	_	
134-5	27628-27631	may	_	
134-6	27632-27638	reduce	_	
134-7	27639-27646	craving	_	
134-8	27647-27650	via	_	
134-9	27651-27661	increasing	_	
134-10	27662-27670	dopamine	_	
134-11	27671-27677	levels	_	
134-12	27678-27681	and	_	
134-13	27682-27692	decreasing	_	
134-14	27693-27707	norepinephrine	_	
134-15	27708-27714	levels	_	
134-16	27714-27715	.	_	

#Text=Accordingly, clinical case reports suggest that disulfiram may reduce gambling urges in PG.
135-1	27716-27727	Accordingly	_	
135-2	27727-27728	,	_	
135-3	27729-27737	clinical	_	
135-4	27738-27742	case	_	
135-5	27743-27750	reports	_	
135-6	27751-27758	suggest	_	
135-7	27759-27763	that	_	
135-8	27764-27774	disulfiram	_	
135-9	27775-27778	may	_	
135-10	27779-27785	reduce	_	
135-11	27786-27794	gambling	_	
135-12	27795-27800	urges	_	
135-13	27801-27803	in	_	
135-14	27804-27806	PG	_	
135-15	27806-27807	.	_	

#Text=These reports provide a proof-of-principle for PG treatment via DBH inhibition to regulate the balance between dopamine and norepinephrine, which have both been implicated to varying degrees in PG.
136-1	27808-27813	These	_	
136-2	27814-27821	reports	_	
136-3	27822-27829	provide	_	
136-4	27830-27831	a	_	
136-5	27832-27850	proof-of-principle	_	
136-6	27851-27854	for	_	
136-7	27855-27857	PG	_	
136-8	27858-27867	treatment	_	
136-9	27868-27871	via	_	
136-10	27872-27875	DBH	_	
136-11	27876-27886	inhibition	_	
136-12	27887-27889	to	_	
136-13	27890-27898	regulate	_	
136-14	27899-27902	the	_	
136-15	27903-27910	balance	_	
136-16	27911-27918	between	_	
136-17	27919-27927	dopamine	_	
136-18	27928-27931	and	_	
136-19	27932-27946	norepinephrine	_	
136-20	27946-27947	,	_	
136-21	27948-27953	which	_	
136-22	27954-27958	have	_	
136-23	27959-27963	both	_	
136-24	27964-27968	been	_	
136-25	27969-27979	implicated	_	
136-26	27980-27982	to	_	
136-27	27983-27990	varying	_	
136-28	27991-27998	degrees	_	
136-29	27999-28001	in	_	
136-30	28002-28004	PG	_	
136-31	28004-28005	.	_	

#Text=Subjective reports of greater sadness to sad videos were reported in the CC group, relative to the T-carriers (Table 1B), a finding that is consistent with reports of lowered empathic characteristics in the T-carrier group.
137-1	28006-28016	Subjective	_	
137-2	28017-28024	reports	_	
137-3	28025-28027	of	_	
137-4	28028-28035	greater	_	
137-5	28036-28043	sadness	_	
137-6	28044-28046	to	_	
137-7	28047-28050	sad	_	
137-8	28051-28057	videos	_	
137-9	28058-28062	were	_	
137-10	28063-28071	reported	_	
137-11	28072-28074	in	_	
137-12	28075-28078	the	_	
137-13	28079-28081	CC	_	
137-14	28082-28087	group	_	
137-15	28087-28088	,	_	
137-16	28089-28097	relative	_	
137-17	28098-28100	to	_	
137-18	28101-28104	the	_	
137-19	28105-28115	T-carriers	_	
137-20	28116-28117	(	_	
137-21	28117-28122	Table	_	
137-22	28122-28123	 	_	
137-23	28123-28125	1B	_	
137-24	28125-28126	)	_	
137-25	28126-28127	,	_	
137-26	28128-28129	a	_	
137-27	28130-28137	finding	_	
137-28	28138-28142	that	_	
137-29	28143-28145	is	_	
137-30	28146-28156	consistent	_	
137-31	28157-28161	with	_	
137-32	28162-28169	reports	_	
137-33	28170-28172	of	_	
137-34	28173-28180	lowered	_	
137-35	28181-28189	empathic	_	
137-36	28190-28205	characteristics	_	
137-37	28206-28208	in	_	
137-38	28209-28212	the	_	
137-39	28213-28222	T-carrier	_	
137-40	28223-28228	group	_	
137-41	28228-28229	.	_	

#Text=Our results with fMRI extend these findings to demonstrate diminished recruitment of frontostriatal circuitry in T-carriers, specifically during the sad condition.
138-1	28230-28233	Our	_	
138-2	28234-28241	results	_	
138-3	28242-28246	with	_	
138-4	28247-28251	fMRI	_	
138-5	28252-28258	extend	_	
138-6	28259-28264	these	_	
138-7	28265-28273	findings	_	
138-8	28274-28276	to	_	
138-9	28277-28288	demonstrate	_	
138-10	28289-28299	diminished	_	
138-11	28300-28311	recruitment	_	
138-12	28312-28314	of	_	
138-13	28315-28329	frontostriatal	_	
138-14	28330-28339	circuitry	_	
138-15	28340-28342	in	_	
138-16	28343-28353	T-carriers	_	
138-17	28353-28354	,	_	
138-18	28355-28367	specifically	_	
138-19	28368-28374	during	_	
138-20	28375-28378	the	_	
138-21	28379-28382	sad	_	
138-22	28383-28392	condition	_	
138-23	28392-28393	.	_	

#Text=These data link the DBH polymorphism with alterations in frontostriatal responses while listening to the personal distress of another person.
139-1	28394-28399	These	_	
139-2	28400-28404	data	_	
139-3	28405-28409	link	_	
139-4	28410-28413	the	_	
139-5	28414-28417	DBH	_	
139-6	28418-28430	polymorphism	_	
139-7	28431-28435	with	_	
139-8	28436-28447	alterations	_	
139-9	28448-28450	in	_	
139-10	28451-28465	frontostriatal	_	
139-11	28466-28475	responses	_	
139-12	28476-28481	while	_	
139-13	28482-28491	listening	_	
139-14	28492-28494	to	_	
139-15	28495-28498	the	_	
139-16	28499-28507	personal	_	
139-17	28508-28516	distress	_	
139-18	28517-28519	of	_	
139-19	28520-28527	another	_	
139-20	28528-28534	person	_	
139-21	28534-28535	.	_	

#Text=Specifically, the observed DBH-genotype-by-condition differences implicate the dlPFC, midbrain, hippocampus, insula, caudate, putamen, and thalamus.
140-1	28536-28548	Specifically	_	
140-2	28548-28549	,	_	
140-3	28550-28553	the	_	
140-4	28554-28562	observed	_	
140-5	28563-28588	DBH-genotype-by-condition	_	
140-6	28589-28600	differences	_	
140-7	28601-28610	implicate	_	
140-8	28611-28614	the	_	
140-9	28615-28620	dlPFC	_	
140-10	28620-28621	,	_	
140-11	28622-28630	midbrain	_	
140-12	28630-28631	,	_	
140-13	28632-28643	hippocampus	_	
140-14	28643-28644	,	_	
140-15	28645-28651	insula	_	
140-16	28651-28652	,	_	
140-17	28653-28660	caudate	_	
140-18	28660-28661	,	_	
140-19	28662-28669	putamen	_	
140-20	28669-28670	,	_	
140-21	28671-28674	and	_	
140-22	28675-28683	thalamus	_	
140-23	28683-28684	.	_	

#Text=These brain regions are associated with dopaminergic network differences in multiple addictive behaviors and neuropsychiatric disorders.
141-1	28685-28690	These	_	
141-2	28691-28696	brain	_	
141-3	28697-28704	regions	_	
141-4	28705-28708	are	_	
141-5	28709-28719	associated	_	
141-6	28720-28724	with	_	
141-7	28725-28737	dopaminergic	_	
141-8	28738-28745	network	_	
141-9	28746-28757	differences	_	
141-10	28758-28760	in	_	
141-11	28761-28769	multiple	_	
141-12	28770-28779	addictive	_	
141-13	28780-28789	behaviors	_	
141-14	28790-28793	and	_	
141-15	28794-28810	neuropsychiatric	_	
141-16	28811-28820	disorders	_	
141-17	28820-28821	.	_	

#Text=The dlPFC is sensitive to levels of norepinephrine and dopamine, in which imbalances may impair prefrontal cortex function and influence emotional regulation.
142-1	28822-28825	The	_	
142-2	28826-28831	dlPFC	_	
142-3	28832-28834	is	_	
142-4	28835-28844	sensitive	_	
142-5	28845-28847	to	_	
142-6	28848-28854	levels	_	
142-7	28855-28857	of	_	
142-8	28858-28872	norepinephrine	_	
142-9	28873-28876	and	_	
142-10	28877-28885	dopamine	_	
142-11	28885-28886	,	_	
142-12	28887-28889	in	_	
142-13	28890-28895	which	_	
142-14	28896-28906	imbalances	_	
142-15	28907-28910	may	_	
142-16	28911-28917	impair	_	
142-17	28918-28928	prefrontal	_	
142-18	28929-28935	cortex	_	
142-19	28936-28944	function	_	
142-20	28945-28948	and	_	
142-21	28949-28958	influence	_	
142-22	28959-28968	emotional	_	
142-23	28969-28979	regulation	_	
142-24	28979-28980	.	_	

#Text=As the T allele is associated with impulsivity, aggressive hostility, addiction vulnerability, and altered noradrenergic function, the diminished recruitment of corticostriatal areas by T-carriers suggests possible neural substrates of emotion dysregulation that may be conferred by the “risk” T allele.
143-1	28981-28983	As	_	
143-2	28984-28987	the	_	
143-3	28988-28989	T	_	
143-4	28990-28996	allele	_	
143-5	28997-28999	is	_	
143-6	29000-29010	associated	_	
143-7	29011-29015	with	_	
143-8	29016-29027	impulsivity	_	
143-9	29027-29028	,	_	
143-10	29029-29039	aggressive	_	
143-11	29040-29049	hostility	_	
143-12	29049-29050	,	_	
143-13	29051-29060	addiction	_	
143-14	29061-29074	vulnerability	_	
143-15	29074-29075	,	_	
143-16	29076-29079	and	_	
143-17	29080-29087	altered	_	
143-18	29088-29101	noradrenergic	_	
143-19	29102-29110	function	_	
143-20	29110-29111	,	_	
143-21	29112-29115	the	_	
143-22	29116-29126	diminished	_	
143-23	29127-29138	recruitment	_	
143-24	29139-29141	of	_	
143-25	29142-29157	corticostriatal	_	
143-26	29158-29163	areas	_	
143-27	29164-29166	by	_	
143-28	29167-29177	T-carriers	_	
143-29	29178-29186	suggests	_	
143-30	29187-29195	possible	_	
143-31	29196-29202	neural	_	
143-32	29203-29213	substrates	_	
143-33	29214-29216	of	_	
143-34	29217-29224	emotion	_	
143-35	29225-29238	dysregulation	_	
143-36	29239-29243	that	_	
143-37	29244-29247	may	_	
143-38	29248-29250	be	_	
143-39	29251-29260	conferred	_	
143-40	29261-29263	by	_	
143-41	29264-29267	the	_	
143-42	29268-29269	“	_	
143-43	29269-29273	risk	_	
143-44	29273-29274	”	_	
143-45	29275-29276	T	_	
143-46	29277-29283	allele	_	
143-47	29283-29284	.	_	

#Text=The identified brain areas, including left insula, caudate, and putamen, are implicated in effort-based decision-making, preferences for rewarding substances, and, arguably most relevant to the current task, emotional regulation.
144-1	29285-29288	The	_	
144-2	29289-29299	identified	_	
144-3	29300-29305	brain	_	
144-4	29306-29311	areas	_	
144-5	29311-29312	,	_	
144-6	29313-29322	including	_	
144-7	29323-29327	left	_	
144-8	29328-29334	insula	_	
144-9	29334-29335	,	_	
144-10	29336-29343	caudate	_	
144-11	29343-29344	,	_	
144-12	29345-29348	and	_	
144-13	29349-29356	putamen	_	
144-14	29356-29357	,	_	
144-15	29358-29361	are	_	
144-16	29362-29372	implicated	_	
144-17	29373-29375	in	_	
144-18	29376-29388	effort-based	_	
144-19	29389-29404	decision-making	_	
144-20	29404-29405	,	_	
144-21	29406-29417	preferences	_	
144-22	29418-29421	for	_	
144-23	29422-29431	rewarding	_	
144-24	29432-29442	substances	_	
144-25	29442-29443	,	_	
144-26	29444-29447	and	_	
144-27	29447-29448	,	_	
144-28	29449-29457	arguably	_	
144-29	29458-29462	most	_	
144-30	29463-29471	relevant	_	
144-31	29472-29474	to	_	
144-32	29475-29478	the	_	
144-33	29479-29486	current	_	
144-34	29487-29491	task	_	
144-35	29491-29492	,	_	
144-36	29493-29502	emotional	_	
144-37	29503-29513	regulation	_	
144-38	29513-29514	.	_	

#Text=Although small, the current sample demonstrated numerically but not statistically higher impulsivity in the T-carrier group (p < .10, Table 1B), consistent with reports of a more impulsive personality style associated with this genotype.
145-1	29515-29523	Although	_	
145-2	29524-29529	small	_	
145-3	29529-29530	,	_	
145-4	29531-29534	the	_	
145-5	29535-29542	current	_	
145-6	29543-29549	sample	_	
145-7	29550-29562	demonstrated	_	
145-8	29563-29574	numerically	_	
145-9	29575-29578	but	_	
145-10	29579-29582	not	_	
145-11	29583-29596	statistically	_	
145-12	29597-29603	higher	_	
145-13	29604-29615	impulsivity	_	
145-14	29616-29618	in	_	
145-15	29619-29622	the	_	
145-16	29623-29632	T-carrier	_	
145-17	29633-29638	group	_	
145-18	29639-29640	(	_	
145-19	29640-29641	p	_	
145-20	29642-29643	<	_	
145-21	29644-29647	.10	_	
145-22	29647-29648	,	_	
145-23	29649-29654	Table	_	
145-24	29654-29655	 	_	
145-25	29655-29657	1B	_	
145-26	29657-29658	)	_	
145-27	29658-29659	,	_	
145-28	29660-29670	consistent	_	
145-29	29671-29675	with	_	
145-30	29676-29683	reports	_	
145-31	29684-29686	of	_	
145-32	29687-29688	a	_	
145-33	29689-29693	more	_	
145-34	29694-29703	impulsive	_	
145-35	29704-29715	personality	_	
145-36	29716-29721	style	_	
145-37	29722-29732	associated	_	
145-38	29733-29737	with	_	
145-39	29738-29742	this	_	
145-40	29743-29751	genotype	_	
145-41	29751-29752	.	_	

#Text=Higher impulsivity has been related to lower D2/D3 dopamine receptor availability in the midbrain, with greater amphetamine-related dopamine release related to mibrain (substantia nigra) levels of D3 dopamine receptors in PG subjects.
146-1	29753-29759	Higher	_	
146-2	29760-29771	impulsivity	_	
146-3	29772-29775	has	_	
146-4	29776-29780	been	_	
146-5	29781-29788	related	_	
146-6	29789-29791	to	_	
146-7	29792-29797	lower	_	
146-8	29798-29800	D2	_	
146-9	29800-29801	/	_	
146-10	29801-29803	D3	_	
146-11	29804-29812	dopamine	_	
146-12	29813-29821	receptor	_	
146-13	29822-29834	availability	_	
146-14	29835-29837	in	_	
146-15	29838-29841	the	_	
146-16	29842-29850	midbrain	_	
146-17	29850-29851	,	_	
146-18	29852-29856	with	_	
146-19	29857-29864	greater	_	
146-20	29865-29884	amphetamine-related	_	
146-21	29885-29893	dopamine	_	
146-22	29894-29901	release	_	
146-23	29902-29909	related	_	
146-24	29910-29912	to	_	
146-25	29913-29920	mibrain	_	
146-26	29921-29922	(	_	
146-27	29922-29932	substantia	_	
146-28	29933-29938	nigra	_	
146-29	29938-29939	)	_	
146-30	29940-29946	levels	_	
146-31	29947-29949	of	_	
146-32	29950-29952	D3	_	
146-33	29953-29961	dopamine	_	
146-34	29962-29971	receptors	_	
146-35	29972-29974	in	_	
146-36	29975-29977	PG	_	
146-37	29978-29986	subjects	_	
146-38	29986-29987	.	_	

#Text=In PG, a disorder characterized by increased impulsivity, striatal dopamine D2/D3 receptor binding negatively correlates with mood-related impulsivity.
147-1	29988-29990	In	_	
147-2	29991-29993	PG	_	
147-3	29993-29994	,	_	
147-4	29995-29996	a	_	
147-5	29997-30005	disorder	_	
147-6	30006-30019	characterized	_	
147-7	30020-30022	by	_	
147-8	30023-30032	increased	_	
147-9	30033-30044	impulsivity	_	
147-10	30044-30045	,	_	
147-11	30046-30054	striatal	_	
147-12	30055-30063	dopamine	_	
147-13	30064-30066	D2	_	
147-14	30066-30067	/	_	
147-15	30067-30069	D3	_	
147-16	30070-30078	receptor	_	
147-17	30079-30086	binding	_	
147-18	30087-30097	negatively	_	
147-19	30098-30108	correlates	_	
147-20	30109-30113	with	_	
147-21	30114-30126	mood-related	_	
147-22	30127-30138	impulsivity	_	
147-23	30138-30139	.	_	

#Text=Future studies with larger samples could examine potential interactions between impulsivity, mood, and dopaminergic function in PG as compared to non-PG samples.
148-1	30140-30146	Future	_	
148-2	30147-30154	studies	_	
148-3	30155-30159	with	_	
148-4	30160-30166	larger	_	
148-5	30167-30174	samples	_	
148-6	30175-30180	could	_	
148-7	30181-30188	examine	_	
148-8	30189-30198	potential	_	
148-9	30199-30211	interactions	_	
148-10	30212-30219	between	_	
148-11	30220-30231	impulsivity	_	
148-12	30231-30232	,	_	
148-13	30233-30237	mood	_	
148-14	30237-30238	,	_	
148-15	30239-30242	and	_	
148-16	30243-30255	dopaminergic	_	
148-17	30256-30264	function	_	
148-18	30265-30267	in	_	
148-19	30268-30270	PG	_	
148-20	30271-30273	as	_	
148-21	30274-30282	compared	_	
148-22	30283-30285	to	_	
148-23	30286-30292	non-PG	_	
148-24	30293-30300	samples	_	
148-25	30300-30301	.	_	

#Text=Group effects across conditions
#Text=Group differences occurred in ventral PFC and ventral striatal areas.
149-1	30302-30307	Group	_	
149-2	30308-30315	effects	_	
149-3	30316-30322	across	_	
149-4	30323-30333	conditions	_	
149-5	30334-30339	Group	_	
149-6	30340-30351	differences	_	
149-7	30352-30360	occurred	_	
149-8	30361-30363	in	_	
149-9	30364-30371	ventral	_	
149-10	30372-30375	PFC	_	
149-11	30376-30379	and	_	
149-12	30380-30387	ventral	_	
149-13	30388-30396	striatal	_	
149-14	30397-30402	areas	_	
149-15	30402-30403	.	_	

#Text=Specifically, during the sad condition, the PG group demonstrated diminished frontostriatal activity and greater subjective sadness relative to the HC group (Table 3).
150-1	30404-30416	Specifically	_	
150-2	30416-30417	,	_	
150-3	30418-30424	during	_	
150-4	30425-30428	the	_	
150-5	30429-30432	sad	_	
150-6	30433-30442	condition	_	
150-7	30442-30443	,	_	
150-8	30444-30447	the	_	
150-9	30448-30450	PG	_	
150-10	30451-30456	group	_	
150-11	30457-30469	demonstrated	_	
150-12	30470-30480	diminished	_	
150-13	30481-30495	frontostriatal	_	
150-14	30496-30504	activity	_	
150-15	30505-30508	and	_	
150-16	30509-30516	greater	_	
150-17	30517-30527	subjective	_	
150-18	30528-30535	sadness	_	
150-19	30536-30544	relative	_	
150-20	30545-30547	to	_	
150-21	30548-30551	the	_	
150-22	30552-30554	HC	_	
150-23	30555-30560	group	_	
150-24	30561-30562	(	_	
150-25	30562-30567	Table	_	
150-26	30567-30568	 	_	
150-27	30568-30569	3	_	
150-28	30569-30570	)	_	
150-29	30570-30571	.	_	

#Text=A previous study using the same task but an independent sample demonstrated correlations between sadness ratings and medial prefrontal regions in PG but not HC subjects, suggesting differential sensitivities and alterations in affective processing in PG.
151-1	30572-30573	A	_	
151-2	30574-30582	previous	_	
151-3	30583-30588	study	_	
151-4	30589-30594	using	_	
151-5	30595-30598	the	_	
151-6	30599-30603	same	_	
151-7	30604-30608	task	_	
151-8	30609-30612	but	_	
151-9	30613-30615	an	_	
151-10	30616-30627	independent	_	
151-11	30628-30634	sample	_	
151-12	30635-30647	demonstrated	_	
151-13	30648-30660	correlations	_	
151-14	30661-30668	between	_	
151-15	30669-30676	sadness	_	
151-16	30677-30684	ratings	_	
151-17	30685-30688	and	_	
151-18	30689-30695	medial	_	
151-19	30696-30706	prefrontal	_	
151-20	30707-30714	regions	_	
151-21	30715-30717	in	_	
151-22	30718-30720	PG	_	
151-23	30721-30724	but	_	
151-24	30725-30728	not	_	
151-25	30729-30731	HC	_	
151-26	30732-30740	subjects	_	
151-27	30740-30741	,	_	
151-28	30742-30752	suggesting	_	
151-29	30753-30765	differential	_	
151-30	30766-30779	sensitivities	_	
151-31	30780-30783	and	_	
151-32	30784-30795	alterations	_	
151-33	30796-30798	in	_	
151-34	30799-30808	affective	_	
151-35	30809-30819	processing	_	
151-36	30820-30822	in	_	
151-37	30823-30825	PG	_	
151-38	30825-30826	.	_	

#Text=As impairments in emotional clarity and awareness are noted in PG, further investigations could examine how these activations relate to emotional dysregulation in PG.
152-1	30827-30829	As	_	
152-2	30830-30841	impairments	_	
152-3	30842-30844	in	_	
152-4	30845-30854	emotional	_	
152-5	30855-30862	clarity	_	
152-6	30863-30866	and	_	
152-7	30867-30876	awareness	_	
152-8	30877-30880	are	_	
152-9	30881-30886	noted	_	
152-10	30887-30889	in	_	
152-11	30890-30892	PG	_	
152-12	30892-30893	,	_	
152-13	30894-30901	further	_	
152-14	30902-30916	investigations	_	
152-15	30917-30922	could	_	
152-16	30923-30930	examine	_	
152-17	30931-30934	how	_	
152-18	30935-30940	these	_	
152-19	30941-30952	activations	_	
152-20	30953-30959	relate	_	
152-21	30960-30962	to	_	
152-22	30963-30972	emotional	_	
152-23	30973-30986	dysregulation	_	
152-24	30987-30989	in	_	
152-25	30990-30992	PG	_	
152-26	30992-30993	.	_	

#Text=The finding of relatively increased activity within this cluster in the PG group to the cocaine-cue condition was unanticipated and persisted after exclusion of the three subjects with comorbid cocaine abuse/dependence.
153-1	30994-30997	The	_	
153-2	30998-31005	finding	_	
153-3	31006-31008	of	_	
153-4	31009-31019	relatively	_	
153-5	31020-31029	increased	_	
153-6	31030-31038	activity	_	
153-7	31039-31045	within	_	
153-8	31046-31050	this	_	
153-9	31051-31058	cluster	_	
153-10	31059-31061	in	_	
153-11	31062-31065	the	_	
153-12	31066-31068	PG	_	
153-13	31069-31074	group	_	
153-14	31075-31077	to	_	
153-15	31078-31081	the	_	
153-16	31082-31093	cocaine-cue	_	
153-17	31094-31103	condition	_	
153-18	31104-31107	was	_	
153-19	31108-31121	unanticipated	_	
153-20	31122-31125	and	_	
153-21	31126-31135	persisted	_	
153-22	31136-31141	after	_	
153-23	31142-31151	exclusion	_	
153-24	31152-31154	of	_	
153-25	31155-31158	the	_	
153-26	31159-31164	three	_	
153-27	31165-31173	subjects	_	
153-28	31174-31178	with	_	
153-29	31179-31187	comorbid	_	
153-30	31188-31195	cocaine	_	
153-31	31196-31201	abuse	_	
153-32	31201-31202	/	_	
153-33	31202-31212	dependence	_	
153-34	31212-31213	.	_	

#Text=Further research should examine the extent to which PG subjects’ responses to cocaine cues reflect predilections toward or histories of cocaine use, particularly given the elevated co-occurrence between PG and CD and genetic contributions to their co-occurrence.
154-1	31214-31221	Further	_	
154-2	31222-31230	research	_	
154-3	31231-31237	should	_	
154-4	31238-31245	examine	_	
154-5	31246-31249	the	_	
154-6	31250-31256	extent	_	
154-7	31257-31259	to	_	
154-8	31260-31265	which	_	
154-9	31266-31268	PG	_	
154-10	31269-31277	subjects	_	
154-11	31277-31278	’	_	
154-12	31279-31288	responses	_	
154-13	31289-31291	to	_	
154-14	31292-31299	cocaine	_	
154-15	31300-31304	cues	_	
154-16	31305-31312	reflect	_	
154-17	31313-31326	predilections	_	
154-18	31327-31333	toward	_	
154-19	31334-31336	or	_	
154-20	31337-31346	histories	_	
154-21	31347-31349	of	_	
154-22	31350-31357	cocaine	_	
154-23	31358-31361	use	_	
154-24	31361-31362	,	_	
154-25	31363-31375	particularly	_	
154-26	31376-31381	given	_	
154-27	31382-31385	the	_	
154-28	31386-31394	elevated	_	
154-29	31395-31408	co-occurrence	_	
154-30	31409-31416	between	_	
154-31	31417-31419	PG	_	
154-32	31420-31423	and	_	
154-33	31424-31426	CD	_	
154-34	31427-31430	and	_	
154-35	31431-31438	genetic	_	
154-36	31439-31452	contributions	_	
154-37	31453-31455	to	_	
154-38	31456-31461	their	_	
154-39	31462-31475	co-occurrence	_	
154-40	31475-31476	.	_	

#Text=Main effects of condition
#Text=The main effects of condition on brain activations, collapsed across the DBH genotypes and the diagnostic groups, implicated the OFC, vmPFC, anterior and posterior cingulate, thalamus, caudate, left insula, and medial frontal gyrus.
155-1	31477-31481	Main	_	
155-2	31482-31489	effects	_	
155-3	31490-31492	of	_	
155-4	31493-31502	condition	_	
155-5	31503-31506	The	_	
155-6	31507-31511	main	_	
155-7	31512-31519	effects	_	
155-8	31520-31522	of	_	
155-9	31523-31532	condition	_	
155-10	31533-31535	on	_	
155-11	31536-31541	brain	_	
155-12	31542-31553	activations	_	
155-13	31553-31554	,	_	
155-14	31555-31564	collapsed	_	
155-15	31565-31571	across	_	
155-16	31572-31575	the	_	
155-17	31576-31579	DBH	_	
155-18	31580-31589	genotypes	_	
155-19	31590-31593	and	_	
155-20	31594-31597	the	_	
155-21	31598-31608	diagnostic	_	
155-22	31609-31615	groups	_	
155-23	31615-31616	,	_	
155-24	31617-31627	implicated	_	
155-25	31628-31631	the	_	
155-26	31632-31635	OFC	_	
155-27	31635-31636	,	_	
155-28	31637-31642	vmPFC	_	
155-29	31642-31643	,	_	
155-30	31644-31652	anterior	_	
155-31	31653-31656	and	_	
155-32	31657-31666	posterior	_	
155-33	31667-31676	cingulate	_	
155-34	31676-31677	,	_	
155-35	31678-31686	thalamus	_	
155-36	31686-31687	,	_	
155-37	31688-31695	caudate	_	
155-38	31695-31696	,	_	
155-39	31697-31701	left	_	
155-40	31702-31708	insula	_	
155-41	31708-31709	,	_	
155-42	31710-31713	and	_	
155-43	31714-31720	medial	_	
155-44	31721-31728	frontal	_	
155-45	31729-31734	gyrus	_	
155-46	31734-31735	.	_	

#Text=Greater activation of occipital and temporal cortices, i.e., audio-visual-processing regions, was observed during the gambling condition.
156-1	31736-31743	Greater	_	
156-2	31744-31754	activation	_	
156-3	31755-31757	of	_	
156-4	31758-31767	occipital	_	
156-5	31768-31771	and	_	
156-6	31772-31780	temporal	_	
156-7	31781-31789	cortices	_	
156-8	31789-31790	,	_	
156-9	31791-31794	i.e	_	
156-10	31794-31795	.	_	
156-11	31795-31796	,	_	
156-12	31797-31820	audio-visual-processing	_	
156-13	31821-31828	regions	_	
156-14	31828-31829	,	_	
156-15	31830-31833	was	_	
156-16	31834-31842	observed	_	
156-17	31843-31849	during	_	
156-18	31850-31853	the	_	
156-19	31854-31862	gambling	_	
156-20	31863-31872	condition	_	
156-21	31872-31873	.	_	

#Text=These findings complement those that have implicated in PG patient’s dorsal visual processing stream involving the cuneus in motivational states underlying gambling urges, although the findings may also reflect qualities of the gambling tape given the finding across diagnostic groups.
157-1	31874-31879	These	_	
157-2	31880-31888	findings	_	
157-3	31889-31899	complement	_	
157-4	31900-31905	those	_	
157-5	31906-31910	that	_	
157-6	31911-31915	have	_	
157-7	31916-31926	implicated	_	
157-8	31927-31929	in	_	
157-9	31930-31932	PG	_	
157-10	31933-31940	patient	_	
157-11	31940-31941	’	_	
157-12	31941-31942	s	_	
157-13	31943-31949	dorsal	_	
157-14	31950-31956	visual	_	
157-15	31957-31967	processing	_	
157-16	31968-31974	stream	_	
157-17	31975-31984	involving	_	
157-18	31985-31988	the	_	
157-19	31989-31995	cuneus	_	
157-20	31996-31998	in	_	
157-21	31999-32011	motivational	_	
157-22	32012-32018	states	_	
157-23	32019-32029	underlying	_	
157-24	32030-32038	gambling	_	
157-25	32039-32044	urges	_	
157-26	32044-32045	,	_	
157-27	32046-32054	although	_	
157-28	32055-32058	the	_	
157-29	32059-32067	findings	_	
157-30	32068-32071	may	_	
157-31	32072-32076	also	_	
157-32	32077-32084	reflect	_	
157-33	32085-32094	qualities	_	
157-34	32095-32097	of	_	
157-35	32098-32101	the	_	
157-36	32102-32110	gambling	_	
157-37	32111-32115	tape	_	
157-38	32116-32121	given	_	
157-39	32122-32125	the	_	
157-40	32126-32133	finding	_	
157-41	32134-32140	across	_	
157-42	32141-32151	diagnostic	_	
157-43	32152-32158	groups	_	
157-44	32158-32159	.	_	

#Text=Future studies with larger samples may dissect effects of cue conditions in individuals with different characteristics.
158-1	32160-32166	Future	_	
158-2	32167-32174	studies	_	
158-3	32175-32179	with	_	
158-4	32180-32186	larger	_	
158-5	32187-32194	samples	_	
158-6	32195-32198	may	_	
158-7	32199-32206	dissect	_	
158-8	32207-32214	effects	_	
158-9	32215-32217	of	_	
158-10	32218-32221	cue	_	
158-11	32222-32232	conditions	_	
158-12	32233-32235	in	_	
158-13	32236-32247	individuals	_	
158-14	32248-32252	with	_	
158-15	32253-32262	different	_	
158-16	32263-32278	characteristics	_	
158-17	32278-32279	.	_	

#Text=Main effect of diagnostic group
#Text=In contrast to our previous studies using this task, the current study did not detect a main effect of group on BOLD signal changes.
159-1	32280-32284	Main	_	
159-2	32285-32291	effect	_	
159-3	32292-32294	of	_	
159-4	32295-32305	diagnostic	_	
159-5	32306-32311	group	_	
159-6	32312-32314	In	_	
159-7	32315-32323	contrast	_	
159-8	32324-32326	to	_	
159-9	32327-32330	our	_	
159-10	32331-32339	previous	_	
159-11	32340-32347	studies	_	
159-12	32348-32353	using	_	
159-13	32354-32358	this	_	
159-14	32359-32363	task	_	
159-15	32363-32364	,	_	
159-16	32365-32368	the	_	
159-17	32369-32376	current	_	
159-18	32377-32382	study	_	
159-19	32383-32386	did	_	
159-20	32387-32390	not	_	
159-21	32391-32397	detect	_	
159-22	32398-32399	a	_	
159-23	32400-32404	main	_	
159-24	32405-32411	effect	_	
159-25	32412-32414	of	_	
159-26	32415-32420	group	_	
159-27	32421-32423	on	_	
159-28	32424-32428	BOLD	_	
159-29	32429-32435	signal	_	
159-30	32436-32443	changes	_	
159-31	32443-32444	.	_	

#Text=Sample characteristics and analytic technique differences may underlie the discrepant findings.
160-1	32445-32451	Sample	_	
160-2	32452-32467	characteristics	_	
160-3	32468-32471	and	_	
160-4	32472-32480	analytic	_	
160-5	32481-32490	technique	_	
160-6	32491-32502	differences	_	
160-7	32503-32506	may	_	
160-8	32507-32515	underlie	_	
160-9	32516-32519	the	_	
160-10	32520-32530	discrepant	_	
160-11	32531-32539	findings	_	
160-12	32539-32540	.	_	

#Text=Our previous study focused on male-only PG versus HC, while the recent study aimed at comparing neurobiological similarities and differences between cocaine craving and gambling urges using both males and females of multi-ethnic backgrounds in three diagnostic groups of PG, CD, and HC individuals.
161-1	32541-32544	Our	_	
161-2	32545-32553	previous	_	
161-3	32554-32559	study	_	
161-4	32560-32567	focused	_	
161-5	32568-32570	on	_	
161-6	32571-32580	male-only	_	
161-7	32581-32583	PG	_	
161-8	32584-32590	versus	_	
161-9	32591-32593	HC	_	
161-10	32593-32594	,	_	
161-11	32595-32600	while	_	
161-12	32601-32604	the	_	
161-13	32605-32611	recent	_	
161-14	32612-32617	study	_	
161-15	32618-32623	aimed	_	
161-16	32624-32626	at	_	
161-17	32627-32636	comparing	_	
161-18	32637-32652	neurobiological	_	
161-19	32653-32665	similarities	_	
161-20	32666-32669	and	_	
161-21	32670-32681	differences	_	
161-22	32682-32689	between	_	
161-23	32690-32697	cocaine	_	
161-24	32698-32705	craving	_	
161-25	32706-32709	and	_	
161-26	32710-32718	gambling	_	
161-27	32719-32724	urges	_	
161-28	32725-32730	using	_	
161-29	32731-32735	both	_	
161-30	32736-32741	males	_	
161-31	32742-32745	and	_	
161-32	32746-32753	females	_	
161-33	32754-32756	of	_	
161-34	32757-32769	multi-ethnic	_	
161-35	32770-32781	backgrounds	_	
161-36	32782-32784	in	_	
161-37	32785-32790	three	_	
161-38	32791-32801	diagnostic	_	
161-39	32802-32808	groups	_	
161-40	32809-32811	of	_	
161-41	32812-32814	PG	_	
161-42	32814-32815	,	_	
161-43	32816-32818	CD	_	
161-44	32818-32819	,	_	
161-45	32820-32823	and	_	
161-46	32824-32826	HC	_	
161-47	32827-32838	individuals	_	
161-48	32838-32839	.	_	

#Text=These two previous studies evaluated the first and the last viewing periods, and investigated between-group differences in neural activities during viewing of videos of gambling, happy, or sad content, or with gambling, sad, and cocaine content.
162-1	32840-32845	These	_	
162-2	32846-32849	two	_	
162-3	32850-32858	previous	_	
162-4	32859-32866	studies	_	
162-5	32867-32876	evaluated	_	
162-6	32877-32880	the	_	
162-7	32881-32886	first	_	
162-8	32887-32890	and	_	
162-9	32891-32894	the	_	
162-10	32895-32899	last	_	
162-11	32900-32907	viewing	_	
162-12	32908-32915	periods	_	
162-13	32915-32916	,	_	
162-14	32917-32920	and	_	
162-15	32921-32933	investigated	_	
162-16	32934-32947	between-group	_	
162-17	32948-32959	differences	_	
162-18	32960-32962	in	_	
162-19	32963-32969	neural	_	
162-20	32970-32980	activities	_	
162-21	32981-32987	during	_	
162-22	32988-32995	viewing	_	
162-23	32996-32998	of	_	
162-24	32999-33005	videos	_	
162-25	33006-33008	of	_	
162-26	33009-33017	gambling	_	
162-27	33017-33018	,	_	
162-28	33019-33024	happy	_	
162-29	33024-33025	,	_	
162-30	33026-33028	or	_	
162-31	33029-33032	sad	_	
162-32	33033-33040	content	_	
162-33	33040-33041	,	_	
162-34	33042-33044	or	_	
162-35	33045-33049	with	_	
162-36	33050-33058	gambling	_	
162-37	33058-33059	,	_	
162-38	33060-33063	sad	_	
162-39	33063-33064	,	_	
162-40	33065-33068	and	_	
162-41	33069-33076	cocaine	_	
162-42	33077-33084	content	_	
162-43	33084-33085	.	_	

#Text=The study found that the most pronounced between-group differences (PG versus HC) in neural activities were observed during the initial period of viewing of the gambling conditions.
163-1	33086-33089	The	_	
163-2	33090-33095	study	_	
163-3	33096-33101	found	_	
163-4	33102-33106	that	_	
163-5	33107-33110	the	_	
163-6	33111-33115	most	_	
163-7	33116-33126	pronounced	_	
163-8	33127-33140	between-group	_	
163-9	33141-33152	differences	_	
163-10	33153-33154	(	_	
163-11	33154-33156	PG	_	
163-12	33157-33163	versus	_	
163-13	33164-33166	HC	_	
163-14	33166-33167	)	_	
163-15	33168-33170	in	_	
163-16	33171-33177	neural	_	
163-17	33178-33188	activities	_	
163-18	33189-33193	were	_	
163-19	33194-33202	observed	_	
163-20	33203-33209	during	_	
163-21	33210-33213	the	_	
163-22	33214-33221	initial	_	
163-23	33222-33228	period	_	
163-24	33229-33231	of	_	
163-25	33232-33239	viewing	_	
163-26	33240-33242	of	_	
163-27	33243-33246	the	_	
163-28	33247-33255	gambling	_	
163-29	33256-33266	conditions	_	
163-30	33266-33267	.	_	

#Text=In that study, PG subjects displayed relatively decreased activity in frontal and OFC, caudate/basal ganglia, and thalamus compared with controls.
164-1	33268-33270	In	_	
164-2	33271-33275	that	_	
164-3	33276-33281	study	_	
164-4	33281-33282	,	_	
164-5	33283-33285	PG	_	
164-6	33286-33294	subjects	_	
164-7	33295-33304	displayed	_	
164-8	33305-33315	relatively	_	
164-9	33316-33325	decreased	_	
164-10	33326-33334	activity	_	
164-11	33335-33337	in	_	
164-12	33338-33345	frontal	_	
164-13	33346-33349	and	_	
164-14	33350-33353	OFC	_	
164-15	33353-33354	,	_	
164-16	33355-33362	caudate	_	
164-17	33362-33363	/	_	
164-18	33363-33368	basal	_	
164-19	33369-33376	ganglia	_	
164-20	33376-33377	,	_	
164-21	33378-33381	and	_	
164-22	33382-33390	thalamus	_	
164-23	33391-33399	compared	_	
164-24	33400-33404	with	_	
164-25	33405-33413	controls	_	
164-26	33413-33414	.	_	

#Text=In our recent study, a diagnostic group by video interaction identified mPFC, which was activated mainly to cocaine videos in CD participants during the initial viewing period, and a more dorsal mPFC region that was most strongly activated for cocaine videos in CD participants, gambling videos in PG participants, and sad videos in HC during the last viewing period.
165-1	33415-33417	In	_	
165-2	33418-33421	our	_	
165-3	33422-33428	recent	_	
165-4	33429-33434	study	_	
165-5	33434-33435	,	_	
165-6	33436-33437	a	_	
165-7	33438-33448	diagnostic	_	
165-8	33449-33454	group	_	
165-9	33455-33457	by	_	
165-10	33458-33463	video	_	
165-11	33464-33475	interaction	_	
165-12	33476-33486	identified	_	
165-13	33487-33491	mPFC	_	
165-14	33491-33492	,	_	
165-15	33493-33498	which	_	
165-16	33499-33502	was	_	
165-17	33503-33512	activated	_	
165-18	33513-33519	mainly	_	
165-19	33520-33522	to	_	
165-20	33523-33530	cocaine	_	
165-21	33531-33537	videos	_	
165-22	33538-33540	in	_	
165-23	33541-33543	CD	_	
165-24	33544-33556	participants	_	
165-25	33557-33563	during	_	
165-26	33564-33567	the	_	
165-27	33568-33575	initial	_	
165-28	33576-33583	viewing	_	
165-29	33584-33590	period	_	
165-30	33590-33591	,	_	
165-31	33592-33595	and	_	
165-32	33596-33597	a	_	
165-33	33598-33602	more	_	
165-34	33603-33609	dorsal	_	
165-35	33610-33614	mPFC	_	
165-36	33615-33621	region	_	
165-37	33622-33626	that	_	
165-38	33627-33630	was	_	
165-39	33631-33635	most	_	
165-40	33636-33644	strongly	_	
165-41	33645-33654	activated	_	
165-42	33655-33658	for	_	
165-43	33659-33666	cocaine	_	
165-44	33667-33673	videos	_	
165-45	33674-33676	in	_	
165-46	33677-33679	CD	_	
165-47	33680-33692	participants	_	
165-48	33692-33693	,	_	
165-49	33694-33702	gambling	_	
165-50	33703-33709	videos	_	
165-51	33710-33712	in	_	
165-52	33713-33715	PG	_	
165-53	33716-33728	participants	_	
165-54	33728-33729	,	_	
165-55	33730-33733	and	_	
165-56	33734-33737	sad	_	
165-57	33738-33744	videos	_	
165-58	33745-33747	in	_	
165-59	33748-33750	HC	_	
165-60	33751-33757	during	_	
165-61	33758-33761	the	_	
165-62	33762-33766	last	_	
165-63	33767-33774	viewing	_	
165-64	33775-33781	period	_	
165-65	33781-33782	.	_	

#Text=Our current study includes both men and women of EA-only PG versus HC, and investigates signal changes during the entire period of tape-viewing (a different analytic approach used in).
166-1	33783-33786	Our	_	
166-2	33787-33794	current	_	
166-3	33795-33800	study	_	
166-4	33801-33809	includes	_	
166-5	33810-33814	both	_	
166-6	33815-33818	men	_	
166-7	33819-33822	and	_	
166-8	33823-33828	women	_	
166-9	33829-33831	of	_	
166-10	33832-33839	EA-only	_	
166-11	33840-33842	PG	_	
166-12	33843-33849	versus	_	
166-13	33850-33852	HC	_	
166-14	33852-33853	,	_	
166-15	33854-33857	and	_	
166-16	33858-33870	investigates	_	
166-17	33871-33877	signal	_	
166-18	33878-33885	changes	_	
166-19	33886-33892	during	_	
166-20	33893-33896	the	_	
166-21	33897-33903	entire	_	
166-22	33904-33910	period	_	
166-23	33911-33913	of	_	
166-24	33914-33926	tape-viewing	_	
166-25	33927-33928	(	_	
166-26	33928-33929	a	_	
166-27	33930-33939	different	_	
166-28	33940-33948	analytic	_	
166-29	33949-33957	approach	_	
166-30	33958-33962	used	_	
166-31	33963-33965	in	_	
166-32	33965-33966	)	_	
166-33	33966-33967	.	_	

#Text=We have reanalyzed the current study data separated by sex using the previous approaches, partially replicating our previous findings in an independent sample with relatively decreased activities in VS (p = .033) of PG versus HC for the male-only sample, but not for the vmPFC (see Supplementary Material X).
167-1	33968-33970	We	_	
167-2	33971-33975	have	_	
167-3	33976-33986	reanalyzed	_	
167-4	33987-33990	the	_	
167-5	33991-33998	current	_	
167-6	33999-34004	study	_	
167-7	34005-34009	data	_	
167-8	34010-34019	separated	_	
167-9	34020-34022	by	_	
167-10	34023-34026	sex	_	
167-11	34027-34032	using	_	
167-12	34033-34036	the	_	
167-13	34037-34045	previous	_	
167-14	34046-34056	approaches	_	
167-15	34056-34057	,	_	
167-16	34058-34067	partially	_	
167-17	34068-34079	replicating	_	
167-18	34080-34083	our	_	
167-19	34084-34092	previous	_	
167-20	34093-34101	findings	_	
167-21	34102-34104	in	_	
167-22	34105-34107	an	_	
167-23	34108-34119	independent	_	
167-24	34120-34126	sample	_	
167-25	34127-34131	with	_	
167-26	34132-34142	relatively	_	
167-27	34143-34152	decreased	_	
167-28	34153-34163	activities	_	
167-29	34164-34166	in	_	
167-30	34167-34169	VS	_	
167-31	34170-34171	(	_	
167-32	34171-34172	p	_	
167-33	34173-34174	=	_	
167-34	34175-34179	.033	_	
167-35	34179-34180	)	_	
167-36	34181-34183	of	_	
167-37	34184-34186	PG	_	
167-38	34187-34193	versus	_	
167-39	34194-34196	HC	_	
167-40	34197-34200	for	_	
167-41	34201-34204	the	_	
167-42	34205-34214	male-only	_	
167-43	34215-34221	sample	_	
167-44	34221-34222	,	_	
167-45	34223-34226	but	_	
167-46	34227-34230	not	_	
167-47	34231-34234	for	_	
167-48	34235-34238	the	_	
167-49	34239-34244	vmPFC	_	
167-50	34245-34246	(	_	
167-51	34246-34249	see	_	
167-52	34250-34263	Supplementary	_	
167-53	34264-34272	Material	_	
167-54	34273-34274	X	_	
167-55	34274-34275	)	_	
167-56	34275-34276	.	_	

#Text=Strengths, limitations and future directions
#Text=Together, the findings suggest important roles for dopamine and norepinephrine in emotion regulation and impulse control and provide a context for the novel DBH-related findings reported here.
168-1	34277-34286	Strengths	_	
168-2	34286-34287	,	_	
168-3	34288-34299	limitations	_	
168-4	34300-34303	and	_	
168-5	34304-34310	future	_	
168-6	34311-34321	directions	_	
168-7	34322-34330	Together	_	
168-8	34330-34331	,	_	
168-9	34332-34335	the	_	
168-10	34336-34344	findings	_	
168-11	34345-34352	suggest	_	
168-12	34353-34362	important	_	
168-13	34363-34368	roles	_	
168-14	34369-34372	for	_	
168-15	34373-34381	dopamine	_	
168-16	34382-34385	and	_	
168-17	34386-34400	norepinephrine	_	
168-18	34401-34403	in	_	
168-19	34404-34411	emotion	_	
168-20	34412-34422	regulation	_	
168-21	34423-34426	and	_	
168-22	34427-34434	impulse	_	
168-23	34435-34442	control	_	
168-24	34443-34446	and	_	
168-25	34447-34454	provide	_	
168-26	34455-34456	a	_	
168-27	34457-34464	context	_	
168-28	34465-34468	for	_	
168-29	34469-34472	the	_	
168-30	34473-34478	novel	_	
168-31	34479-34490	DBH-related	_	
168-32	34491-34499	findings	_	
168-33	34500-34508	reported	_	
168-34	34509-34513	here	_	
168-35	34513-34514	.	_	

#Text=Strengths of this initial study lie in the whole-brain analytic approach to assess neural activity and sizable samples of CC and T-carrier subjects.
169-1	34515-34524	Strengths	_	
169-2	34525-34527	of	_	
169-3	34528-34532	this	_	
169-4	34533-34540	initial	_	
169-5	34541-34546	study	_	
169-6	34547-34550	lie	_	
169-7	34551-34553	in	_	
169-8	34554-34557	the	_	
169-9	34558-34569	whole-brain	_	
169-10	34570-34578	analytic	_	
169-11	34579-34587	approach	_	
169-12	34588-34590	to	_	
169-13	34591-34597	assess	_	
169-14	34598-34604	neural	_	
169-15	34605-34613	activity	_	
169-16	34614-34617	and	_	
169-17	34618-34625	sizable	_	
169-18	34626-34633	samples	_	
169-19	34634-34636	of	_	
169-20	34637-34639	CC	_	
169-21	34640-34643	and	_	
169-22	34644-34653	T-carrier	_	
169-23	34654-34662	subjects	_	
169-24	34662-34663	.	_	

#Text=While some effects between cue conditions may linger, the counterbalancing approach was designed to mitigate this possibility.
170-1	34664-34669	While	_	
170-2	34670-34674	some	_	
170-3	34675-34682	effects	_	
170-4	34683-34690	between	_	
170-5	34691-34694	cue	_	
170-6	34695-34705	conditions	_	
170-7	34706-34709	may	_	
170-8	34710-34716	linger	_	
170-9	34716-34717	,	_	
170-10	34718-34721	the	_	
170-11	34722-34738	counterbalancing	_	
170-12	34739-34747	approach	_	
170-13	34748-34751	was	_	
170-14	34752-34760	designed	_	
170-15	34761-34763	to	_	
170-16	34764-34772	mitigate	_	
170-17	34773-34777	this	_	
170-18	34778-34789	possibility	_	
170-19	34789-34790	.	_	

#Text=Responses to sad-scenario content (parental divorce, a relative’s death) may differ based on individual subjects’ experiences; information regarding parental divorce or death was not collected and limited us from evaluation of its impact on the responses to sad cues.
171-1	34791-34800	Responses	_	
171-2	34801-34803	to	_	
171-3	34804-34816	sad-scenario	_	
171-4	34817-34824	content	_	
171-5	34825-34826	(	_	
171-6	34826-34834	parental	_	
171-7	34835-34842	divorce	_	
171-8	34842-34843	,	_	
171-9	34844-34845	a	_	
171-10	34846-34854	relative	_	
171-11	34854-34855	’	_	
171-12	34855-34856	s	_	
171-13	34857-34862	death	_	
171-14	34862-34863	)	_	
171-15	34864-34867	may	_	
171-16	34868-34874	differ	_	
171-17	34875-34880	based	_	
171-18	34881-34883	on	_	
171-19	34884-34894	individual	_	
171-20	34895-34903	subjects	_	
171-21	34903-34904	’	_	
171-22	34905-34916	experiences	_	
171-23	34916-34917	;	_	
171-24	34918-34929	information	_	
171-25	34930-34939	regarding	_	
171-26	34940-34948	parental	_	
171-27	34949-34956	divorce	_	
171-28	34957-34959	or	_	
171-29	34960-34965	death	_	
171-30	34966-34969	was	_	
171-31	34970-34973	not	_	
171-32	34974-34983	collected	_	
171-33	34984-34987	and	_	
171-34	34988-34995	limited	_	
171-35	34996-34998	us	_	
171-36	34999-35003	from	_	
171-37	35004-35014	evaluation	_	
171-38	35015-35017	of	_	
171-39	35018-35021	its	_	
171-40	35022-35028	impact	_	
171-41	35029-35031	on	_	
171-42	35032-35035	the	_	
171-43	35036-35045	responses	_	
171-44	35046-35048	to	_	
171-45	35049-35052	sad	_	
171-46	35053-35057	cues	_	
171-47	35057-35058	.	_	

#Text=Nonetheless, the qualitative and emotional intensity ratings by participants provide support that the scenarios were successful in generating the intended emotional responses.
172-1	35059-35070	Nonetheless	_	
172-2	35070-35071	,	_	
172-3	35072-35075	the	_	
172-4	35076-35087	qualitative	_	
172-5	35088-35091	and	_	
172-6	35092-35101	emotional	_	
172-7	35102-35111	intensity	_	
172-8	35112-35119	ratings	_	
172-9	35120-35122	by	_	
172-10	35123-35135	participants	_	
172-11	35136-35143	provide	_	
172-12	35144-35151	support	_	
172-13	35152-35156	that	_	
172-14	35157-35160	the	_	
172-15	35161-35170	scenarios	_	
172-16	35171-35175	were	_	
172-17	35176-35186	successful	_	
172-18	35187-35189	in	_	
172-19	35190-35200	generating	_	
172-20	35201-35204	the	_	
172-21	35205-35213	intended	_	
172-22	35214-35223	emotional	_	
172-23	35224-35233	responses	_	
172-24	35233-35234	.	_	

#Text=Additionally, findings in this study substantiate previous reports of diminished empathy in T-carriers and extend these findings to demonstrate the neural substrates underlying this effect.
173-1	35235-35247	Additionally	_	
173-2	35247-35248	,	_	
173-3	35249-35257	findings	_	
173-4	35258-35260	in	_	
173-5	35261-35265	this	_	
173-6	35266-35271	study	_	
173-7	35272-35284	substantiate	_	
173-8	35285-35293	previous	_	
173-9	35294-35301	reports	_	
173-10	35302-35304	of	_	
173-11	35305-35315	diminished	_	
173-12	35316-35323	empathy	_	
173-13	35324-35326	in	_	
173-14	35327-35337	T-carriers	_	
173-15	35338-35341	and	_	
173-16	35342-35348	extend	_	
173-17	35349-35354	these	_	
173-18	35355-35363	findings	_	
173-19	35364-35366	to	_	
173-20	35367-35378	demonstrate	_	
173-21	35379-35382	the	_	
173-22	35383-35389	neural	_	
173-23	35390-35400	substrates	_	
173-24	35401-35411	underlying	_	
173-25	35412-35416	this	_	
173-26	35417-35423	effect	_	
173-27	35423-35424	.	_	

#Text=Together with subjective reports, these findings therefore provide proof-of-concept of the video task.
174-1	35425-35433	Together	_	
174-2	35434-35438	with	_	
174-3	35439-35449	subjective	_	
174-4	35450-35457	reports	_	
174-5	35457-35458	,	_	
174-6	35459-35464	these	_	
174-7	35465-35473	findings	_	
174-8	35474-35483	therefore	_	
174-9	35484-35491	provide	_	
174-10	35492-35508	proof-of-concept	_	
174-11	35509-35511	of	_	
174-12	35512-35515	the	_	
174-13	35516-35521	video	_	
174-14	35522-35526	task	_	
174-15	35526-35527	.	_	

#Text=Small sample sizes when classifying by both diagnostic group and DBH genotypes may have precluded identification of some significant findings, such as the two-way and three-way interaction effects of group-by-DBH-genotype and group-by-DBH-genotype-by-condition, respectively.
175-1	35528-35533	Small	_	
175-2	35534-35540	sample	_	
175-3	35541-35546	sizes	_	
175-4	35547-35551	when	_	
175-5	35552-35563	classifying	_	
175-6	35564-35566	by	_	
175-7	35567-35571	both	_	
175-8	35572-35582	diagnostic	_	
175-9	35583-35588	group	_	
175-10	35589-35592	and	_	
175-11	35593-35596	DBH	_	
175-12	35597-35606	genotypes	_	
175-13	35607-35610	may	_	
175-14	35611-35615	have	_	
175-15	35616-35625	precluded	_	
175-16	35626-35640	identification	_	
175-17	35641-35643	of	_	
175-18	35644-35648	some	_	
175-19	35649-35660	significant	_	
175-20	35661-35669	findings	_	
175-21	35669-35670	,	_	
175-22	35671-35675	such	_	
175-23	35676-35678	as	_	
175-24	35679-35682	the	_	
175-25	35683-35690	two-way	_	
175-26	35691-35694	and	_	
175-27	35695-35704	three-way	_	
175-28	35705-35716	interaction	_	
175-29	35717-35724	effects	_	
175-30	35725-35727	of	_	
175-31	35728-35749	group-by-DBH-genotype	_	
175-32	35750-35753	and	_	
175-33	35754-35788	group-by-DBH-genotype-by-condition	_	
175-34	35788-35789	,	_	
175-35	35790-35802	respectively	_	
175-36	35802-35803	.	_	

#Text=Nonetheless, the sample sizes for main effects of DBH genotype (N-CC = 20/N-T-carrier = 23) and condition (N = 43) and for two-way interactions of group-by-condition (N-PG = 18/N-HC = 25) and DBH-genotype-by-condition (N-CC = 20/N-T-carrier = 23) comply with recommended guidelines for power and sample size consideration for clinical fMRI studies.
176-1	35804-35815	Nonetheless	_	
176-2	35815-35816	,	_	
176-3	35817-35820	the	_	
176-4	35821-35827	sample	_	
176-5	35828-35833	sizes	_	
176-6	35834-35837	for	_	
176-7	35838-35842	main	_	
176-8	35843-35850	effects	_	
176-9	35851-35853	of	_	
176-10	35854-35857	DBH	_	
176-11	35858-35866	genotype	_	
176-12	35867-35868	(	_	
176-13	35868-35872	N-CC	_	
176-14	35873-35874	=	_	
176-15	35875-35877	20	_	
176-16	35877-35878	/	_	
176-17	35878-35889	N-T-carrier	_	
176-18	35890-35891	=	_	
176-19	35892-35894	23	_	
176-20	35894-35895	)	_	
176-21	35896-35899	and	_	
176-22	35900-35909	condition	_	
176-23	35910-35911	(	_	
176-24	35911-35912	N	_	
176-25	35913-35914	=	_	
176-26	35915-35917	43	_	
176-27	35917-35918	)	_	
176-28	35919-35922	and	_	
176-29	35923-35926	for	_	
176-30	35927-35934	two-way	_	
176-31	35935-35947	interactions	_	
176-32	35948-35950	of	_	
176-33	35951-35969	group-by-condition	_	
176-34	35970-35971	(	_	
176-35	35971-35975	N-PG	_	
176-36	35976-35977	=	_	
176-37	35978-35980	18	_	
176-38	35980-35981	/	_	
176-39	35981-35985	N-HC	_	
176-40	35986-35987	=	_	
176-41	35988-35990	25	_	
176-42	35990-35991	)	_	
176-43	35992-35995	and	_	
176-44	35996-36021	DBH-genotype-by-condition	_	
176-45	36022-36023	(	_	
176-46	36023-36027	N-CC	_	
176-47	36028-36029	=	_	
176-48	36030-36032	20	_	
176-49	36032-36033	/	_	
176-50	36033-36044	N-T-carrier	_	
176-51	36045-36046	=	_	
176-52	36047-36049	23	_	
176-53	36049-36050	)	_	
176-54	36051-36057	comply	_	
176-55	36058-36062	with	_	
176-56	36063-36074	recommended	_	
176-57	36075-36085	guidelines	_	
176-58	36086-36089	for	_	
176-59	36090-36095	power	_	
176-60	36096-36099	and	_	
176-61	36100-36106	sample	_	
176-62	36107-36111	size	_	
176-63	36112-36125	consideration	_	
176-64	36126-36129	for	_	
176-65	36130-36138	clinical	_	
176-66	36139-36143	fMRI	_	
176-67	36144-36151	studies	_	
176-68	36151-36152	.	_	

#Text=Additionally, some p values may not withstand correction for multiple comparisons (e.g., with respect to allelic variation and subjective responses to sad videos).
177-1	36153-36165	Additionally	_	
177-2	36165-36166	,	_	
177-3	36167-36171	some	_	
177-4	36172-36173	p	_	
177-5	36174-36180	values	_	
177-6	36181-36184	may	_	
177-7	36185-36188	not	_	
177-8	36189-36198	withstand	_	
177-9	36199-36209	correction	_	
177-10	36210-36213	for	_	
177-11	36214-36222	multiple	_	
177-12	36223-36234	comparisons	_	
177-13	36235-36236	(	_	
177-14	36236-36239	e.g	_	
177-15	36239-36240	.	_	
177-16	36240-36241	,	_	
177-17	36241-36242	 	_	
177-18	36242-36246	with	_	
177-19	36247-36254	respect	_	
177-20	36255-36257	to	_	
177-21	36258-36265	allelic	_	
177-22	36266-36275	variation	_	
177-23	36276-36279	and	_	
177-24	36280-36290	subjective	_	
177-25	36291-36300	responses	_	
177-26	36301-36303	to	_	
177-27	36304-36307	sad	_	
177-28	36308-36314	videos	_	
177-29	36314-36315	)	_	
177-30	36315-36316	.	_	

#Text=Imbalances in co-occurring psychiatric disorders existed between PG and HC groups; however, the PG pattern of comorbidity is reflective of this clinical population.
178-1	36317-36327	Imbalances	_	
178-2	36328-36330	in	_	
178-3	36331-36343	co-occurring	_	
178-4	36344-36355	psychiatric	_	
178-5	36356-36365	disorders	_	
178-6	36366-36373	existed	_	
178-7	36374-36381	between	_	
178-8	36382-36384	PG	_	
178-9	36385-36388	and	_	
178-10	36389-36391	HC	_	
178-11	36392-36398	groups	_	
178-12	36398-36399	;	_	
178-13	36400-36407	however	_	
178-14	36407-36408	,	_	
178-15	36409-36412	the	_	
178-16	36413-36415	PG	_	
178-17	36416-36423	pattern	_	
178-18	36424-36426	of	_	
178-19	36427-36438	comorbidity	_	
178-20	36439-36441	is	_	
178-21	36442-36452	reflective	_	
178-22	36453-36455	of	_	
178-23	36456-36460	this	_	
178-24	36461-36469	clinical	_	
178-25	36470-36480	population	_	
178-26	36480-36481	.	_	

#Text=After controlling for comorbid conditions (i.e., cocaine and alcohol dependence), results remained similar (see Supplementary Material VIII).
179-1	36482-36487	After	_	
179-2	36488-36499	controlling	_	
179-3	36500-36503	for	_	
179-4	36504-36512	comorbid	_	
179-5	36513-36523	conditions	_	
179-6	36524-36525	(	_	
179-7	36525-36528	i.e	_	
179-8	36528-36529	.	_	
179-9	36529-36530	,	_	
179-10	36531-36538	cocaine	_	
179-11	36539-36542	and	_	
179-12	36543-36550	alcohol	_	
179-13	36551-36561	dependence	_	
179-14	36561-36562	)	_	
179-15	36562-36563	,	_	
179-16	36564-36571	results	_	
179-17	36572-36580	remained	_	
179-18	36581-36588	similar	_	
179-19	36589-36590	(	_	
179-20	36590-36593	see	_	
179-21	36594-36607	Supplementary	_	
179-22	36608-36616	Material	_	
179-23	36617-36621	VIII	_	
179-24	36621-36622	)	_	
179-25	36622-36623	.	_	

#Text=Further analyses contrasting smokers versus non-smokers within the PG group found no difference between PG smokers and PG non-smokers for the gambling and cocaine scenarios but discovered some differences in the sad scenario (see Supplementary Material IX).
180-1	36624-36631	Further	_	
180-2	36632-36640	analyses	_	
180-3	36641-36652	contrasting	_	
180-4	36653-36660	smokers	_	
180-5	36661-36667	versus	_	
180-6	36668-36679	non-smokers	_	
180-7	36680-36686	within	_	
180-8	36687-36690	the	_	
180-9	36691-36693	PG	_	
180-10	36694-36699	group	_	
180-11	36700-36705	found	_	
180-12	36706-36708	no	_	
180-13	36709-36719	difference	_	
180-14	36720-36727	between	_	
180-15	36728-36730	PG	_	
180-16	36731-36738	smokers	_	
180-17	36739-36742	and	_	
180-18	36743-36745	PG	_	
180-19	36746-36757	non-smokers	_	
180-20	36758-36761	for	_	
180-21	36762-36765	the	_	
180-22	36766-36774	gambling	_	
180-23	36775-36778	and	_	
180-24	36779-36786	cocaine	_	
180-25	36787-36796	scenarios	_	
180-26	36797-36800	but	_	
180-27	36801-36811	discovered	_	
180-28	36812-36816	some	_	
180-29	36817-36828	differences	_	
180-30	36829-36831	in	_	
180-31	36832-36835	the	_	
180-32	36836-36839	sad	_	
180-33	36840-36848	scenario	_	
180-34	36849-36850	(	_	
180-35	36850-36853	see	_	
180-36	36854-36867	Supplementary	_	
180-37	36868-36876	Material	_	
180-38	36877-36879	IX	_	
180-39	36879-36880	)	_	
180-40	36880-36881	.	_	

#Text=However, the brain regions in response to the sad condition differ from the brain regions, implicating corticostriatal-limbic neurocircuitry we identified across the three conditions.
181-1	36882-36889	However	_	
181-2	36889-36890	,	_	
181-3	36891-36894	the	_	
181-4	36895-36900	brain	_	
181-5	36901-36908	regions	_	
181-6	36909-36911	in	_	
181-7	36912-36920	response	_	
181-8	36921-36923	to	_	
181-9	36924-36927	the	_	
181-10	36928-36931	sad	_	
181-11	36932-36941	condition	_	
181-12	36942-36948	differ	_	
181-13	36949-36953	from	_	
181-14	36954-36957	the	_	
181-15	36958-36963	brain	_	
181-16	36964-36971	regions	_	
181-17	36971-36972	,	_	
181-18	36973-36984	implicating	_	
181-19	36985-37007	corticostriatal-limbic	_	
181-20	37008-37022	neurocircuitry	_	
181-21	37023-37025	we	_	
181-22	37026-37036	identified	_	
181-23	37037-37043	across	_	
181-24	37044-37047	the	_	
181-25	37048-37053	three	_	
181-26	37054-37064	conditions	_	
181-27	37064-37065	.	_	

#Text=Therefore, the differences between PG versus HC groups for the sad condition do not appear attributable to smoking status.
182-1	37066-37075	Therefore	_	
182-2	37075-37076	,	_	
182-3	37077-37080	the	_	
182-4	37081-37092	differences	_	
182-5	37093-37100	between	_	
182-6	37101-37103	PG	_	
182-7	37104-37110	versus	_	
182-8	37111-37113	HC	_	
182-9	37114-37120	groups	_	
182-10	37121-37124	for	_	
182-11	37125-37128	the	_	
182-12	37129-37132	sad	_	
182-13	37133-37142	condition	_	
182-14	37143-37145	do	_	
182-15	37146-37149	not	_	
182-16	37150-37156	appear	_	
182-17	37157-37169	attributable	_	
182-18	37170-37172	to	_	
182-19	37173-37180	smoking	_	
182-20	37181-37187	status	_	
182-21	37187-37188	.	_	

#Text=Despite limitations, the current study identified DBH-related differences in brain function in the processing of affective and motivational cues in PG and HC groups.
183-1	37189-37196	Despite	_	
183-2	37197-37208	limitations	_	
183-3	37208-37209	,	_	
183-4	37210-37213	the	_	
183-5	37214-37221	current	_	
183-6	37222-37227	study	_	
183-7	37228-37238	identified	_	
183-8	37239-37250	DBH-related	_	
183-9	37251-37262	differences	_	
183-10	37263-37265	in	_	
183-11	37266-37271	brain	_	
183-12	37272-37280	function	_	
183-13	37281-37283	in	_	
183-14	37284-37287	the	_	
183-15	37288-37298	processing	_	
183-16	37299-37301	of	_	
183-17	37302-37311	affective	_	
183-18	37312-37315	and	_	
183-19	37316-37328	motivational	_	
183-20	37329-37333	cues	_	
183-21	37334-37336	in	_	
183-22	37337-37339	PG	_	
183-23	37340-37343	and	_	
183-24	37344-37346	HC	_	
183-25	37347-37353	groups	_	
183-26	37353-37354	.	_	

#Text=Given DBH’s role in dopamine/norepinephrine balance, future studies should investigate the extent to which targeting dopamine and/or norepinephrine function in corticostriatal-limbic brain regions might be helpful for PG treatment, particularly in individuals with specific DBH allelic identities.
184-1	37355-37360	Given	_	
184-2	37361-37364	DBH	_	
184-3	37364-37365	’	_	
184-4	37365-37366	s	_	
184-5	37367-37371	role	_	
184-6	37372-37374	in	_	
184-7	37375-37383	dopamine	_	
184-8	37383-37384	/	_	
184-9	37384-37398	norepinephrine	_	
184-10	37399-37406	balance	_	
184-11	37406-37407	,	_	
184-12	37408-37414	future	_	
184-13	37415-37422	studies	_	
184-14	37423-37429	should	_	
184-15	37430-37441	investigate	_	
184-16	37442-37445	the	_	
184-17	37446-37452	extent	_	
184-18	37453-37455	to	_	
184-19	37456-37461	which	_	
184-20	37462-37471	targeting	_	
184-21	37472-37480	dopamine	_	
184-22	37481-37484	and	_	
184-23	37484-37485	/	_	
184-24	37485-37487	or	_	
184-25	37488-37502	norepinephrine	_	
184-26	37503-37511	function	_	
184-27	37512-37514	in	_	
184-28	37515-37537	corticostriatal-limbic	_	
184-29	37538-37543	brain	_	
184-30	37544-37551	regions	_	
184-31	37552-37557	might	_	
184-32	37558-37560	be	_	
184-33	37561-37568	helpful	_	
184-34	37569-37572	for	_	
184-35	37573-37575	PG	_	
184-36	37576-37585	treatment	_	
184-37	37585-37586	,	_	
184-38	37587-37599	particularly	_	
184-39	37600-37602	in	_	
184-40	37603-37614	individuals	_	
184-41	37615-37619	with	_	
184-42	37620-37628	specific	_	
184-43	37629-37632	DBH	_	
184-44	37633-37640	allelic	_	
184-45	37641-37651	identities	_	
184-46	37651-37652	.	_	

#Text=Authors’ contribution
#Text=B-ZY analyzed the data, wrote the draft of the manuscript and revised the manuscript and addressed the reviewers’ comments.
185-1	37653-37660	Authors	_	
185-2	37660-37661	’	_	
185-3	37662-37674	contribution	_	
185-4	37675-37679	B-ZY	_	
185-5	37680-37688	analyzed	_	
185-6	37689-37692	the	_	
185-7	37693-37697	data	_	
185-8	37697-37698	,	_	
185-9	37699-37704	wrote	_	
185-10	37705-37708	the	_	
185-11	37709-37714	draft	_	
185-12	37715-37717	of	_	
185-13	37718-37721	the	_	
185-14	37722-37732	manuscript	_	
185-15	37733-37736	and	_	
185-16	37737-37744	revised	_	
185-17	37745-37748	the	_	
185-18	37749-37759	manuscript	_	
185-19	37760-37763	and	_	
185-20	37764-37773	addressed	_	
185-21	37774-37777	the	_	
185-22	37778-37787	reviewers	_	
185-23	37787-37788	’	_	
185-24	37789-37797	comments	_	
185-25	37797-37798	.	_	

#Text=IMB helped revise the manuscript and provided guidance of the revision.
186-1	37799-37802	IMB	_	
186-2	37803-37809	helped	_	
186-3	37810-37816	revise	_	
186-4	37817-37820	the	_	
186-5	37821-37831	manuscript	_	
186-6	37832-37835	and	_	
186-7	37836-37844	provided	_	
186-8	37845-37853	guidance	_	
186-9	37854-37856	of	_	
186-10	37857-37860	the	_	
186-11	37861-37869	revision	_	
186-12	37869-37870	.	_	

#Text=CML analyzed the imaging data.
187-1	37871-37874	CML	_	
187-2	37875-37883	analyzed	_	
187-3	37884-37887	the	_	
187-4	37888-37895	imaging	_	
187-5	37896-37900	data	_	
187-6	37900-37901	.	_	

#Text=JX offered interpretation of the results and discussion.
188-1	37902-37904	JX	_	
188-2	37905-37912	offered	_	
188-3	37913-37927	interpretation	_	
188-4	37928-37930	of	_	
188-5	37931-37934	the	_	
188-6	37935-37942	results	_	
188-7	37943-37946	and	_	
188-8	37947-37957	discussion	_	
188-9	37957-37958	.	_	

#Text=MP designed and guided the study, proposed the analyses, and revised the manuscript.
189-1	37959-37961	MP	_	
189-2	37962-37970	designed	_	
189-3	37971-37974	and	_	
189-4	37975-37981	guided	_	
189-5	37982-37985	the	_	
189-6	37986-37991	study	_	
189-7	37991-37992	,	_	
189-8	37993-38001	proposed	_	
189-9	38002-38005	the	_	
189-10	38006-38014	analyses	_	
189-11	38014-38015	,	_	
189-12	38016-38019	and	_	
189-13	38020-38027	revised	_	
189-14	38028-38031	the	_	
189-15	38032-38042	manuscript	_	
189-16	38042-38043	.	_	

#Text=All authors read and approved the manuscript.
190-1	38044-38047	All	_	
190-2	38048-38055	authors	_	
190-3	38056-38060	read	_	
190-4	38061-38064	and	_	
190-5	38065-38073	approved	_	
190-6	38074-38077	the	_	
190-7	38078-38088	manuscript	_	
190-8	38088-38089	.	_	

#Text=Conflict of interest
#Text=The authors declare no conflict of interest.
191-1	38090-38098	Conflict	_	
191-2	38099-38101	of	_	
191-3	38102-38110	interest	_	
191-4	38111-38114	The	_	
191-5	38115-38122	authors	_	
191-6	38123-38130	declare	_	
191-7	38131-38133	no	_	
191-8	38134-38142	conflict	_	
191-9	38143-38145	of	_	
191-10	38146-38154	interest	_	
191-11	38154-38155	.	_	

#Text=MP has received financial support or compensation for the following: MP has consulted for Ironwood, Lundbeck, Shire, INSYS, RiverMend Health and Lakelight Theraputics/Opiant; has received research support from Mohegan Sun Casino, the National Center for Responsible Gaming, and Psyadon pharmaceuticals; has participated in surveys, mailings or telephone consultations related to drug addiction, impulse control disorders or other health topics; has consulted for law offices and gambling entities on issues related to impulse control disorders; provides clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; has performed grant reviews for the National Institutes of Health and other agencies; has guest-edited journal sections; has given academic lectures in grand rounds, CME events and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts.
192-1	38156-38158	MP	_	
192-2	38159-38162	has	_	
192-3	38163-38171	received	_	
192-4	38172-38181	financial	_	
192-5	38182-38189	support	_	
192-6	38190-38192	or	_	
192-7	38193-38205	compensation	_	
192-8	38206-38209	for	_	
192-9	38210-38213	the	_	
192-10	38214-38223	following	_	
192-11	38223-38224	:	_	
192-12	38225-38227	MP	_	
192-13	38228-38231	has	_	
192-14	38232-38241	consulted	_	
192-15	38242-38245	for	_	
192-16	38246-38254	Ironwood	_	
192-17	38254-38255	,	_	
192-18	38256-38264	Lundbeck	_	
192-19	38264-38265	,	_	
192-20	38266-38271	Shire	_	
192-21	38271-38272	,	_	
192-22	38273-38278	INSYS	_	
192-23	38278-38279	,	_	
192-24	38280-38289	RiverMend	_	
192-25	38290-38296	Health	_	
192-26	38297-38300	and	_	
192-27	38301-38310	Lakelight	_	
192-28	38311-38322	Theraputics	_	
192-29	38322-38323	/	_	
192-30	38323-38329	Opiant	_	
192-31	38329-38330	;	_	
192-32	38331-38334	has	_	
192-33	38335-38343	received	_	
192-34	38344-38352	research	_	
192-35	38353-38360	support	_	
192-36	38361-38365	from	_	
192-37	38366-38373	Mohegan	_	
192-38	38374-38377	Sun	_	
192-39	38378-38384	Casino	_	
192-40	38384-38385	,	_	
192-41	38386-38389	the	_	
192-42	38390-38398	National	_	
192-43	38399-38405	Center	_	
192-44	38406-38409	for	_	
192-45	38410-38421	Responsible	_	
192-46	38422-38428	Gaming	_	
192-47	38428-38429	,	_	
192-48	38430-38433	and	_	
192-49	38434-38441	Psyadon	_	
192-50	38442-38457	pharmaceuticals	_	
192-51	38457-38458	;	_	
192-52	38459-38462	has	_	
192-53	38463-38475	participated	_	
192-54	38476-38478	in	_	
192-55	38479-38486	surveys	_	
192-56	38486-38487	,	_	
192-57	38488-38496	mailings	_	
192-58	38497-38499	or	_	
192-59	38500-38509	telephone	_	
192-60	38510-38523	consultations	_	
192-61	38524-38531	related	_	
192-62	38532-38534	to	_	
192-63	38535-38539	drug	_	
192-64	38540-38549	addiction	_	
192-65	38549-38550	,	_	
192-66	38551-38558	impulse	_	
192-67	38559-38566	control	_	
192-68	38567-38576	disorders	_	
192-69	38577-38579	or	_	
192-70	38580-38585	other	_	
192-71	38586-38592	health	_	
192-72	38593-38599	topics	_	
192-73	38599-38600	;	_	
192-74	38601-38604	has	_	
192-75	38605-38614	consulted	_	
192-76	38615-38618	for	_	
192-77	38619-38622	law	_	
192-78	38623-38630	offices	_	
192-79	38631-38634	and	_	
192-80	38635-38643	gambling	_	
192-81	38644-38652	entities	_	
192-82	38653-38655	on	_	
192-83	38656-38662	issues	_	
192-84	38663-38670	related	_	
192-85	38671-38673	to	_	
192-86	38674-38681	impulse	_	
192-87	38682-38689	control	_	
192-88	38690-38699	disorders	_	
192-89	38699-38700	;	_	
192-90	38701-38709	provides	_	
192-91	38710-38718	clinical	_	
192-92	38719-38723	care	_	
192-93	38724-38726	in	_	
192-94	38727-38730	the	_	
192-95	38731-38742	Connecticut	_	
192-96	38743-38753	Department	_	
192-97	38754-38756	of	_	
192-98	38757-38763	Mental	_	
192-99	38764-38770	Health	_	
192-100	38771-38774	and	_	
192-101	38775-38784	Addiction	_	
192-102	38785-38793	Services	_	
192-103	38794-38801	Problem	_	
192-104	38802-38810	Gambling	_	
192-105	38811-38819	Services	_	
192-106	38820-38827	Program	_	
192-107	38827-38828	;	_	
192-108	38829-38832	has	_	
192-109	38833-38842	performed	_	
192-110	38843-38848	grant	_	
192-111	38849-38856	reviews	_	
192-112	38857-38860	for	_	
192-113	38861-38864	the	_	
192-114	38865-38873	National	_	
192-115	38874-38884	Institutes	_	
192-116	38885-38887	of	_	
192-117	38888-38894	Health	_	
192-118	38895-38898	and	_	
192-119	38899-38904	other	_	
192-120	38905-38913	agencies	_	
192-121	38913-38914	;	_	
192-122	38915-38918	has	_	
192-123	38919-38931	guest-edited	_	
192-124	38932-38939	journal	_	
192-125	38940-38948	sections	_	
192-126	38948-38949	;	_	
192-127	38950-38953	has	_	
192-128	38954-38959	given	_	
192-129	38960-38968	academic	_	
192-130	38969-38977	lectures	_	
192-131	38978-38980	in	_	
192-132	38981-38986	grand	_	
192-133	38987-38993	rounds	_	
192-134	38993-38994	,	_	
192-135	38995-38998	CME	_	
192-136	38999-39005	events	_	
192-137	39006-39009	and	_	
192-138	39010-39015	other	_	
192-139	39016-39024	clinical	_	
192-140	39025-39027	or	_	
192-141	39028-39038	scientific	_	
192-142	39039-39045	venues	_	
192-143	39045-39046	;	_	
192-144	39047-39050	and	_	
192-145	39051-39054	has	_	
192-146	39055-39064	generated	_	
192-147	39065-39070	books	_	
192-148	39071-39073	or	_	
192-149	39074-39078	book	_	
192-150	39079-39087	chapters	_	
192-151	39088-39091	for	_	
192-152	39092-39102	publishers	_	
192-153	39103-39105	of	_	
192-154	39106-39112	mental	_	
192-155	39113-39119	health	_	
192-156	39120-39125	texts	_	
192-157	39125-39126	.	_	

#Text=References
#Text=Catecholamine influences on dorsolateral prefrontal cortical networks
#Text=A preliminary study of the neural correlates of the intensities of self-reported gambling urges and emotions in men with pathological gambling
#Text=Gambling and substance use: Co-occurrence among adults in a recent general population study in the United States
#Text=In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: A positron emission tomography study with [(11)C]-(+)-PHNO
#Text=Dopaminergic network differences in human impulsivity
#Text=Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial
#Text=Optimizing the design and analysis of clinical functional magnetic resonance imaging research studies
#Text=Striatal dopamine D(2)/D(3) receptor binding in pathological gambling is correlated with mood-related impulsivity
#Text=Cue-induced brain activity in pathological gamblers
#Text=A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia
#Text=
#Text=Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications
#Text=Dopamine beta-hydroxylase gene modulates individuals’ empathic ability
#Text=A proof of concept study of tolcapone for pathological gambling: Relationships with COMT genotype and brain activation
#Text=
#Text=The genetics of problem and pathological gambling: A systematic review
#Text=Administration of the beta-adrenoceptor blocker propranolol impairs the processing of facial expressions of sadness
#Text=A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders
#Text=Dopamine beta-hydroxylase gene (DbetaH)-1021C-->T influences self-reported paranoia during cocaine self-administration
#Text=Brain activity during cocaine craving and gambling urges: An fMRI study
#Text=A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: Evidence for alcohol-related differences in noradrenergic function
#Text=Pharmacogenetic randomized trial for cocaine abuse: Disulfiram and dopamine beta-hydroxylase
#Text=Similarities and differences between pathological gambling and substance use disorders: A focus on impulsivity and compulsivity
#Text=Inhibitory control and emotional stress regulation: Neuroimaging evidence for frontal-limbic dysfunction in psycho-stimulant addiction
#Text=Genome-wide association study of a quantitative disordered gambling trait
#Text=Striatal dopamine release codes uncertainty in pathological gambling
#Text=What is new for monoamine neurotransmitter disorders?
193-1	39127-39137	References	_	
193-2	39138-39151	Catecholamine	_	
193-3	39152-39162	influences	_	
193-4	39163-39165	on	_	
193-5	39166-39178	dorsolateral	_	
193-6	39179-39189	prefrontal	_	
193-7	39190-39198	cortical	_	
193-8	39199-39207	networks	_	
193-9	39208-39209	A	_	
193-10	39210-39221	preliminary	_	
193-11	39222-39227	study	_	
193-12	39228-39230	of	_	
193-13	39231-39234	the	_	
193-14	39235-39241	neural	_	
193-15	39242-39252	correlates	_	
193-16	39253-39255	of	_	
193-17	39256-39259	the	_	
193-18	39260-39271	intensities	_	
193-19	39272-39274	of	_	
193-20	39275-39288	self-reported	_	
193-21	39289-39297	gambling	_	
193-22	39298-39303	urges	_	
193-23	39304-39307	and	_	
193-24	39308-39316	emotions	_	
193-25	39317-39319	in	_	
193-26	39320-39323	men	_	
193-27	39324-39328	with	_	
193-28	39329-39341	pathological	_	
193-29	39342-39350	gambling	_	
193-30	39351-39359	Gambling	_	
193-31	39360-39363	and	_	
193-32	39364-39373	substance	_	
193-33	39374-39377	use	_	
193-34	39377-39378	:	_	
193-35	39379-39392	Co-occurrence	_	
193-36	39393-39398	among	_	
193-37	39399-39405	adults	_	
193-38	39406-39408	in	_	
193-39	39409-39410	a	_	
193-40	39411-39417	recent	_	
193-41	39418-39425	general	_	
193-42	39426-39436	population	_	
193-43	39437-39442	study	_	
193-44	39443-39445	in	_	
193-45	39446-39449	the	_	
193-46	39450-39456	United	_	
193-47	39457-39463	States	_	
193-48	39464-39466	In	_	
193-49	39467-39471	vivo	_	
193-50	39472-39480	evidence	_	
193-51	39481-39484	for	_	
193-52	39485-39492	greater	_	
193-53	39493-39512	amphetamine-induced	_	
193-54	39513-39521	dopamine	_	
193-55	39522-39529	release	_	
193-56	39530-39532	in	_	
193-57	39533-39545	pathological	_	
193-58	39546-39554	gambling	_	
193-59	39554-39555	:	_	
193-60	39556-39557	A	_	
193-61	39558-39566	positron	_	
193-62	39567-39575	emission	_	
193-63	39576-39586	tomography	_	
193-64	39587-39592	study	_	
193-65	39593-39597	with	_	
193-66	39598-39599	[	_	
193-67	39599-39600	(	_	
193-68	39600-39602	11	_	
193-69	39602-39603	)	_	
193-70	39603-39604	C	_	
193-71	39604-39605	]	_	
193-72	39605-39606	-	_	
193-73	39606-39607	(	_	
193-74	39607-39608	+	_	
193-75	39608-39609	)	_	
193-76	39609-39610	-	_	
193-77	39610-39614	PHNO	_	
193-78	39615-39627	Dopaminergic	_	
193-79	39628-39635	network	_	
193-80	39636-39647	differences	_	
193-81	39648-39650	in	_	
193-82	39651-39656	human	_	
193-83	39657-39668	impulsivity	_	
193-84	39669-39677	Efficacy	_	
193-85	39678-39680	of	_	
193-86	39681-39691	disulfiram	_	
193-87	39692-39695	and	_	
193-88	39696-39705	cognitive	_	
193-89	39706-39714	behavior	_	
193-90	39715-39722	therapy	_	
193-91	39723-39725	in	_	
193-92	39726-39743	cocaine-dependent	_	
193-93	39744-39755	outpatients	_	
193-94	39755-39756	:	_	
193-95	39757-39758	A	_	
193-96	39759-39769	randomized	_	
193-97	39770-39788	placebo-controlled	_	
193-98	39789-39794	trial	_	
193-99	39795-39805	Optimizing	_	
193-100	39806-39809	the	_	
193-101	39810-39816	design	_	
193-102	39817-39820	and	_	
193-103	39821-39829	analysis	_	
193-104	39830-39832	of	_	
193-105	39833-39841	clinical	_	
193-106	39842-39852	functional	_	
193-107	39853-39861	magnetic	_	
193-108	39862-39871	resonance	_	
193-109	39872-39879	imaging	_	
193-110	39880-39888	research	_	
193-111	39889-39896	studies	_	
193-112	39897-39905	Striatal	_	
193-113	39906-39914	dopamine	_	
193-114	39915-39916	D	_	
193-115	39916-39917	(	_	
193-116	39917-39918	2	_	
193-117	39918-39919	)	_	
193-118	39919-39920	/	_	
193-119	39920-39921	D	_	
193-120	39921-39922	(	_	
193-121	39922-39923	3	_	
193-122	39923-39924	)	_	
193-123	39925-39933	receptor	_	
193-124	39934-39941	binding	_	
193-125	39942-39944	in	_	
193-126	39945-39957	pathological	_	
193-127	39958-39966	gambling	_	
193-128	39967-39969	is	_	
193-129	39970-39980	correlated	_	
193-130	39981-39985	with	_	
193-131	39986-39998	mood-related	_	
193-132	39999-40010	impulsivity	_	
193-133	40011-40022	Cue-induced	_	
193-134	40023-40028	brain	_	
193-135	40029-40037	activity	_	
193-136	40038-40040	in	_	
193-137	40041-40053	pathological	_	
193-138	40054-40062	gamblers	_	
193-139	40063-40064	A	_	
193-140	40065-40074	haplotype	_	
193-141	40075-40077	at	_	
193-142	40078-40081	the	_	
193-143	40082-40085	DBH	_	
193-144	40086-40091	locus	_	
193-145	40091-40092	,	_	
193-146	40093-40103	associated	_	
193-147	40104-40108	with	_	
193-148	40109-40112	low	_	
193-149	40113-40119	plasma	_	
193-150	40120-40128	dopamine	_	
193-151	40129-40145	beta-hydroxylase	_	
193-152	40146-40154	activity	_	
193-153	40154-40155	,	_	
193-154	40156-40160	also	_	
193-155	40161-40171	associates	_	
193-156	40172-40176	with	_	
193-157	40177-40192	cocaine-induced	_	
193-158	40193-40201	paranoia	_	
193-159	40203-40214	Dysfunction	_	
193-160	40215-40217	of	_	
193-161	40218-40221	the	_	
193-162	40222-40232	prefrontal	_	
193-163	40233-40239	cortex	_	
193-164	40240-40242	in	_	
193-165	40243-40252	addiction	_	
193-166	40252-40253	:	_	
193-167	40254-40266	Neuroimaging	_	
193-168	40267-40275	findings	_	
193-169	40276-40279	and	_	
193-170	40280-40288	clinical	_	
193-171	40289-40301	implications	_	
193-172	40302-40310	Dopamine	_	
193-173	40311-40327	beta-hydroxylase	_	
193-174	40328-40332	gene	_	
193-175	40333-40342	modulates	_	
193-176	40343-40354	individuals	_	
193-177	40354-40355	’	_	
193-178	40356-40364	empathic	_	
193-179	40365-40372	ability	_	
193-180	40373-40374	A	_	
193-181	40375-40380	proof	_	
193-182	40381-40383	of	_	
193-183	40384-40391	concept	_	
193-184	40392-40397	study	_	
193-185	40398-40400	of	_	
193-186	40401-40410	tolcapone	_	
193-187	40411-40414	for	_	
193-188	40415-40427	pathological	_	
193-189	40428-40436	gambling	_	
193-190	40436-40437	:	_	
193-191	40438-40451	Relationships	_	
193-192	40452-40456	with	_	
193-193	40457-40461	COMT	_	
193-194	40462-40470	genotype	_	
193-195	40471-40474	and	_	
193-196	40475-40480	brain	_	
193-197	40481-40491	activation	_	
193-198	40493-40496	The	_	
193-199	40497-40505	genetics	_	
193-200	40506-40508	of	_	
193-201	40509-40516	problem	_	
193-202	40517-40520	and	_	
193-203	40521-40533	pathological	_	
193-204	40534-40542	gambling	_	
193-205	40542-40543	:	_	
193-206	40544-40545	A	_	
193-207	40546-40556	systematic	_	
193-208	40557-40563	review	_	
193-209	40564-40578	Administration	_	
193-210	40579-40581	of	_	
193-211	40582-40585	the	_	
193-212	40586-40603	beta-adrenoceptor	_	
193-213	40604-40611	blocker	_	
193-214	40612-40623	propranolol	_	
193-215	40624-40631	impairs	_	
193-216	40632-40635	the	_	
193-217	40636-40646	processing	_	
193-218	40647-40649	of	_	
193-219	40650-40656	facial	_	
193-220	40657-40668	expressions	_	
193-221	40669-40671	of	_	
193-222	40672-40679	sadness	_	
193-223	40680-40681	A	_	
193-224	40682-40692	functional	_	
193-225	40693-40718	dopamine-beta-hydroxylase	_	
193-226	40719-40723	gene	_	
193-227	40724-40732	promoter	_	
193-228	40733-40745	polymorphism	_	
193-229	40746-40748	is	_	
193-230	40749-40759	associated	_	
193-231	40760-40764	with	_	
193-232	40765-40774	impulsive	_	
193-233	40775-40786	personality	_	
193-234	40787-40793	styles	_	
193-235	40793-40794	,	_	
193-236	40795-40798	but	_	
193-237	40799-40802	not	_	
193-238	40803-40807	with	_	
193-239	40808-40817	affective	_	
193-240	40818-40827	disorders	_	
193-241	40828-40836	Dopamine	_	
193-242	40837-40853	beta-hydroxylase	_	
193-243	40854-40858	gene	_	
193-244	40859-40860	(	_	
193-245	40860-40866	DbetaH	_	
193-246	40866-40867	)	_	
193-247	40867-40868	-	_	
193-248	40868-40873	1021C	_	
193-249	40873-40874	-	_	
193-250	40874-40875	-	_	
193-251	40875-40876	>	_	
193-252	40876-40877	T	_	
193-253	40878-40888	influences	_	
193-254	40889-40902	self-reported	_	
193-255	40903-40911	paranoia	_	
193-256	40912-40918	during	_	
193-257	40919-40926	cocaine	_	
193-258	40927-40946	self-administration	_	
193-259	40947-40952	Brain	_	
193-260	40953-40961	activity	_	
193-261	40962-40968	during	_	
193-262	40969-40976	cocaine	_	
193-263	40977-40984	craving	_	
193-264	40985-40988	and	_	
193-265	40989-40997	gambling	_	
193-266	40998-41003	urges	_	
193-267	41003-41004	:	_	
193-268	41005-41007	An	_	
193-269	41008-41012	fMRI	_	
193-270	41013-41018	study	_	
193-271	41019-41020	A	_	
193-272	41021-41040	genotype-controlled	_	
193-273	41041-41049	analysis	_	
193-274	41050-41052	of	_	
193-275	41053-41059	plasma	_	
193-276	41060-41068	dopamine	_	
193-277	41069-41085	beta-hydroxylase	_	
193-278	41086-41088	in	_	
193-279	41089-41096	healthy	_	
193-280	41097-41100	and	_	
193-281	41101-41110	alcoholic	_	
193-282	41111-41119	subjects	_	
193-283	41119-41120	:	_	
193-284	41121-41129	Evidence	_	
193-285	41130-41133	for	_	
193-286	41134-41149	alcohol-related	_	
193-287	41150-41161	differences	_	
193-288	41162-41164	in	_	
193-289	41165-41178	noradrenergic	_	
193-290	41179-41187	function	_	
193-291	41188-41203	Pharmacogenetic	_	
193-292	41204-41214	randomized	_	
193-293	41215-41220	trial	_	
193-294	41221-41224	for	_	
193-295	41225-41232	cocaine	_	
193-296	41233-41238	abuse	_	
193-297	41238-41239	:	_	
193-298	41240-41250	Disulfiram	_	
193-299	41251-41254	and	_	
193-300	41255-41263	dopamine	_	
193-301	41264-41280	beta-hydroxylase	_	
193-302	41281-41293	Similarities	_	
193-303	41294-41297	and	_	
193-304	41298-41309	differences	_	
193-305	41310-41317	between	_	
193-306	41318-41330	pathological	_	
193-307	41331-41339	gambling	_	
193-308	41340-41343	and	_	
193-309	41344-41353	substance	_	
193-310	41354-41357	use	_	
193-311	41358-41367	disorders	_	
193-312	41367-41368	:	_	
193-313	41369-41370	A	_	
193-314	41371-41376	focus	_	
193-315	41377-41379	on	_	
193-316	41380-41391	impulsivity	_	
193-317	41392-41395	and	_	
193-318	41396-41408	compulsivity	_	
193-319	41409-41419	Inhibitory	_	
193-320	41420-41427	control	_	
193-321	41428-41431	and	_	
193-322	41432-41441	emotional	_	
193-323	41442-41448	stress	_	
193-324	41449-41459	regulation	_	
193-325	41459-41460	:	_	
193-326	41461-41473	Neuroimaging	_	
193-327	41474-41482	evidence	_	
193-328	41483-41486	for	_	
193-329	41487-41501	frontal-limbic	_	
193-330	41502-41513	dysfunction	_	
193-331	41514-41516	in	_	
193-332	41517-41533	psycho-stimulant	_	
193-333	41534-41543	addiction	_	
193-334	41544-41555	Genome-wide	_	
193-335	41556-41567	association	_	
193-336	41568-41573	study	_	
193-337	41574-41576	of	_	
193-338	41577-41578	a	_	
193-339	41579-41591	quantitative	_	
193-340	41592-41602	disordered	_	
193-341	41603-41611	gambling	_	
193-342	41612-41617	trait	_	
193-343	41618-41626	Striatal	_	
193-344	41627-41635	dopamine	_	
193-345	41636-41643	release	_	
193-346	41644-41649	codes	_	
193-347	41650-41661	uncertainty	_	
193-348	41662-41664	in	_	
193-349	41665-41677	pathological	_	
193-350	41678-41686	gambling	_	
193-351	41687-41691	What	_	
193-352	41692-41694	is	_	
193-353	41695-41698	new	_	
193-354	41699-41702	for	_	
193-355	41703-41712	monoamine	_	
193-356	41713-41729	neurotransmitter	_	
193-357	41730-41739	disorders	_	
193-358	41739-41740	?	_	

#Text=Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation
#Text=Treatment of pathological gambling with disulfiram: A report of 2 cases
#Text=XMedCon – An open-source medical image conversion toolkit
#Text=Dissociation in human prefrontal cortex of affective influences on working memory-related activity
#Text=Effect of dopamine therapy on nonverbal affect burst recognition in Parkinson’s disease
#Text=Review.
194-1	41741-41750	Decreased	_	
194-2	41751-41762	presynaptic	_	
194-3	41763-41771	dopamine	_	
194-4	41772-41780	function	_	
194-5	41781-41783	in	_	
194-6	41784-41787	the	_	
194-7	41788-41792	left	_	
194-8	41793-41800	caudate	_	
194-9	41801-41803	of	_	
194-10	41804-41813	depressed	_	
194-11	41814-41822	patients	_	
194-12	41823-41827	with	_	
194-13	41828-41837	affective	_	
194-14	41838-41848	flattening	_	
194-15	41849-41852	and	_	
194-16	41853-41864	psychomotor	_	
194-17	41865-41876	retardation	_	
194-18	41877-41886	Treatment	_	
194-19	41887-41889	of	_	
194-20	41890-41902	pathological	_	
194-21	41903-41911	gambling	_	
194-22	41912-41916	with	_	
194-23	41917-41927	disulfiram	_	
194-24	41927-41928	:	_	
194-25	41929-41930	A	_	
194-26	41931-41937	report	_	
194-27	41938-41940	of	_	
194-28	41941-41942	2	_	
194-29	41943-41948	cases	_	
194-30	41949-41956	XMedCon	_	
194-31	41957-41958	–	_	
194-32	41959-41961	An	_	
194-33	41962-41973	open-source	_	
194-34	41974-41981	medical	_	
194-35	41982-41987	image	_	
194-36	41988-41998	conversion	_	
194-37	41999-42006	toolkit	_	
194-38	42007-42019	Dissociation	_	
194-39	42020-42022	in	_	
194-40	42023-42028	human	_	
194-41	42029-42039	prefrontal	_	
194-42	42040-42046	cortex	_	
194-43	42047-42049	of	_	
194-44	42050-42059	affective	_	
194-45	42060-42070	influences	_	
194-46	42071-42073	on	_	
194-47	42074-42081	working	_	
194-48	42082-42096	memory-related	_	
194-49	42097-42105	activity	_	
194-50	42106-42112	Effect	_	
194-51	42113-42115	of	_	
194-52	42116-42124	dopamine	_	
194-53	42125-42132	therapy	_	
194-54	42133-42135	on	_	
194-55	42136-42145	nonverbal	_	
194-56	42146-42152	affect	_	
194-57	42153-42158	burst	_	
194-58	42159-42170	recognition	_	
194-59	42171-42173	in	_	
194-60	42174-42183	Parkinson	_	
194-61	42183-42184	’	_	
194-62	42184-42185	s	_	
194-63	42186-42193	disease	_	
194-64	42194-42200	Review	_	
194-65	42200-42201	.	_	

#Text=The neurobiology of pathological gambling and drug addiction: An overview and new findings
#Text=Gambling urges in pathological gambling: A functional magnetic resonance imaging study
#Text=Shared genetic contributions to pathological gambling and major depression in men
#Text=Dissociable but inter-related systems of cognitive control and reward during decision making: Evidence from pupillometry and event-related fMRI
#Text=Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis
#Text=Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice
#Text=Dopaminergic mechanisms of individual differences in human effort-based decision-making
#Text=Amygdala and ventromedial prefrontal cortex are inversely coupled during regulation of negative affect and predict the diurnal pattern of cortisol secretion among older adults
#Text=Functional magnetic resonance imaging of cocaine craving
#Text=Deficits in emotion regulation associated with pathological gambling
#Text=Environmental factors selectively impact co-occurrence of problem/pathological gambling with specific drug-use disorders in male twins
#Text=Positive association between -1021TT genotype of dopamine beta hydroxylase gene and progressive behavior of injection heroin users
#Text=A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus
195-1	42202-42205	The	_	
195-2	42206-42218	neurobiology	_	
195-3	42219-42221	of	_	
195-4	42222-42234	pathological	_	
195-5	42235-42243	gambling	_	
195-6	42244-42247	and	_	
195-7	42248-42252	drug	_	
195-8	42253-42262	addiction	_	
195-9	42262-42263	:	_	
195-10	42264-42266	An	_	
195-11	42267-42275	overview	_	
195-12	42276-42279	and	_	
195-13	42280-42283	new	_	
195-14	42284-42292	findings	_	
195-15	42293-42301	Gambling	_	
195-16	42302-42307	urges	_	
195-17	42308-42310	in	_	
195-18	42311-42323	pathological	_	
195-19	42324-42332	gambling	_	
195-20	42332-42333	:	_	
195-21	42334-42335	A	_	
195-22	42336-42346	functional	_	
195-23	42347-42355	magnetic	_	
195-24	42356-42365	resonance	_	
195-25	42366-42373	imaging	_	
195-26	42374-42379	study	_	
195-27	42380-42386	Shared	_	
195-28	42387-42394	genetic	_	
195-29	42395-42408	contributions	_	
195-30	42409-42411	to	_	
195-31	42412-42424	pathological	_	
195-32	42425-42433	gambling	_	
195-33	42434-42437	and	_	
195-34	42438-42443	major	_	
195-35	42444-42454	depression	_	
195-36	42455-42457	in	_	
195-37	42458-42461	men	_	
195-38	42462-42473	Dissociable	_	
195-39	42474-42477	but	_	
195-40	42478-42491	inter-related	_	
195-41	42492-42499	systems	_	
195-42	42500-42502	of	_	
195-43	42503-42512	cognitive	_	
195-44	42513-42520	control	_	
195-45	42521-42524	and	_	
195-46	42525-42531	reward	_	
195-47	42532-42538	during	_	
195-48	42539-42547	decision	_	
195-49	42548-42554	making	_	
195-50	42554-42555	:	_	
195-51	42556-42564	Evidence	_	
195-52	42565-42569	from	_	
195-53	42570-42582	pupillometry	_	
195-54	42583-42586	and	_	
195-55	42587-42600	event-related	_	
195-56	42601-42605	fMRI	_	
195-57	42606-42616	Disulfiram	_	
195-58	42617-42625	efficacy	_	
195-59	42626-42628	in	_	
195-60	42629-42632	the	_	
195-61	42633-42642	treatment	_	
195-62	42643-42645	of	_	
195-63	42646-42653	alcohol	_	
195-64	42654-42664	dependence	_	
195-65	42664-42665	:	_	
195-66	42666-42667	A	_	
195-67	42668-42681	meta-analysis	_	
195-68	42682-42690	Dopamine	_	
195-69	42691-42701	production	_	
195-70	42702-42704	in	_	
195-71	42705-42708	the	_	
195-72	42709-42716	caudate	_	
195-73	42717-42724	putamen	_	
195-74	42725-42733	restores	_	
195-75	42734-42741	feeding	_	
195-76	42742-42744	in	_	
195-77	42745-42763	dopamine-deficient	_	
195-78	42764-42768	mice	_	
195-79	42769-42781	Dopaminergic	_	
195-80	42782-42792	mechanisms	_	
195-81	42793-42795	of	_	
195-82	42796-42806	individual	_	
195-83	42807-42818	differences	_	
195-84	42819-42821	in	_	
195-85	42822-42827	human	_	
195-86	42828-42840	effort-based	_	
195-87	42841-42856	decision-making	_	
195-88	42857-42865	Amygdala	_	
195-89	42866-42869	and	_	
195-90	42870-42882	ventromedial	_	
195-91	42883-42893	prefrontal	_	
195-92	42894-42900	cortex	_	
195-93	42901-42904	are	_	
195-94	42905-42914	inversely	_	
195-95	42915-42922	coupled	_	
195-96	42923-42929	during	_	
195-97	42930-42940	regulation	_	
195-98	42941-42943	of	_	
195-99	42944-42952	negative	_	
195-100	42953-42959	affect	_	
195-101	42960-42963	and	_	
195-102	42964-42971	predict	_	
195-103	42972-42975	the	_	
195-104	42976-42983	diurnal	_	
195-105	42984-42991	pattern	_	
195-106	42992-42994	of	_	
195-107	42995-43003	cortisol	_	
195-108	43004-43013	secretion	_	
195-109	43014-43019	among	_	
195-110	43020-43025	older	_	
195-111	43026-43032	adults	_	
195-112	43033-43043	Functional	_	
195-113	43044-43052	magnetic	_	
195-114	43053-43062	resonance	_	
195-115	43063-43070	imaging	_	
195-116	43071-43073	of	_	
195-117	43074-43081	cocaine	_	
195-118	43082-43089	craving	_	
195-119	43090-43098	Deficits	_	
195-120	43099-43101	in	_	
195-121	43102-43109	emotion	_	
195-122	43110-43120	regulation	_	
195-123	43121-43131	associated	_	
195-124	43132-43136	with	_	
195-125	43137-43149	pathological	_	
195-126	43150-43158	gambling	_	
195-127	43159-43172	Environmental	_	
195-128	43173-43180	factors	_	
195-129	43181-43192	selectively	_	
195-130	43193-43199	impact	_	
195-131	43200-43213	co-occurrence	_	
195-132	43214-43216	of	_	
195-133	43217-43224	problem	_	
195-134	43224-43225	/	_	
195-135	43225-43237	pathological	_	
195-136	43238-43246	gambling	_	
195-137	43247-43251	with	_	
195-138	43252-43260	specific	_	
195-139	43261-43269	drug-use	_	
195-140	43270-43279	disorders	_	
195-141	43280-43282	in	_	
195-142	43283-43287	male	_	
195-143	43288-43293	twins	_	
195-144	43294-43302	Positive	_	
195-145	43303-43314	association	_	
195-146	43315-43322	between	_	
195-147	43323-43324	-	_	
195-148	43324-43330	1021TT	_	
195-149	43331-43339	genotype	_	
195-150	43340-43342	of	_	
195-151	43343-43351	dopamine	_	
195-152	43352-43356	beta	_	
195-153	43357-43368	hydroxylase	_	
195-154	43369-43373	gene	_	
195-155	43374-43377	and	_	
195-156	43378-43389	progressive	_	
195-157	43390-43398	behavior	_	
195-158	43399-43401	of	_	
195-159	43402-43411	injection	_	
195-160	43412-43418	heroin	_	
195-161	43419-43424	users	_	
195-162	43425-43426	A	_	
195-163	43427-43445	quantitative-trait	_	
195-164	43446-43454	analysis	_	
195-165	43455-43457	of	_	
195-166	43458-43463	human	_	
195-167	43464-43479	plasma-dopamine	_	
195-168	43480-43496	beta-hydroxylase	_	
195-169	43497-43505	activity	_	
195-170	43505-43506	:	_	
195-171	43507-43515	Evidence	_	
195-172	43516-43519	for	_	
195-173	43520-43521	a	_	
195-174	43522-43527	major	_	
195-175	43528-43538	functional	_	
195-176	43539-43551	polymorphism	_	
195-177	43552-43554	at	_	
195-178	43555-43558	the	_	
195-179	43559-43562	DBH	_	
195-180	43563-43568	locus	_	
